Citation Report
List of articles citing

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

DOI: 10.1016/j.cell.2007.11.019
Cell, 2007, 131, 861-72.

Source: https://exaly.com/paper-pdf/42032058/citation-report.pdf
Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2229	References. 205-220		
2228	Modulation of hepatic mitochondrial energy efficiency with age. **2004**, 61, 1366-71		12
2227	Stretch of the vascular wall induces smooth muscle differentiation by promoting actin polymerization. **2004**, 279, 34849-55		119
2226	Cutting edge: Rac GTPases sensitize activated T cells to die via Fas. **2007**, 179, 6384-8		34
2225	Development. Is therapeutic cloning dead?. **2007**, 318, 1879-80		18
2224	Race to mimic human embryonic stem cells. **2007**,		1
2223	Cardiovascular regenerative medicine: digging in for the long haul. **2007**, 1, 628-33		14
2222	Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*, **2007**, 131, 861-72	56.2	14786
2221	Gene targeting in embryonic stem cells scores a knockout in Stockholm. *Cell*, **2007**, 131, 1027-31	56.2	48
2220	Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. **2007**, 318, 1920-3		1218
2219	Adult cells reprogrammed to pluripotency, without tumors. **2007**,		5
2218	Can opposition to research spur innovation?. **2007**,		1
2217	Research highlights 2007. **2007**, 450, 1131-1133		6
2216	Having it both ways: Sox protein function between conservation and innovation. **2008**, 65, 3000-18		125
2215	Cell electrophoresis on a chip: what can we know from the changes in electrophoretic mobility?. **2008**, 391, 2433-41		29
2214	Combining transcriptional profiling and genetic linkage analysis to uncover gene networks operating in hematopoietic stem cells and their progeny. **2008**, 60, 411-22		17
2213	Application of stem cells in bone repair. **2008**, 37, 601-8		43

2212	[Human embryonic stem cells within the context of international research activity]. **2008**, 51, 994-1004	
2211	[From basic research to the clinic. Obstacles and options for stem cell therapies]. **2008**, 51, 1014-20	1
2210	[Human embryonic stem cells. Perspectives for the study and therapy of neurological disorders]. **2008**, 51, 1026-32	
2209	[Regenerative medicine. New therapeutic methods in otorhinolaryngology and head and neck surgery]. **2008**, 56, 252-7	
2208	Deconstructing human embryonic stem cell cultures: niche regulation of self-renewal and pluripotency. **2008**, 86, 875-86	51
2207	Advances in the study on induced pluripotent stem cells. **2008**, 53, 709-717	1
2206	Human ESC vs. iPSC-pros and cons. **2008**, 1, 96-9	15
2205	Cardiac stem cell therapy and arrhythmogenicity: prometheus and the arrows of Apollo and Artemis. **2008**, 1, 207-16	1
2204	Adhesion proteins, stem cells, and arrhythmogenesis. **2008**, 8, 1-13	5
2203	Sources of stem cells for regenerative medicine. **2008**, 4, 3-11	146
2202	Commentary: "re-programming or selecting adult stem cells?". **2008**, 4, 81-8	21
2201	The therapeutic potential of embryonic and adult stem cells for skeletal muscle regeneration. **2008** , 4, 217-25	22
2200	The pursuit of ES cell lines of domesticated ungulates. **2008**, 4, 235-54	71
2199	Parthenogenesis as an approach to pluripotency: advantages and limitations involved. **2008**, 4, 127-35	19
2198	Embryonic stem cells and their genetic modification. **2008**, 13, 172-180	
2197	Kidney regeneration by xeno-embryonic nephrogenesis. **2008**, 41, 5-13	4
2196	Induced pluripotent stem (iPS) cells as in vitro models of human neurogenetic disorders. **2008**, 9, 227-35	49
2195	Kidney organogenesis and regeneration: a new era in the treatment of chronic renal failure?. **2008**, 12, 326-331	17

2194	Das Schicksal kardialer Zelltransplantate. **2008**, 22, 224-232	
2193	Cells captured from spatium intermusculare by porous material exhibit the characteristics of stem cells. **2008**, 130, 741-8	4
2192	Regenerating cochlear hair cells: quo vadis stem cell. **2008**, 333, 373-9	33
2191	Human embryonic stem cell research, justice, and the problem of unequal biological access. **2008**, 3, 22	6
2190	Locally induced neural stem cells/pluripotent stem cells for in vivo cell replacement therapy. **2008**, 1, 17	6
2189	Purification, crystallization and preliminary X-ray diffraction analysis of the HMG domain of Sox17 in complex with DNA. **2008**, 64, 1184-7	12
2188	Cell surface biomarkers of embryonic stem cells. **2008**, 8, 4025-35	57
2187	Stem cell markers: insights from membrane proteomics?. **2008**, 8, 4946-57	25
2186	POU5F1, encoding a key regulator of stem cell pluripotency, is fused to EWSR1 in hidradenoma of the skin and mucoepidermoid carcinoma of the salivary glands. **2008**, 215, 78-86	85
2185	Neural commitment of embryonic stem cells: molecules, pathways and potential for cell therapy. **2008**, 215, 355-68	29
2184	[The end of therapeutic clones, before it began?]. **2008**, 37, 117-9	
2183	Mesenchymal stem cells in tissue engineering. **2008**, 83, 397-407	11
2182	Transplantation and beyond. **2008**, 69, 165-176	5
2181	Molecular and developmental biology of the hemangioblast. **2008**, 237, 1218-31	57
2180	Reprogramming multipotent tumor cells with the embryonic neural crest microenvironment. **2008**, 237, 2657-66	75
2179	Iris as a recipient tissue for pigment cells: organized in vivo differentiation of melanocytes and pigmented epithelium derived from embryonic stem cells in vitro. **2008**, 237, 2394-404	7
2178	Stretching the limits: stem cells in regeneration science. **2008**, 237, 3648-71	58
2177	Identification of genes regulated by nanog which is involved in ES cells pluripotency and early differentiation. **2008**, 104, 2348-62	12

2176	From fibroblasts to iPS cells: induced pluripotency by defined factors. **2008**, 105, 949-55	100
2175	Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. **2008**, 105, 940-8	131
2174	Stem cells in development of therapeutics for Parkinson's disease: a perspective. **2008**, 105, 1153-60	9
2173	Taking stem cells to the clinic: Major challenges. **2008**, 105, 1352-60	146
2172	Human stem cells for modeling neurological disorders: accelerating the drug discovery pipeline. **2008**, 105, 1361-6	21
2171	Highly efficient and feeder-free production of subculturable vascular endothelial cells from primate embryonic stem cells. **2008**, 217, 261-80	11
2170	Nuclear proteome analysis of undifferentiated mouse embryonic stem and germ cells. **2008**, 29, 2381-90	33
2169	Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4alpha gene. **2008**, 48, 1528-39	151
2168	Engineered microenvironments for human stem cells. **2008**, 84, 335-47	22
2167	Regeneration in medicine: a plastic surgeons "tail" of disease, stem cells, and a possible future. **2008**, 84, 322-34	7
2166	Losing B cell identity. **2008**, 30, 203-7	16
2165	Compagen, a comparative genomics platform for early branching metazoan animals, reveals early origins of genes regulating stem-cell differentiation. **2008**, 30, 1010-8	96
2164	Regenerative medicine and stem cell based drug discovery. **2008**, 47, 5718-38	33
2163	Repairing the human brain after stroke. II. Restorative therapies. **2008**, 63, 549-60	206
2162	Regenerative Medizin und stammzellbasierte Wirkstoffentwicklung. **2008**, 120, 5802-5823	3
2161	Innovation in the culture and derivation of pluripotent human stem cells. **2008**, 19, 527-33	65
2160	A potential model for studying the plasticity and reprogramming of human epidermal stem cells through preimplantation blastocyst microinjection. **2008**, 32, 1567-73	2
2159	Development of electrospun poly(vinyl alcohol) fibers immobilizing lipase highly activated by alkyl-silicate for flow-through reactors. **2008**, 325, 454-459	21

2158	Current Stem Cell Technology: Limitations and Realistic Expectations. **2008**, 8, 13-18	5
2157	Neural stem cells: mechanisms of fate specification and nuclear reprogramming in regenerative medicine. **2008**, 3, 1521-38	9
2156	Biotech methods, news and views. **2008**, 3, 12-22	
2155	Stem cells use distinct self-renewal programs at different ages. **2008**, 73, 539-53	41
2154	Toward a cell-based cure for diabetes: advances in production and transplant of beta cells. **2008**, 75, 362-71	17
2153	Heterozygous embryonic stem cell lines derived from nonhuman primate parthenotes. **2008**, 26, 756-66	56
2152	Androgenetic embryonic stem cells form neural progenitor cells in vivo and in vitro. **2008**, 26, 1474-83	16
2151	Reprogramming battle: Egg vs. Virus. **2008**, 26, 1-2	6
2150	Regulation of self-renewal and pluripotency by Sox2 in human embryonic stem cells. **2008**, 26, 1931-8	231
2149	Lineage selection of functional and cryopreservable human embryonic stem cell-derived neurons. **2008**, 26, 1705-12	35
2148	Commentary: somatic cell nuclear transfer--progress and promise. **2008**, 26, 494-5	7
2147	Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. **2008**, 26, 1537-46	204
2146	Embryonic stem cells and their differentiated derivatives have a fragile immune privilege but still represent novel targets of immune attack. **2008**, 26, 1939-50	78
2145	Spermatogonial stem cell self-renewal requires OCT4, a factor downregulated during retinoic acid-induced differentiation. **2008**, 26, 2928-37	151
2144	Hepatocyte nuclear factor-1 as marker of epithelial phenotype reveals marrow-derived hepatocytes, but not duct cells, after liver injury in mice. **2008**, 26, 1768-77	14
2143	Adult germ line stem cells as a source of functional neurons and glia. **2008**, 26, 2434-43	35
2142	Control of human embryonic stem cell colony and aggregate size heterogeneity influences differentiation trajectories. **2008**, 26, 2300-10	361
2141	Tcf3 functions as a steady-state limiter of transcriptional programs of mouse embryonic stem cell self-renewal. **2008**, 26, 1951-60	127

2140	Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression. **2008**, 26, 2467-74	262
2139	Bone marrow-derived mesenchymal stromal cells express cardiac-specific markers, retain the stromal phenotype, and do not become functional cardiomyocytes in vitro. **2008**, 26, 2884-92	176
2138	Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. **2008**, 26, 1998-2005	235
2137	Regulatory issues for personalized pluripotent cells. **2008**, 26, 2753-8	55
2136	Costimulation blockade induces tolerance to HESC transplanted to the testis and induces regulatory T-cells to HESC transplanted into the heart. **2008**, 26, 1850-7	39
2135	Generation of pluripotent stem cells from adult mouse liver and stomach cells. **2008**, 321, 699-702	841
2134	Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism. **2008**, 223, 334-60	28
2133	Reviews in Medical Ethics - Stem Cell Century: Law and Policy for a Breakthrough Technology by Russell Korobkin, with Stephen R. Munzer (Yale University Press, 2007): 312 pages: Decoding the Stem Cell Debate: A Primer Par Excellence. **2008**, 36, 184-190	
2132	Lazarus's gate: challenges and potential of epigenetic reprogramming of somatic cells. **2008**, 83, 889-93	7
2131	More new lines of human parthenogenetic embryonic stem cells. **2008**, 18, 215-7	15
2130	The magic continues for the iPS strategy. **2008**, 18, 221-3	17
2129	Yamanaka factors critically regulate the developmental signaling network in mouse embryonic stem cells. **2008**, 18, 1177-89	85
2128	Enhanced efficiency of generating induced pluripotent stem (iPS) cells from human somatic cells by a combination of six transcription factors. **2008**, 18, 600-3	140
2127	Actions of human telomerase beyond telomeres. **2008**, 18, 725-32	179
2126	Gene-modified bone marrow cell therapy for prostate cancer. **2008**, 15, 787-96	4
2125	Stem and progenitor cell-mediated tumor selective gene therapy. **2008**, 15, 739-52	239
2124	Reprogramming of human somatic cells to pluripotency with defined factors. **2008**, 451, 141-6	2364
2123	Regenerative medicine and human models of human disease. **2008**, 453, 302-5	73

2122	Stem-cell-based therapy and lessons from the heart. **2008**, 453, 322-9	465
2121	Tolerance strategies for stem-cell-based therapies. **2008**, 453, 330-7	95
2120	A chemical approach to stem-cell biology and regenerative medicine. **2008**, 453, 338-44	287
2119	Dissecting direct reprogramming through integrative genomic analysis. **2008**, 454, 49-55	1205
2118	Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. **2008**, 454, 646-50	803
2117	In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. **2008**, 455, 627-32	1618
2116	Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. **2008**, 26, 1269-75	1114
2115	Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. **2008**, 26, 1276-84	1126
2114	Simpler and safer cell reprogramming. **2008**, 26, 59-60	25
2113	Primate therapeutic cloning in practice. **2008**, 26, 64-5	3
2112	Genome resequencing and genetic variation. **2008**, 26, 65-6	50
2111	iPS cells and the politics of promise. **2008**, 26, 271-2	21
2110	Patenting pluripotence: the next battle for stem cell intellectual property. **2008**, 26, 393-5	20
2109	Stem cells. A new year and a new era. **2008**, 451, 135-6	19
2108	Law should recognize value of interspecies embryos. **2008**, 451, 627	3
2107	Stem cells: 5 things to know before jumping on the iPS bandwagon. **2008**, 452, 406-8	50
2106	Japan ramps up patent effort to keep iPS lead. **2008**, 453, 962-3	8
2105	Stem cells: Tips for priming potency. **2008**, 454, 45-6	2

2104	Climate change: Acid test for marine biodiversity. **2008**, 454, 46-7	43
2103	Embryonic stem cells and the problem of directed differentiation. **2008**, 73, 1438-52	10
2102	A bumper month for stem cells. **2008**, 9, 3-3	
2101	HLA-haplotype banking and iPS cells. **2008**, 26, 739-40	233
2100	Epidermal cells rev up reprogramming. **2008**, 26, 1243-4	2
2099	Nanotubes light up protein arrays. **2008**, 26, 1244-6	19
2098	The many ways to make an iPS cell. **2008**, 26, 1246-8	39
2097	Fast forward genetics. **2008**, 26, 1248-9	9
2096	Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. **2008** , 26, 101-6	2239
2095	Toward the generation of rod and cone photoreceptors from mouse, monkey and human embryonic stem cells. **2008**, 26, 215-24	500
2094	Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. **2008**, 26, 795-7	1313
2093	A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types. **2008**, 26, 916-24	343
2092	Epigenetic memory: H3.3 steps in the groove. **2008**, 10, 7-9	6
2091	Redox rescues virus from ER trap. **2008**, 10, 9-11	10
2090	Nanog and Oct4 associate with unique transcriptional repression complexes in embryonic stem cells. **2008**, 10, 731-9	375
2089	Chemical biology expands its horizons. **2008**, 4, 1-1	6
2088	An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. **2008**, 40, 499-507	1885
2087	Revamped guidelines aim to keep pace with stem cell advances. **2008**, 14, 993	

2086	Notable advances. **2008**, 14, 1302-1302	
2085	Functional skeletal muscle regeneration from differentiating embryonic stem cells. **2008**, 14, 134-43	269
2084	Generation of human-induced pluripotent stem cells. **2008**, 3, 1180-6	313
2083	Derive and conquer: sourcing and differentiating stem cells for therapeutic applications. **2008**, 7, 131-42	137
2082	The adult human brain in preclinical drug development. **2008**, 7, 659-66	94
2081	Genetic programming of liver and pancreas progenitors: lessons for stem-cell differentiation. **2008**, 9, 329-40	231
2080	In brief. **2008**, 9, 7-7	1
2079	Mediators of reprogramming: transcription factors and transitions through mitosis. **2008**, 9, 505-16	178
2078	The promise of human induced pluripotent stem cells for research and therapy. **2008**, 9, 725-9	344
2077	US policies on human embryonic stem cells. **2008**, 9, 993-7	7
2076	The regulation of human embryo and stem-cell research in the United Kingdom. **2008**, 9, 998-1003	13
2075	Stem cell review series: regulating highly potent stem cells in aging: environmental influences on plasticity. **2008**, 7, 599-604	11
2074	Liver stem cells: a scientific and clinical perspective. **2008**, 23, 687-98	65
2073	Bridging the gap from frog research to human therapy: a tale of neural differentiation in Xenopus animal caps and human pluripotent cells. **2008**, 50 Suppl 1, S47-55	6
2072	Identification and characterization of nucleoplasmin 3 as a histone-binding protein in embryonic stem cells. **2008**, 50, 307-20	14
2071	Can autologous myoblasts be used as a potential bulking agent?. **2008**, 102, 1731-6	7
2070	Induced reprogramming of human somatic cells into pluripotency: a new way how to generate pluripotent stem cells. **2008**, 76, 323-5	4
2069	Embryonic stem cells reduce liver fibrosis in CCl4-treated mice. **2008**, 89, 401-9	33

2068	Genetic engineering and stem cells: combinatorial approaches for cardiac cell therapy. **2008**, 27, 85-8	3
2067	Aging stem cells, latexin, and longevity. **2008**, 314, 1962-72	30
2066	Rapid induction of pluripotency genes after exposure of human somatic cells to mouse ES cell extracts. **2008**, 314, 2634-42	68
2065	Induced pluripotency with endogenous and inducible genes. **2008**, 314, 3255-63	24
2064	CompMoby: comparative MobyDick for detection of cis-regulatory motifs. **2008**, 9, 455	5
2063	Stem cells from skin cells: the ethical questions. **2008**, 38, 20-2	14
2062	Bony endothelium: tumor-mediated transdifferentiation?. **2008**, 14, 193-4	9
2061	Human embryonic stem cells: a model for human ageing in vitro. **2008**, 43, 1005-8	3
2060	Stem cell therapy in myocardial repair and remodeling. **2008**, 207, 423-34	21
2059	Reprogramming of pancreatic beta cells into induced pluripotent stem cells. **2008**, 18, 890-4	343
2058	Engineering tissue from human embryonic stem cells. **2008**, 12, 709-29	44
2057	Stemming heart failure with cardiac- or reprogrammed-stem cells. **2008**, 12, 2217-32	27
2056	Heterogeneity of pluripotent marker gene expression in colonies generated in human iPS cell induction culture. **2007**, 1, 105-15	63
2055	Mining for JAK-STAT mutations in cancer. **2008**, 33, 122-31	120
2054	The challenges of regulating stem cell-based products. **2008**, 26, 653-8	24
2053	Alternative sources of pluripotency: science, ethics, and stem cells. **2008**, 22, 215-22	38
2052	hESCCO: development of good practice models for hES cell derivation. **2008**, 3, 105-16	24
2051	Development of a European human embryonic stem cell registry. **2008**, 3, 945-51	11

2050	Multipotent stem cells in cardiac regenerative therapy. **2008**, 3, 189-98	5
2049	Mechanical control of stem cell differentiation. **2008**,	15
2048	Epigenetic regulation of mammalian stem cells. **2008**, 17, 1043-52	65
2047	Defining molecular cornerstones during fibroblast to iPS cell reprogramming in mouse. **2008**, 2, 230-40	669
2046	Low molecular weight compounds for in vitro fate determination of human embryonic stem cells. **2008**, 58, 152-7	6
2045	Functional network reconstruction reveals somatic stemness genetic maps and dedifferentiation-like transcriptome reprogramming induced by GATA2. **2008**, 26, 1186-201	39
2044	Mouse meningiocytes express Sox2 and yield high efficiency of chimeras after nuclear reprogramming with exogenous factors. **2008**, 283, 33730-5	38
2043	Induced pluripotent stem cells generated without viral integration. **2008**, 322, 945-9	1316
2042	The Krüppel-like factor 9 (KLF9) network in HEC-1-A endometrial carcinoma cells suggests the carcinogenic potential of dys-regulated KLF9 expression. **2008**, 6, 41	47
2041	Training the next generation of pluripotent stem cell researchers. **2008**, 6, 40	
2040	Potential of adult neural stem cells in stroke therapy. **2008**, 3, 893-905	41
2039	Stem cells in animal models of regeneration. **2008**,	7
2038	Immunological considerations for cell therapy using human embryonic stem cell derivatives. **2008**,	9
2037	Medical applications of epidermal stem cells. **2008**,	
2036	Engineering microenvironments to control stem cell fate and function. **2008**,	9
2035	Protein expression profile of the mouse metaphase-II oocyte. **2008**, 7, 4821-30	48
2034	Promotion of reprogramming to ground state pluripotency by signal inhibition. **2008**, 6, e253	619
2033	Reversible membrane permeabilization of mammalian cells treated with digitonin and its use for inducing nuclear reprogramming by Xenopus egg extracts. **2008**, 10, 535-42	47

2032	Stochasticity and the molecular mechanisms of induced pluripotency. **2008**, 3, e3086	73
2031	To be or not to be: generation of hepatocytes from cells outside the liver. **2008**, 134, 878-81	24
2030	Stable embryonic stem cell lines in rabbits: potential small animal models for human research. **2008** , 17, 706-15	49
2029	The mouse as a model system to study cardiac regeneration. **2008**, 5, 165-171	3
2028	Embryonic Stem Cells as a Model for Cardiac Development and Disease. **2008**, 5, 147-155	7
2027	Cardiomyocytes from human embryonic stem cells as predictors of cardiotoxicity. **2008**, 5, 223-232	17
2026	Cardiovascular Stem Cells in Regenerative Medicine: Ready for Prime Time?. **2008**, 5, 201-207	9
2025	cell regeneration. **2008**, 5, 215-221	1
2024	Viral and non-viral gene delivery and its role in pluripotent stem cell engineering. **2008**, 5, e105-48	10
2023	Stem cell reprogramming: generation of patient-specific stem cells by somatic cell nuclear reprogramming. **2008**, 5, e105-48	1
2022	Mesenchymal stem cells: isolation, characterisation and in vivo fluorescent dye tracking. **2008**, 17, 395-403	77
2021	Stem cells in urology. **2008**, 5, 621-31	34
2020	The significance of induced pluripotent stem cells for basic research and clinical therapy. **2008**, 34, 849-51	14
2019	Current Perspectives in microRNAs (miRNA). **2008**,	2
2018	Nanoparticles for gene transfer to human embryonic stem cell colonies. **2008**, 8, 3126-30	94
2017	Human embryonic stem cells: lessons from stem cell niches in vivo. **2008**, 3, 365-76	23
2016	Immunological barriers to embryonic stem cell-derived therapies. **2008**, 188, 78-90	38
2015	Induced Pluripotent Stem Cells Generated from Reprogramming Differentiated Cells by Defined Factors. **2008**, 24, 1121-1127	2

2014	Tissue engineering and regenerative science in pediatrics. **2008**, 63, 459-60	5
2013	Stem Cell Research and Therapeutics. **2008**,	1
2012	Invincible, but not invisible: imaging approaches toward in vivo detection of cancer stem cells. **2008** , 26, 2901-10	57
2011	Eradication of HIV: current challenges and new directions. **2009**, 63, 7-10	48
2010	Stem cells in the heart: what's the buzz all about? Part 2: Arrhythmic risks and clinical studies. **2008**, 5, 880-7	46
2009	Tissue engineering in cleft palate and other congenital malformations. **2008**, 63, 545-51	42
2008	Regulation of spermatogonial stem cell self-renewal in mammals. **2008**, 24, 263-86	416
2007	Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. **2008**, 321, 1218-21	1572
2006	Stem cells for reproductive medicine. **2008**, 288, 104-10	9
2005	Embryonic stem cells to beta-cells by understanding pancreas development. **2008**, 288, 86-94	22
2004	Pax6 promotes neurogenesis in human neural stem cells. **2008**, 38, 616-28	37
2003	The undoing of differentiation by four defined factors: A big step forward towards generating patient specific pluripotent stem cells. **2008**, 49, 876-8	2
2002	Pluripotent human stem cell lines: what we can learn about cancer initiation. **2008**, 14, 323-32	26
2001	let-7 microRNAs in development, stem cells and cancer. **2008**, 14, 400-9	483
2000	Orchestrating brain-cell renewal: the role of immune cells in adult neurogenesis in health and disease. **2008**, 14, 471-8	52
1999	Glioma stem cells: a midterm exam. **2008**, 58, 832-46	257
1998	Innate and adaptive immune responses in tissue engineering. **2008**, 20, 83-5	29
1997	Embryonic stem cell biology. **2008**, 55, 43-77	8

1996	Stem cells for cardiovascular repair - the challenges of the aging heart. **2008**, 45, 582-92	12
1995	Bones of contention: marrow-derived cells in myocardial regeneration. **2008**, 44, 950-3	50
1994	Cardiomyogenic stem and progenitor cell plasticity and the dissection of cardiopoiesis. **2008**, 45, 475-94	27
1993	Human embryonic stem cells for cardiomyogenesis. **2008**, 45, 462-74	43
1992	Differentiation of neural lineage cells from human pluripotent stem cells. **2008**, 45, 142-58	59
1991	Methods for studying stem cells: adult stem cells for lung repair. **2008**, 45, 121-32	15
1990	Do cells let-7 determine stemness?. **2008**, 2, 8-9	33
1989	Why myc? An unexpected ingredient in the stem cell cocktail. **2008**, 2, 18-21	101
1988	Challenges to human embryonic stem cell patents. **2008**, 2, 13-7	23
1987	Stem cells shine in Shanghai. **2008**, 2, 34-7	6
1986	Sequential expression of pluripotency markers during direct reprogramming of mouse somatic cells. **2008**, 2, 151-9	661
1985	Unraveling epigenetic regulation in embryonic stem cells. **2008**, 2, 123-34	137
1984	Nuclear transfer and iPS may work best together. **2008**, 2, 135-8	14
1983	Cell delivery mechanisms for tissue repair. **2008**, 2, 205-13	280
1982	Module map of stem cell genes guides creation of epithelial cancer stem cells. **2008**, 2, 333-44	542
1981	Cancer: inappropriate expression of stem cell programs?. **2008**, 2, 297-9	18
1980	Illuminating the black box of reprogramming. **2008**, 2, 295-7	24
1979	The use of fresh embryos in stem cell research: ethical and policy issues. **2008**, 2, 416-21	15

1978	Genetic modification of human embryonic stem cells for derivation of target cells. **2008**, 2, 422-33	94
1977	Global Forum Discusses Stem Cell Research Strategy. **2008**, 2, 435-436	1
1976	Neural regeneration and cell replacement: a view from the eye. **2008**, 2, 538-49	140
1975	Identifying under- and overperforming countries in research related to human embryonic stem cells. **2008**, 2, 521-4	27
1974	A combined chemical and genetic approach for the generation of induced pluripotent stem cells. **2008**, 2, 525-8	601
1973	Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches. **2008**, 3, 85-98	252
1972	Establishment of endoderm progenitors by SOX transcription factor expression in human embryonic stem cells. **2008**, 3, 182-95	164
1971	Wnt signaling promotes reprogramming of somatic cells to pluripotency. **2008**, 3, 132-5	357
1970	A niche-defying feat: induced oligoneogenesis in the adult dentate gyrus. **2008**, 3, 125-6	4
1969	A high-efficiency system for the generation and study of human induced pluripotent stem cells. **2008**, 3, 340-5	445
1968	A drug-inducible system for direct reprogramming of human somatic cells to pluripotency. **2008**, 3, 346-353	266
1967	Periodic activation of Wnt/beta-catenin signaling enhances somatic cell reprogramming mediated by cell fusion. **2008**, 3, 493-507	121
1966	Self-organized formation of polarized cortical tissues from ESCs and its active manipulation by extrinsic signals. **2008**, 3, 519-32	910
1965	Krüppel-like factor 5 is essential for blastocyst development and the normal self-renewal of mouse ESCs. **2008**, 3, 555-67	151
1964	Extreme makeover: converting one cell into another. **2008**, 3, 382-8	209
1963	Generation of induced pluripotent stem cells from adult rhesus monkey fibroblasts. **2008**, 3, 587-90	384
1962	Guidelines and techniques for the generation of induced pluripotent stem cells. **2008**, 3, 595-605	392
1961	Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. **2008**, 31, 192-8	82

1960	Mesenchymal cells for skeletal tissue engineering. **2008**, 8, 885-93		29
1959	iPS cells: a more critical review. **2008**, 17, 391-7		61
1958	Current approaches and challenges in making a bio-tooth. **2008**, 14, 307-19		31
1957	Common themes of dedifferentiation in somatic cell reprogramming and cancer. **2008**, 73, 171-4		54
1956	Neural stem cells: balancing self-renewal with differentiation. **2008**, 135, 1575-87		317
1955	Small activating mRNA (samRNA): A hypothesis for a specific positive feedback regulation of gene expression. **2008**, 1, 44-47		1
1954	Cardiomyocyte death and renewal in the normal and diseased heart. **2008**, 17, 349-74		118
1953	Differentially expressed genes of reprogrammed human pluripotent stem cells in breast cancer. **2008**, 44, 1789-92		8
1952	Induction of neural stem cell-like cells (NSCLCs) from mouse astrocytes by Bmi1. **2008**, 371, 267-72		30
1951	Paracrine factors of vascular endothelial cells facilitate cardiomyocyte differentiation of mouse embryonic stem cells. **2008**, 377, 413-418		17
1950	The reprogramming language of pluripotency. **2008**, 18, 123-9		24
1949	Human embryonic stem cells: emerging technologies and practical applications. **2008**, 18, 324-9		20
1948	Toward a systems-level understanding of developmental regulatory networks. **2008**, 18, 521-9		31
1947	[Cord blood banks]. **2008**, 36, 489-90		
1946	[Human embryo stem cells and gametes: science fiction or near future?]. **2008**, 36, 908-12		1
1945	Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell*, **2008**, 132, 567-82	56.2	1126
1944	Stem cell research in Singapore. *Cell*, **2008**, 132, 519-21	56.2	3
1943	Stem cells and early lineage development. *Cell*, **2008**, 132, 527-31	56.2	257

1942	Slicing across kingdoms: regeneration in plants and animals. *Cell*, **2008**, 132, 697-710	56.2	272
1941	Origins and fates of cardiovascular progenitor cells. *Cell*, **2008**, 132, 537-43	56.2	160
1940	Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. *Cell*, **2008**, 132, 661-80	56.2	1369
1939	Prospects for stem cell-based therapy. *Cell*, **2008**, 132, 544-8	56.2	258
1938	Stem cells and drug discovery: the beginning of a new era?. *Cell*, **2008**, 132, 549-52	56.2	122
1937	An extended transcriptional network for pluripotency of embryonic stem cells. *Cell*, **2008**, 132, 1049-61	56.2	1095
1936	Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. *Cell*, **2008**, 133, 250-64	56.2	684
1935	Ronin is essential for embryogenesis and the pluripotency of mouse embryonic stem cells. *Cell*, **2008**, 133, 1162-74	56.2	148
1934	Disease-specific induced pluripotent stem cells. *Cell*, **2008**, 134, 877-86	56.2	1787
1933	The growth factor environment defines distinct pluripotent ground states in novel blastocyst-derived stem cells. *Cell*, **2008**, 135, 449-61	56.2	183
1932	Regulatory networks define phenotypic classes of human stem cell lines. **2008**, 455, 401-5		283
1931	Generation of functional murine cardiac myocytes from induced pluripotent stem cells. **2008**, 118, 507-17		414
1930	The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype. **2008**, 173, 561-74		94
1929	Construction of a high-performance human fetal liver-derived lentiviral cDNA library. **2008**, 319, 181-7		6
1928	Induction of pluripotent stem cells from mouse embryonic fibroblasts by Oct4 and Klf4 with small-molecule compounds. **2008**, 3, 568-74		731
1927	Paper of the year 2007. **2008**, 371, 370-371		6
1926	Prospects for health-systems research. **2008**, 371, 1913-4		1
1925	Prospects for health-systems research. **2008**, 371, 1914		2

1924	Origin of stem cells in organogenesis. **2008**, 322, 1498-501	140
1923	Induced pluripotency of mouse and human somatic cells. **2008**, 73, 157-62	21
1922	The tumorigenicity of human embryonic stem cells. **2008**, 100, 133-58	329
1921	Developmental biology. Neuron research leaps ahead. **2008**, 321, 1169-70	3
1920	Stem cells and nuclear reprogramming. **2008**, 17, 64-78	10
1919	Therapeutic stem-cells for cancer treatment: hopes and hurdles in tactical warfare. **2008**, 9, 376-84	114
1918	Generation of patient-specific pluripotent stem cells and directed differentiation of embryonic stem cells for regenerative medicine. **2008**, 22, 135-142	2
1917	Therapeutic potential of stem cells in skin repair and regeneration. **2008**, 11, 209-21	59
1916	In vitro Differentiation Potential of Mesenchymal Stem Cells. **2008**, 35, 228-238	85
1915	Development. Deconstructing pluripotency. **2008**, 320, 58-9	12
1914	Generation of mouse induced pluripotent stem cells without viral vectors. **2008**, 322, 949-53	1595
1913	DNA packaging via combinative self-assembly. **2008**, 4, 515-7	2
1912	Embryonic stem cell transplantation: promise and progress in the treatment of heart disease. **2008**, 22, 361-74	27
1911	Activation of antigen-specific cytotoxic T lymphocytes by beta 2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells. **2008**, 181, 6635-43	23
1910	Cardiomyocytes from embryonic stem cells: towards human therapy. **2008**, 8, 1473-83	5
1909	Cardiogenic differentiation and transdifferentiation of progenitor cells. **2008**, 103, 1058-71	127
1908	Evolving concepts in liver tissue modeling and implications for in vitro toxicology. **2008**, 4, 1279-94	109
1907	Animal eggs for stem cell research: a path not worth taking. **2008**, 8, 18-32	27

1906	Reproductive Technologies and Related Studies in the Cynomolgus Monkey. **2008**, 25, 133-142	
1905	In vitro production of transfusable red blood cells. **2008**, 25, 187-201	6
1904	A brief definition of regenerative medicine. **2008**, 3, 1-5	466
1903	Generation of insulin-secreting islet-like clusters from human skin fibroblasts. **2008**, 283, 31601-7	278
1902	Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. **2008**, 118, 498-506	424
1901	Stem Cells through Stem Beliefs: The Co-production of Biotechnological Pluralism. **2008**, 17, 435-448	12
1900	Extensive genomic copy number variation in embryonic stem cells. **2008**, 105, 17453-6	64
1899	The road to pluripotence: the research response to the embryonic stem cell debate. **2008**, 17, R3-9	11
1898	Epigenetic regulation of stem cell fate. **2008**, 17, R28-36	114
1897	Glycan stem-cell markers are specifically expressed by spermatogonia in the adult non-human primate testis. **2008**, 23, 2292-8	30
1896	The WNT receptor FZD7 contributes to self-renewal signaling of human embryonic stem cells. **2008** , 389, 897-903	45
1895	Gene expression profiling of human mesenchymal stem cells for identification of novel markers in early- and late-stage cell culture. **2008**, 144, 399-408	44
1894	Stem Cell Technologies 1998–2008: Controversies and Silences. **2008**, 17, 351-362	25
1893	Fearing a non-existing Minotaur? The ethical challenges of research on cytoplasmic hybrid embryos. **2008**, 34, 821-5	12
1892	Highlight: self-renewal signaling in stem cells. **2008**, 389, 787	
1891	Epigenetic reprogramming in embryonic and foetal development upon somatic cell nuclear transfer cloning. **2008**, 135, 151-63	174
1890	Adherent self-renewable human embryonic stem cell-derived neural stem cell line: functional engraftment in experimental stroke model. **2008**, 3, 275-279	
1889	Human embryonic stem cells: the real challenge for research as well as for bioethics is still ahead of us. **2008**, 187, 250-6	17

1888	Nature versus nurture in cardiac conduction: toward integrative paradigm of cardiac tissue engineering. **2008**, 103, 119-21	2
1887	Breaches in good regulatory practice the HFEA policy on compensated egg sharing for stem cell research. **2008**, 3, 20-24	3
1886	Generation of isogenic pluripotent stem cells. **2008**, 17, R37-41	30
1885	Of germ cells, trophoblasts, and cancer stem cells. **2008**, 7, 276-81	12
1884	Oct25 represses transcription of nodal/activin target genes by interaction with signal transducers during Xenopus gastrulation. **2008**, 283, 34168-77	34
1883	Generation of transducible versions of transcription factors Oct4 and Sox2. **2008**, 389, 851-61	60
1882	The Regulation of Embryo and Stem Cell Research in Australia: Licensing with a Restrictive Tilt. **2008**, 5,	1
1881	Plasticity after allogeneic hematopoietic stem cell transplantation. **2008**, 389, 825-36	23
1880	Connexin 40 promoter-based enrichment of embryonic stem cell-derived cardiovascular progenitor cells. **2008**, 188, 62-9	6
1879	Stem Cell Stories 1998–2008. **2008**, 17, 1-11	27
1878	Understanding the cardiovascular actions of soy isoflavones: potential novel targets for antihypertensive drug development. **2008**, 8, 297-312	28
1877	Molecular framework underlying pluripotency. **2008**, 7, 885-91	45
1876	Stem cells: what can we learn from flies?. **2008**, 2, 19-28	6
1875	Assessment of the developmental competence of human somatic cell nuclear transfer embryos by oocyte morphology classification. **2009**, 24, 649-57	31
1874	Frontiers in the surgical treatment of Parkinson's disease. **2008**, 8, 897-906	9
1873	X-ray microtomographic imaging of three-dimensional structure of soft tissues. **2008**, 14, 359-63	27
1872	Bringing together clinical embryology and basic reproduction around human cloning. **2008**, 23, 2875-6	1
1871	Multipotent hair follicle stem cells promote repair of spinal cord injury and recovery of walking function. **2008**, 7, 1865-9	131

1870	2007: signaling breakthroughs of the year. **2008**, 1, eg1	1
1869	Regenerative medicine: clinical relevance, implications and limitations of the stem cell-based therapies. **2008**, 7, 3292-3	3
1868	Mechanisms of MYC stabilization in human malignancies. **2008**, 7, 592-6	115
1867	Epigenetic Basis for the Differentiation Potential of Mesenchymal and Embryonic Stem Cells. **2008**, 35, 205-215	20
1866	Cell therapy for age-related disorders: myocardial infarction and stroke--a mini-review. **2008**, 54, 300-11	14
1865	Differential interaction of retroviral vector with target cell: quantitative effect of cellular receptor, soluble proteoglycan, and cell type on gene delivery efficiency. **2008**, 14, 1497-506	
1864	Use of xenofree matrices and molecularly-defined media to control human embryonic stem cell pluripotency: effect of low physiological TGF-beta concentrations. **2008**, 17, 519-33	23
1863	Get with the (re)program: cardiovascular potential of skin-derived induced pluripotent stem cells. **2008**, 118, 472-5	14
1862	Recent advances in cardiovascular regenerative medicine: the induced pluripotent stem cell era. **2008**, 6, 803-10	28
1861	Reprogramming of somatic cell identity. **2008**, 73, 147-55	30
1860	Reprogramming and differentiation in mammals: motifs and mechanisms. **2008**, 73, 33-8	21
1859	Pluripotency and nuclear reprogramming. **2008**, 363, 2079-87	118
1858	Myc's broad reach. **2008**, 22, 2755-66	698
1857	Can patient-specific stem cell therapy enhance renal repair?. **2008**, 23, 1826-30	1
1856	Human ESC-derived neural rosettes and neural stem cell progression. **2008**, 73, 377-87	79
1855	Stem cells for ALS. **2008**, 1, 695-695	
1854	PU.1 and C/EBPalpha/beta convert fibroblasts into macrophage-like cells. **2008**, 105, 6057-62	270
1853	Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells. **2008**, 105, 19756-61	148

1852	Generation of human induced pluripotent stem cells from dermal fibroblasts. **2008**, 105, 2883-8	857
1851	Nuclear reprogramming in cells. **2008**, 322, 1811-5	249
1850	Kruppel-like factor 4 is essential for inflammatory monocyte differentiation in vivo. **2008**, 180, 5645-52	157
1849	Highly efficient transient gene expression and gene targeting in primate embryonic stem cells with helper-dependent adenoviral vectors. **2008**, 105, 13781-6	99
1848	Skin and hair: models for exploring organ regeneration. **2008**, 17, R54-9	31
1847	Multiple layers of molecular controls modulate self-renewal and neuronal lineage specification of embryonic stem cells. **2008**, 17, R67-75	13
1846	Heterokaryon-based reprogramming of human B lymphocytes for pluripotency requires Oct4 but not Sox2. **2008**, 4, e1000170	103
1845	Induced Pluripotent Stem Cells (iPSC)--can direct delivery of transcription factors into the cytosol overcome the perils of permanent genetic modification?. **2008**, 17, 326-7; author reply 328	4
1844	Isolation of an embryogenic line from non-embryogenic Brassica napus cv. Westar through microspore embryogenesis. **2008**, 59, 2857-73	40
1843	The ethics of stem cell research: can the disagreements be resolved?. **2008**, 34, 831-2	1
1842	Effects of extracellular matrixes and growth factors on the hepatic differentiation of human embryonic stem cells. **2008**, 295, G313-21	67
1841	Extracting sequence features to predict protein-DNA interactions: a comparative study. **2008**, 36, 4137-48	39
1840	Understanding pluripotency--how embryonic stem cells keep their options open. **2008**, 14, 513-20	14
1839	Stem cell engineering for the treatment of severe hemoglobinopathies. **2008**, 8, 690-7	22
1838	Human papillomavirus type 16 E7 oncoprotein associates with E2F6. **2008**, 82, 8695-705	92
1837	Hsp90 affecting chromatin remodeling might explain transgenerational epigenetic inheritance in Drosophila. **2008**, 9, 500-8	63
1836	Seminal discoveries in regenerative medicine: contributions of the male germ line to understanding pluripotency. **2008**, 17, R16-22	6
1835	The management of heart failure: the past, the present, and the future. **2008**, 1, 58-62	25

1834	Algorithms and complexity analyses for control of singleton attractors in Boolean networks. **2008**, 521407	7
1833	Minimally invasive stem cell therapy. **2008**, 17, 59-60	
1832	The physiological basis of intracrine stem cell regulation. **2008**, 295, H447-53	14
1831	Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. **2008**, 17, 2507-17	55
1830	Global mapping of DNA methylation in mouse promoters reveals epigenetic reprogramming of pluripotency genes. **2008**, 4, e1000116	279
1829	Canine embryo-derived stem cells and models for human diseases. **2008**, 17, R42-7	42
1828	Human neural crest cells display molecular and phenotypic hallmarks of stem cells. **2008**, 17, 3411-25	79
1827	Fertility preservation techniques: laboratory and clinical progress and current issues. **2008**, 136, 667-9	13
1826	Placental rescue reveals a sole requirement for c-Myc in embryonic erythroblast survival and hematopoietic stem cell function. **2008**, 135, 2455-65	62
1825	Reproductive cloning in humans and therapeutic cloning in primates: is the ethical debate catching up with the recent scientific advances?. **2008**, 34, e15	2
1824	Genetic enhancement of stem cell engraftment, survival, and efficacy. **2008**, 102, 1471-82	119
1823	SUMOylation regulates nuclear localization of Krüppel-like factor 5. **2008**, 283, 31991-2002	69
1822	Cell-free embryonic stem cell extract-mediated derivation of multipotent stem cells from NIH3T3 fibroblasts for functional and anatomical ischemic tissue repair. **2008**, 102, e107-17	58
1821	Pluripotent stem cell lines. **2008**, 22, 1987-97	265
1820	Role of mir-302 MicroRNA Family in Stem Cell Pluripotency and Renewal. **2008**, 167-185	5
1819	Embryo as epiphenomenon: some cultural, social and economic forces driving the stem cell debate. **2008**, 34, 840-4	3
1818	Adam's fibroblast? The (pluri)potential of iPCs. **2008**, 34, 64-6	6
1817	Molecular basis of pluripotency. **2008**, 17, R23-7	94

1816	Cell-based therapies for skeletal regenerative medicine. **2008**, 17, R93-8	53
1815	Cellular repair of CNS disorders: an immunological perspective. **2008**, 17, R84-92	46
1814	Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. **2008**, 22, 3282-91	247
1813	Modelling germ cell development in vitro. **2008**, 14, 501-11	22
1812	Identity, developmental restriction and reactivity of extralaminar cells capping mammalian neuromuscular junctions. **2008**, 121, 3901-11	51
1811	Stem cells bioprocessing: an important milestone to move regenerative medicine research into the clinical arena. **2008**, 63, 461-6	24
1810	Lung vascular cell heterogeneity: endothelium, smooth muscle, and fibroblasts. **2008**, 5, 783-91	72
1809	The need for a regen industry voice. **2008**, 3, 621-31	10
1808	Embryonic stem cells as a source of pulmonary epithelium in vitro and in vivo. **2008**, 5, 717-22	37
1807	Stem cells for kidney repair: useful tool for acute renal failure?. **2008**, 74, 847-9	23
1806	Human embryonic stem cells: a potential source of transplantable neural progenitor cells. **2008**, 24, E3	14
1805	Breathtaking advances in stem cell biology. **2008**, 4, 57	
1804	Human Embryonic Stem Cells: Derivation and Culture. **2008**, 63-82	
1803	The strong financial case for regenerative medicine and the regen industry. **2008**, 3, 351-63	26
1802	Faith, heresy and the cancer stem cell hypothesis. **2008**, 4, 585-9	13
1801	Cellular therapy for childhood neurodegenerative disease. Part II: clinical trial design and implementation. **2008**, 24, E23	18
1800	Generation of embryonic stem cells: limitations of and alternatives to inner cell mass harvest. **2008**, 24, E4	10
1799	Stem cells for heart cell therapies. **2008**, 14, 393-406	62

1798	Stem cell therapy for heart failure: the science and current progress. **2008**, 4, 285-98	6
1797	Potential of embryonic stem cells for in vivo bone regeneration. **2008**, 3, 783-5	7
1796	Identifying genetic components of drug response in mice. **2008**, 9, 1323-30	2
1795	Stem cells and cell therapies in lung biology and lung diseases. **2008**, 5, 637-67	142
1794	Cellular therapy for childhood neurodegenerative disease. Part I: rationale and preclinical studies. **2008**, 24, E22	18
1793	Stem Cell Research and Health Education. **2008**, 39, 167-179	4
1792	Mir-302 reprograms human skin cancer cells into a pluripotent ES-cell-like state. **2008**, 14, 2115-24	346
1791	Expression of genes involved in early cell fate decisions in human embryos and their regulation by growth factors. **2008**, 135, 635-47	72
1790	Stem cells for neuroprotection in glaucoma. **2008**, 173, 511-9	25
1789	Development of single mouse blastomeres into blastocysts, outgrowths and the establishment of embryonic stem cells. **2008**, 135, 805-13	37
1788	Liver cancer stem cells. **2008**, 26, 2800-5	185
1787	Generation of germline-competent induced pluripotent stem cells. **2008**, 2008, 299-300	
1786	Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells. **2008**, 2008, 301-302	
1785	Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. **2008**, 2008, 302-303	
1784	Potential strategies for myocardial regeneration in pediatric patients. **2008**, 2, 503-516	2
1783	A Brief Introduction to Different Cell Types. **2008**, 15-41	
1782	Stammzelltherapie. **2008**, 56, 301-304	
1781	What's new in orthopaedic research. **2008**, 90, 1800-8	7

1780	Future Cell- and Gene-Based Therapies for Parkinson's Disease. **2008**, 145-156	
1779	Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35. **2008**, 31, 1819-25	11
1778	Cardiac regenerative medicine. **2008**, 72 Suppl A, A49-55	20
1777	Gene replacement therapy for sickle cell disease and other blood disorders. **2008**, 193-6	19
1776	Tyrosine kinase signalling in embryonic stem cells. **2008**, 115, 43-55	27
1775	Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. **2008**, 111, 5298-306	245
1774	SALL4 is a key regulator of survival and apoptosis in human leukemic cells. **2008**, 112, 805-13	108
1773	Biologic properties and enucleation of red blood cells from human embryonic stem cells. **2008**, 112, 4475-84	235
1772	Study on Human Embryonic Stem Cells and IPS Stem Cells. **2008**, 97, 1341-1347	
1771	Inflammation and stem cells in gastrointestinal carcinogenesis. **2008**, 23, 350-9	50
1770	Mouse induced pluripotent stem cells. **2008**, 52, 1015-22	16
1769	Towards the genetic treatment of beta-thalassemia: new disease models, new vectors, new cells. **2008**, 93, 325-30	8
1768	[Cell therapy in cartilage repair: cellular and molecular bases]. **2008**, 202, 313-21	2
1767	Looking into the future of cell-based therapy. **2008**, 101, 79-82	2
1766	In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. **2008**, 2008, 300-301	
1765	Biology of Mesenchymal Stem Cells. **2008**, 4, 148-154	2
1764	Stem cell based therapy for skeletal muscle diseases. **2008**, 3, 219-28	17
1763	New paths to pluripotent stem cells. **2008**, 3, 151-62	18

1762	Researchers Clone First Embryonic Fibroblasts from Adult Skin Cells. **2008**, 8, 1	
1761	Suggested ethical guidelines and legislation for egg donation in Singapore. **2008**, 3, 181-188	
1760	Pluripotential Stem Cells From Mature Human Somatic Cells. **2008**, 19, 1713-1714	
1759	Mapping key features of transcriptional regulatory circuitry in embryonic stem cells. **2008**, 73, 183-93	32
1758	Directed differentiation of pluripotent stem cells: from developmental biology to therapeutic applications. **2008**, 73, 101-10	61
1757	Another Breathtaking Stem Cell Advance. **2008**, 19, 1713	
1756	Computational Modeling Approaches for Studying of Synthetic Biological Networks. **2008**, 3, 130-141	4
1755	Adult and Embryonic Stem Cell Therapy. **2008**, 373-384	
1754	Cellular Therapy for Cardiovascular Disease Part 1 - Preclinical Insights. **2008**, 2, CMC.S571	
1753	?1? HLA??????????????????????????. **2008**, 15, 51-60	
1752	??????????????. **2008**, 46, 531-538	
1751	Regenerative Biology and Medicine. **2008**, 3, 477-482	
1750	Stem cells: new frontiers of ethics, law, and policy. **2008**, 24, E24	10
1749	Regenerative medicine: the next frontier. **2008**, 86, 206-7	6
1748	Oligodendrocyte differentiation and implantation: new insights for remyelinating cell therapy. **2008**, 21, 607-14	40
1747	Pathways to New ´Cells. **2008**, 73, 175-181	14
1746	Differentiation of embryonic stem cells towards hematopoietic cells: progress and pitfalls. **2008**, 15, 312-8	18
1745	Advances in science and technology: impact on craniofacial surgery. **2008**, 19, 1136-9	3

1744	Stem cell factors in plants: chromatin connections. **2008**, 73, 235-42	8
1743	Advances in stroke regenerative medicine 2007. **2008**, 39, 273-5	8
1742	Regeneration and adult stem cells in the human female reproductive tract. **2008**, 1, 23-9	7
1741	Stem cell therapy to treat diabetes mellitus. **2008**, 5, 203-19	14
1740	[Stem cells, time for scale-up]. **2008**, 24, 335-7	1
1739	Cell therapy for cardiovascular diseases. **2008**, 1, 66-79	2
1738	Establishment of mouse induced pluripotent stem cells selected for Nanog expression. **2008**, 28, 96-99	1
1737	Reproducible, ultra high-throughput formation of multicellular organization from single cell suspension-derived human embryonic stem cell aggregates. **2008**, 3, e1565	329
1736	Dorsomorphin, a selective small molecule inhibitor of BMP signaling, promotes cardiomyogenesis in embryonic stem cells. **2008**, 3, e2904	177
1735	The Rho-Rock-Myosin signaling axis determines cell-cell integrity of self-renewing pluripotent stem cells. **2008**, 3, e3001	123
1734	Evolutionarily conserved transcriptional co-expression guiding embryonic stem cell differentiation. **2008**, 3, e3406	39
1733	A computational model for understanding stem cell, trophectoderm and endoderm lineage determination. **2008**, 3, e3478	107
1732	c-Myc is required for maintenance of glioma cancer stem cells. **2008**, 3, e3769	295
1731	The controversial clinicobiological role of breast cancer stem cells. **2008**, 2008, 492643	5
1730	Regenerative Medicine for Cardiovascular Disease. **2008**, 54, 441-446	
1729	Personalizing pluripotency. **2008**,	
1728	Smash the (Cell) State!. **2008**,	
1727	Adult monkey cells reprogrammed. **2008**,	

1726	CIRM's stance after pluripotency. **2008**,	
1725	More induced pluripotency. **2008**,	
1724	Embryonic Stem Cells 2.0. **2008**,	3
1723	[Human reprogrammed iPS cells: so fast]. **2008**, 24, 102-4	1
1722	Epigenetic modifications of embryonic stem cells: current trends and relevance in developing regenerative medicine. **2008**, 1, 11-21	5
1721	The stem-cell century a new epoch and fresh challenges. **2009**, 52, 126-33	
1720	Opening The Mesenchymal Stem Cell Tool Box. **2009**, 03, 240-249	12
1719	. **2009**,	3
1718	Ethical aspects of stem cell therapy and gene therapy. 123-130	
1717	The LIF cytokine: towards adulthood. **2009**, 20, 51-62	29
1716	Automated selection and collection of pluripotent stem cell colonies using the CellCelector **2009**, 6, iii-iv	4
1715	Induced pluripotent stem cells: advances to applications. **2010**, 3, 29-37	13
1714	Adult stem cells and repair through granulation tissue. **2009**, 14, 1433-70	24
1713	Induced pluripotent stem cells, new tools for drug discovery and new hope for stem cell therapies. **2009**, 2, 15-8	17
1712	Cancer Stem Cells. **2009**, 467-483	0
1711	Emerging molecular approaches in stem cell biology. **2009**, 46, 367-71	0
1710	[Embryonic stem cells in pharmacology]. **2009**, 25 Spec No 2, 32-8	3
1709	Specification of the germ cell lineage in mice. **2009**, 14, 1068-87	25

1708	PROPOSALS FOR EMBRYONIC STEM CELL PRODUCTION WITHOUT DESTROYING HUMAN EMBRYOS: SCIENTIFIC AND BIOETHICAL CHALLENGES. **2009**, 15,	
1707	Lentiviral vectors and protocols for creation of stable hESC lines for fluorescent tracking and drug resistance selection of cardiomyocytes. **2009**, 4, e5046	184
1706	Germline-competent mouse-induced pluripotent stem cell lines generated on human fibroblasts without exogenous leukemia inhibitory factor. **2009**, 4, e6724	27
1705	MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy. **2009**, 4, e6810	55
1704	Two factor reprogramming of human neural stem cells into pluripotency. **2009**, 4, e7044	54
1703	Enhanced generation of induced pluripotent stem cells from a subpopulation of human fibroblasts. **2009**, 4, e7118	62
1702	Regulation of adipose tissue stromal cells behaviors by endogenic Oct4 expression control. **2009**, 4, e7166	45
1701	G(i)-coupled GPCR signaling controls the formation and organization of human pluripotent colonies. **2009**, 4, e7780	24
1700	State of the stem cell. **2009**,	
1699	What does reprogramming do?. **2009**,	
1698	Melanoma cancer stem cells. 31-48	
1697	Stem cell-based models and therapies for neurodegenerative diseases. **2009**, 37, 321-53	12
1696	Embryonic and induced pluripotent stem cells as a model for liver disease. **2009**, 37, 377-98	8
1695	Stem cells for skin tissue engineering and wound healing. **2009**, 37, 399-421	110
1694	Gene expression in stem cells. **2009**, 19, 289-300	9
1693	Systems level analysis of transgenerational spermatogenic inheritance predicts biomarkers and underlying pathways. **2009**,	
1692	Foetal germ cells: striking the balance between pluripotency and differentiation. **2009**, 53, 393-409	35
1691	Dynamic epigenetic regulation of the Oct4 and Nanog regulatory regions during neural differentiation in rhesus nuclear transfer embryonic stem cells. **2009**, 11, 483-96	18

1690	Novel culture system of mesenchymal stromal cells from human subcutaneous adipose tissue. **2009** , 18, 533-43	43
1689	Induction and isolation of vascular cells from human induced pluripotent stem cells--brief report. **2009**, 29, 1100-3	162
1688	Embryonic stem cells, nuclear transfer and parthenogenesis-derived stem cells for urological reconstruction. **2009**, 357-377	
1687	The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. **2009**, 8, 3274-84	613
1686	Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells. **2009**, 122, 3502-10	264
1685	Leukemia inhibitory factor secretion is a predictor and indicator of early progenitor status in adult bone marrow stromal cells. **2009**, 15, 33-44	21
1684	Potential application of adult stem cells in retinal repair--challenge for regenerative medicine. **2009** , 34, 748-60	24
1683	Pluripotent stem cells derived from adult human testes. **2009**, 18, 1115-26	177
1682	Ensemble stimulation of embryoid bodies using microfabricated ITO substrates. **2009**, 2009, 5993-6	1
1681	Integration-deficient lentiviral vectors: a slow coming of age. **2009**, 17, 1316-32	154
1680	Induced pluripotent stem cells offer new approach to therapy in thalassemia and sickle cell anemia and option in prenatal diagnosis in genetic diseases. **2009**, 106, 9826-30	183
1679	Cardiac repair and regeneration: the Rubik's cube of cell therapy for heart disease. **2009**, 2, 344-58	70
1678	Molecular Bases of Pluripotency. **2009**, 37-60	2
1677	Direct Reprogramming of Somatic Cells to a Pluripotent State. **2009**, 29-31	
1676	Why Stem Cell Research. **2009**, xix	1
1675	Embryonic Stem Cells in Perspective. **2009**, 13-15	
1674	Identification of differentially expressed genes between cloned and zygote-developing zebrafish (Danio rerio) embryos at the dome stage using suppression subtractive hybridization. **2009**, 80, 674-84	20
1673	Generation of induced pluripotent stem cells from human blood. **2009**, 113, 5476-9	492

1672	Review paper: cancer stem cells and cancer nonstem cells: from adult stem cells or from reprogramming of differentiated somatic cells. **2009**, 46, 176-93	69
1671	Human embryonic stem cells and genomic instability. **2009**, 4, 899-909	36
1670	A simple and efficient cryopreservation method for feeder-free dissociated human induced pluripotent stem cells and human embryonic stem cells. **2009**, 24, 2468-76	83
1669	Markers that define stemness in ESC are unable to identify the totipotent cells in human preimplantation embryos. **2009**, 24, 63-70	72
1668	Integer programming-based methods for attractor detection and control of boolean networks. **2009**,	5
1667	Skeletal and cardiac myogenesis accompany adipogenesis in P19 embryonal stem cells. **2009**, 18, 1023-32	12
1666	Cell therapies for therapeutic angiogenesis: back to the bench. **2009**, 14, 153-66	95
1665	Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. **2009**, 69, 4116-24	674
1664	Derivation of induced pluripotent stem cells from pig somatic cells. **2009**, 106, 10993-8	381
1663	Cellular repair strategies in Parkinson's disease. **2009**, 2, 51-60	11
1662	Cryopreservation of early postmitotic neuronal cells in culture. **2009**, 19, 265-8	4
1661	Embryonic stem cells: isolation, characterization and culture. **2009**, 114, 173-84	6
1660	Instructing an embryonic stem cell-derived oocyte fate: lessons from endogenous oogenesis. **2009**, 30, 264-83	40
1659	The tumorigenicity of diploid and aneuploid human pluripotent stem cells. **2009**, 8, 3822-30	106
1658	Transcriptional changes in somatic cells recovered from embryonic stem-somatic heterokaryons. **2009**, 18, 1361-8	16
1657	Human embryonic and mesenchymal stem cells express different nuclear proteomes. **2009**, 18, 793-802	14
1656	Immortalized human skin fibroblast feeder cells support growth and maintenance of both human embryonic and induced pluripotent stem cells. **2009**, 24, 2567-81	67
1655	Fatty tissue: not all bad? Optimally cultured adipose tissue-derived stromal cells improve experimentally-induced ischemia. **2009**, 18, 531-2	3

1654	Potential use of endothelial progenitor cells for regeneration of the vasculature. **2009**, 3, 17-27	33
1653	Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. **2009**, 106, 808-13	210
1652	EKLF/KLF1 controls cell cycle entry via direct regulation of E2f2. **2009**, 284, 20966-74	53
1651	Feeder-free derivation of induced pluripotent stem cells from adult human adipose stem cells. **2009**, 106, 15720-5	421
1650	Modeling early retinal development with human embryonic and induced pluripotent stem cells. **2009**, 106, 16698-703	477
1649	Lentiviral delivery of LMX1a enhances dopaminergic phenotype in differentiated human bone marrow mesenchymal stem cells. **2009**, 18, 591-601	52
1648	Transformed Human Brain Cells in Culture as a Model for Brain Tumors. **2009**, 163-180	1
1647	The potential of embryonic stem cells combined with -omics technologies as model systems for toxicology. **2009**, 16, 4814-27	35
1646	Nuclear receptor regulation of stemness and stem cell differentiation. **2009**, 41, 525-37	54
1645	Vascular regeneration: engineering the stem cell microenvironment. **2009**, 4, 435-47	17
1644	Cardiomyocyte differentiation of human induced pluripotent stem cells. **2009**, 120, 1513-23	332
1643	Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. **2009**, 8, 843-52	354
1642	Stem Cells in Human Reproduction. **2009**,	
1641	Regeneration of central nervous tissue using a collagen scaffold and adipose-derived stromal cells. **2009**, 190, 326-35	21
1640	Induced human pluripotent stem cells: promises and open questions. **2009**, 390, 845-9	33
1639	Activin/Nodal signalling maintains pluripotency by controlling Nanog expression. **2009**, 136, 1339-49	317
1638	Neuroscience. Nuclear power for axonal growth. **2009**, 326, 238-9	4
1637	Transcriptional competence and the active marking of tissue-specific enhancers by defined transcription factors in embryonic and induced pluripotent stem cells. **2009**, 23, 2824-38	145

1636	Fabrication of biodegradable scaffold by powder sintering process. **2009**,	
1635	Stable isotope labeling by amino acids in cell culture (SILAC) and quantitative comparison of the membrane proteomes of self-renewing and differentiating human embryonic stem cells. **2009**, 8, 959-70	98
1634	Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. **2009**, 114, 1461-8	115
1633	Methods to Generate Transgenic Animals. **2009**, 31-48	3
1632	Role of DNA Methylation and Epigenetics in Stem Cells. **2009**, 269-276	1
1631	The use of stem cells in kidney disease. **2009**, 14, 72-8	34
1630	Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors. **2009**, 119, 2818-29	153
1629	Comparative methylation profiles and telomerase biology of mouse multipotent adult germline stem cells and embryonic stem cells. **2009**, 15, 345-53	36
1628	High-throughput chromatin information enables accurate tissue-specific prediction of transcription factor binding sites. **2009**, 37, 14-25	46
1627	Protocols for generating ES cell-derived dopamine neurons. **2009**, 651, 101-11	16
1626	Acting locally and globally: Myc's ever-expanding roles on chromatin. **2009**, 69, 7487-90	42
1625	Physiological differences between transplanted and host tissue cause functional decoupling after in vitro transplantation of human embryonic stem cell-derived cardiomyocytes. **2009**, 23, 65-74	14
1624	Engineering craniofacial structures: facing the challenge. **2009**, 88, 1077-91	77
1623	Stem cell biology meets systems biology. **2009**, 136, 3525-30	17
1622	Remuscularizing failing hearts with tissue engineered myocardium. **2009**, 11, 2011-23	23
1621	Optical mapping of impulse propagation in engineered cardiac tissue. **2009**, 15, 851-60	47
1620	Development of serum-free, chemically defined conditions for human embryonic stem cell-derived fibrochondrogenesis. **2009**, 15, 2249-57	19
1619	Identifying needs and opportunities for advancing translational research in cardiovascular disease. **2009**, 83, 425-35	20

1618	A novel embryonic stem cell line derived from the common marmoset monkey (Callithrix jacchus) exhibiting germ cell-like characteristics. **2009**, 24, 1359-72	57
1617	Cell therapy for myocardial regeneration. **2009**, 9, 287-98	16
1616	Moral complicity in induced pluripotent stem cell research. **2009**, 19, 1-22	12
1615	Pressing forward in the hurdles race towards stem cell based therapies. **2009**, 8, 2865-2868	
1614	The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells. **2009**, 8, 2186-93	21
1613	Selective sensitization of cancer cells to DNA damage by a HAT inhibitor. **2009**, 8, 2865-2868	1
1612	Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis?. **2009**, 8, 1148-57	46
1611	Change in gene expression of mouse embryonic stem cells derived from parthenogenetic activation. **2009**, 24, 805-14	19
1610	The roads to tumor starvation. **2009**, 8, 2865-2868	
1609	Neural relay from the liver induces proliferation of pancreatic beta cells: a path to regenerative medicine using the self-renewal capabilities. **2009**, 2, 425-7	3
1608	Transcription factors and neural stem cell self-renewal, growth and differentiation. **2009**, 3, 412-24	38
1607	Effects of N-cadherin overexpression on the adhesion properties of embryonic stem cells. **2009**, 3, 305-10	10
1606	The HFEA public consultation process on hybrids and chimeras: informed, effective, and meaningful?. **2009**, 19, 41-62	7
1605	Potential role of dental stem cells in the cellular therapy of cerebral ischemia. **2009**, 15, 3908-16	42
1604	Embryonic stem cell microRNAs: defining factors in induced pluripotent (iPS) and cancer (CSC) stem cells?. **2009**, 4, 168-77	69
1603	Generation of T cells from human embryonic stem cell-derived hematopoietic zones. **2009**, 182, 6879-88	151
1602	Genetic animal models for schizophrenia: advantages and limitations of genetic manipulation in drosophila, zebrafish, rodents, and primates. **2009**, 179, 3-6	6
1601	DERIVATION AND THERAPEUTIC POTENTIALS OF INDUCED PLURIPOTENT STEM CELLS. **2009**, 04, 81-104	

1600	Human Papillomaviruses and Associated Malignancies. **2009**, 137-207	
1599	Multiple genes exhibit phenobarbital-induced constitutive active/androstane receptor-mediated DNA methylation changes during liver tumorigenesis and in liver tumors. **2009**, 108, 273-89	31
1598	Controllable expansion of primary cardiomyocytes by reversible immortalization. **2009**, 20, 1687-96	20
1597	Regulation of adult hematopoietic stem cells fate for enhanced tissue-specific repair. **2009**, 17, 1594-604	27
1596	Pig induced pluripotent stem cells: a new resource for generating genetically modified pigs. **2009**, 4, 787-9	13
1595	Stem cell and gene therapeutic strategies for the treatment of multiple sclerosis. **2009**, 9, 992-1016	13
1594	A highly stable and nonintegrated human artificial chromosome (HAC) containing the 2.4 Mb entire human dystrophin gene. **2009**, 17, 309-17	88
1593	Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. **2009**, 17, 570-5	53
1592	Upping the ante: recent advances in direct reprogramming. **2009**, 17, 947-53	56
1591	Induction of stem cell gene expression in adult human fibroblasts without transgenes. **2009**, 11, 417-26	66
1590	Stem and progenitor cells for liver repopulation: can we standardise the process from bench to bedside?. **2009**, 58, 594-603	87
1589	Myocardial interstitial fluid inhibits proliferation and cardiomyocyte differentiation in pluripotent embryonic stem cells. **2009**, 297, H1369-76	1
1588	The C-terminal pentapeptide of Nanog tryptophan repeat domain interacts with Nac1 and regulates stem cell proliferation but not pluripotency. **2009**, 284, 16071-16081	21
1587	Cell-free extracts from mammalian oocytes partially induce nuclear reprogramming in somatic cells. **2009**, 80, 935-43	63
1586	Simultaneous overexpression of Oct4 and Nanog abrogates terminal myogenesis. **2009**, 297, C43-54	32
1585	On the road to iPS cell cardiovascular applications. **2009**, 105, 617-9	31
1584	Cellular cardiomyoplasty: what have we learned?. **2009**, 17, 89-101	13
1583	Cell-based therapeutic approaches for Parkinson's disease: progress and perspectives. **2009**, 20, 347-81	15

1582	Articular Cartilage Tissue Engineering. **2009**, 1, 1-182	34
1581	Germ CellSpecific Methylation Pattern: Erasure and Reestablishment. **2009**, 43-56	
1580	Improved coinfection with amphotropic pseudotyped retroviral vectors. **2009**, 2009, 901079	11
1579	Putative tumor-suppressive function of Kruppel-like factor 4 in primary lung carcinoma. **2009**, 15, 5688-95	100
1578	Stem cells are not proarrhythmic: letting the genie out of the bottle. **2009**, 119, 1824-31	32
1577	Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation. **2009**, 106, 12759-64	222
1576	Inhibition of caspase-mediated anoikis is critical for basic fibroblast growth factor-sustained culture of human pluripotent stem cells. **2009**, 284, 34054-64	54
1575	Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. **2009**, 18, 4340-9	146
1574	Human keratinocytes derived from the bulge region of hair follicles are refractory to differentiation. **2009**,	2
1573	Stem Cells, Hypoxia and Hypoxia-Inducible Factors. **2009**, 211-231	1
1572	Transcripts of unknown function in multiple-signaling pathways involved in human stem cell differentiation. **2009**, 37, 4987-5000	45
1571	Stem cells and tissue-engineered skin. **2009**, 22, 55-62	32
1570	European Perspectives. **2009**, 120,	
1569	Cellular reprogramming and pluripotency induction. **2009**, 90, 19-35	8
1568	Cell transplantation strategies for retinal repair. **2009**, 175, 3-21	74
1567	The emergence of lineage-specific chromosomal topologies from coordinate gene regulation. **2009** , 106, 6679-84	81
1566	Interplay of Oct4 with Sox2 and Sox17: a molecular switch from stem cell pluripotency to specifying a cardiac fate. **2009**, 186, 665-73	88
1565	Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. **2009**, 15, 6541-50	139

1564	Emerging strategies for cell and gene therapy of the muscular dystrophies. **2009**, 11, e18	56
1563	Systematic identification of cis-silenced genes by trans complementation. **2009**, 18, 835-46	12
1562	Stem cells in drug discovery, tissue engineering, and regenerative medicine: emerging opportunities and challenges. **2009**, 14, 755-68	59
1561	High-efficiency production of subculturable vascular endothelial cells from feeder-free human embryonic stem cells without cell-sorting technique. **2009**, 11, 509-22	18
1560	Xenopus oocytes reactivate muscle gene transcription in transplanted somatic nuclei independently of myogenic factors. **2009**, 136, 2695-703	17
1559	Reprogramming to a muscle fate by fusion recapitulates differentiation. **2009**, 122, 1045-53	19
1558	MicroRNA-modulated targeting of vascular smooth muscle cells. **2009**, 119, 2526-8	32
1557	Human Embryogenesis. **2009**,	
1556	Proteomics analysis of epithelial cells reprogrammed in cell-free extract. **2009**, 8, 1401-12	7
1555	Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia. **2009**, 668, 141-9	22
1554	Generation of tissue-specific cells from MSC does not require fusion or donor-to-host mitochondrial/membrane transfer. **2009**, 2, 125-38	41
1553	Teratoma formation by human embryonic stem cells: evaluation of essential parameters for future safety studies. **2009**, 2, 198-210	337
1552	Derivation of insulin-producing cells from human embryonic stem cells. **2009**, 3, 73-87	91
1551	Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. **2009**, 25, 528-35	213
1550	Human embryonic stem cells and cardiac repair. **2009**, 23, 53-68	48
1549	Very small embryonic-like stem cells in adult tissues-potential implications for aging. **2009**, 130, 58-66	41
1548	A gene expression signature shared by human mature oocytes and embryonic stem cells. **2009**, 10, 10	99
1547	In silico identification of a core regulatory network of OCT4 in human embryonic stem cells using an integrated approach. **2009**, 10, 314	39

1546	Signed weighted gene co-expression network analysis of transcriptional regulation in murine embryonic stem cells. **2009**, 10, 327	155
1545	Cardiac tissue engineering using stem cells. **2009**, 28, 80, 82, 84-6, 88-9	29
1544	Generation and properties of a new human ventral mesencephalic neural stem cell line. **2009**, 315, 1860-74	41
1543	Mesenchymal to embryonic incomplete transition of human cells by chimeric OCT4/3 (POU5F1) with physiological co-activator EWS. **2009**, 315, 2727-40	48
1542	Progenitor cell therapy for heart disease. **2009**, 315, 3077-85	54
1541	Induced pluripotent reprogramming from promiscuous human stemness related factors. **2009**, 2, 118-26	28
1540	Stem cell platforms for regenerative medicine. **2009**, 2, 222-7	65
1539	Cartilage repair: past and future--lessons for regenerative medicine. **2009**, 13, 792-810	116
1538	The immune boundaries for stem cell based therapies: problems and prospective solutions. **2009**, 13, 1464-75	31
1537	Stem cells, pluripotency and nuclear reprogramming. **2009**, 7 Suppl 1, 21-3	13
1536	Results of gal-knockout porcine thymokidney xenografts. **2009**, 9, 2669-78	79
1535	High-content screening of primary neurons: ready for prime time. **2009**, 19, 537-43	44
1534	Tgfbeta signal inhibition cooperates in the induction of iPSCs and replaces Sox2 and cMyc. **2009**, 19, 1718-23	295
1533	Glutamatergic stimulation triggers rapid Krüppel-like factor 4 expression in neurons and the overexpression of KLF4 sensitizes neurons to NMDA-induced caspase-3 activity. **2009**, 1250, 49-62	21
1532	Bone marrow engraftment but limited expansion of hematopoietic cells from multipotent germline stem cells derived from neonatal mouse testis. **2009**, 37, 1400-10	20
1531	Adipogenic differentiation of human induced pluripotent stem cells: comparison with that of human embryonic stem cells. **2009**, 583, 1029-33	124
1530	Development of cystic embryoid bodies with visceral yolk-sac-like structures from mouse embryonic stem cells using low-adherence 96-well plate. **2009**, 107, 442-6	16
1529	Neuroprotective function in brain microglia. **2009**, 20, 142-147	7

1528	How to make beta cells?. **2009**, 21, 727-32	63
1527	Distinct response in maintenance of human naive and memory B cells via IL-21 receptor and TCL1/Akt pathways. **2009**, 256, 56-63	6
1526	T lineage differentiation from induced pluripotent stem cells. **2009**, 260, 1-5	41
1525	Emerging concepts in neural stem cell research: autologous repair and cell-based disease modelling. **2009**, 8, 819-29	85
1524	Are Stem Cells the Magical Medical Therapy of the Future?. **2009**, 21, 12-17	
1523	Derivation Methods for Human Embryonic Stem Cells: Past, Present, and Future. 1-18	1
1522	Sleeping Beauty-Mediated Transposition in Stem Cells. 341-362	
1521	Human Embryonic Stem Cell-Derived Cardiomyocytes for Cell Therapy and Drug Discovery. 395-415	
1520	Human Embryonic Stem Cells in Drug Discovery. 417-437	1
1519	Reprogramming Developmental Potential. 51-85	1
1518	Cerebrospinal fluid of brain trauma patients inhibits in vitro neuronal network function via NMDA receptors. **2009**, 66, 546-55	12
1517	Loss of hypocretin (orexin) neurons with traumatic brain injury. **2009**, 66, 555-9	152
1516	Induced pluripotent stem cells generated without viral integration. **2009**, 49, 1048-9	11
1515	The reprogramming factors of human somatic cells are novel targets for human hepatocellular carcinoma therapy. **2009**, 50, 2046; author reply 2046-7	3
1514	Differentiation therapy with transcription factors might present as an ideal strategy for the treatment of cancer. **2009**, 50, 2046-2047	6
1513	What is the relationship among microRNA-181, epithelial cell-adhesion molecule (EpCAM) and beta-catenin in hepatic cancer stem cells. **2009**, 50, 2047-8; author reply 448	5
1512	Stem cells for ischemic brain injury: a critical review. **2009**, 515, 125-44	175
1511	Novel perspectives of neural stem cell differentiation: from neurotransmitters to therapeutics. **2009**, 75, 38-53	74

1510	Pleiotropic function of FGF-4: its role in development and stem cells. **2009**, 238, 265-76	30
1509	Brain-specific 1B promoter of FGF1 gene facilitates the isolation of neural stem/progenitor cells with self-renewal and multipotent capacities. **2009**, 238, 302-14	38
1508	Pericellular matrix of decidua-derived mesenchymal cells: a potent human-derived substrate for the maintenance culture of human ES cells. **2009**, 238, 1118-30	11
1507	Expression of stem cell pluripotency factors during regeneration in newts. **2009**, 238, 1613-6	115
1506	In vitro and in vivo differentiation of human embryonic stem cells into retina-like organs and comparison with that from mouse pluripotent epiblast stem cells. **2009**, 238, 2266-79	22
1505	Stem cell sources to treat diabetes. **2009**, 106, 507-11	59
1504	The 4th dimension and adult stem cells: Can timing be everything?. **2009**, 107, 569-78	25
1503	Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models. **2009**, 107, 592-9	76
1502	Collection and culture of alveolar bone marrow multipotent mesenchymal stromal cells from older individuals. **2009**, 107, 1198-204	21
1501	Determinants of pluripotency: from avian, rodents, to primates. **2010**, 109, 16-25	16
1500	BMP4 regulates vascular progenitor development in human embryonic stem cells through a Smad-dependent pathway. **2010**, 109, 363-74	51
1499	Human ES and iPS cells as cell sources for the treatment of Parkinson's disease: current state and problems. **2010**, 109, 292-301	28
1498	Derivation of murine induced pluripotent stem cells (iPS) and assessment of their differentiation toward osteogenic lineage. **2010**, 109, 643-52	74
1497	Pluripotency: toward a gold standard for human ES and iPS cells. **2009**, 220, 21-9	93
1496	Perspectives on human stem cell research. **2009**, 220, 535-7	15
1495	Orderly hematopoietic development of induced pluripotent stem cells via Flk-1(+) hemoangiogenic progenitors. **2009**, 221, 367-77	32
1494	Stem cell pluripotency: a cellular trait that depends on transcription factors, chromatin state and a checkpoint deficient cell cycle. **2009**, 221, 10-7	59
1493	Are induced pluripotent stem cells the future of cell-based regenerative therapies for spinal cord injury?. **2010**, 222, 515-21	42

1492	Cell-fusion-mediated somatic-cell reprogramming: a mechanism for tissue regeneration. **2010**, 223, 6-13	44
1491	Stem cell-based cell therapy in neurological diseases: a review. **2009**, 87, 2183-200	334
1490	Stromal cell-secreted factors promote the survival of embryonic stem cell-derived early neural stem/progenitor cells via the activation of MAPK and PI3K-Akt pathways. **2010**, 88, 722-34	18
1489	Dermal fibroblast-mediated BMP2 therapy to accelerate bone healing in an equine osteotomy model. **2010**, 28, 403-11	33
1488	In vivo bioluminescent imaging of Schwann cells in a poly(DL-lactide-epsilon-caprolactone) nerve guide. **2009**, 40, 867-71	2
1487	Autografts and xenografts of skin fibroblasts delivering BMP-2 effectively promote orthotopic and ectopic osteogenesis. **2009**, 292, 777-86	15
1486	ES cell extract-induced expression of pluripotent factors in somatic cells. **2009**, 292, 1229-34	20
1485	Generation of human embryonic stem cell-derived mesoderm and cardiac cells using size-specified aggregates in an oxygen-controlled bioreactor. **2009**, 102, 493-507	188
1484	Application of a cell sheet-polymer film complex with temperature sensitivity for increased mechanical strength and cell alignment capability. **2009**, 103, 370-7	33
1483	Cell-free production of transducible transcription factors for nuclear reprogramming. **2009**, 104, 1047-58	32
1482	Spermatogonial stem cells: mouse and human comparisons. **2009**, 87, 27-34	112
1481	Gene regulatory networks in embryonic stem cells and brain development. **2009**, 87, 182-91	0
1480	Epigenetic regulatory mechanisms during preimplantation development. **2009**, 87, 297-313	67
1479	Reprogramming cell fates: reconciling rarity with robustness. **2009**, 31, 546-60	221
1478	Genomic analysis of induced pluripotent stem (iPS) cells: routes to reprogramming. **2009**, 31, 134-8	6
1477	The enigmatic primitive streak: prevailing notions and challenges concerning the body axis of mammals. **2009**, 31, 892-902	36
1476	Engineering the embryoid body microenvironment to direct embryonic stem cell differentiation. **2009**, 25, 43-51	217
1475	Stem cells in microfluidics. **2009**, 25, 52-60	59

1474	Expression of osterix inhibits bone morphogenetic protein-induced chondrogenic differentiation of mesenchymal progenitor cells. **2009**, 27, 36-45	14
1473	Das Stammzellkonzept der Mamma. **2009**, 15, 609-622	
1472	Hepatic stem/progenitor cells and stem-cell transplantation for the treatment of liver disease. **2009**, 44, 167-72	53
1471	Strategies for future histocompatible stem cell therapy. **2009**, 10, 339-76	10
1470	Zellersatztherapie am Herzen: Fiktion oder reale Möglichkeit. **2009**, 23, 170-176	
1469	Mesenchymale Stammzellen zur kardialen Regeneration. **2009**, 23, 383-387	
1468	The potential of neural stem cells to repair stroke-induced brain damage. **2009**, 117, 469-80	71
1467	The Stem Cell Network model: clinical implications in cancer. **2009**, 266, 161-70	14
1466	Direct cell entry of gold/iron-oxide magnetic nanoparticles in adenovirus mediated gene delivery. **2009**, 30, 1809-14	56
1465	Stem cells and liver repair. **2009**, 20, 568-74	39
1464	New strategies to generate induced pluripotent stem cells. **2009**, 20, 516-21	48
1463	Evidence that human blastomere cleavage is under unique cell cycle control. **2009**, 26, 187-95	27
1462	Human embryonic stem cell research and the discarded embryo argument. **2009**, 30, 131-45	3
1461	"You are our only hope": trading metaphorical "magic bullets" for stem cell "superheroes". **2009**, 30, 427-42	12
1460	Origins and clinical implications of the brain tumor stem cell hypothesis. **2009**, 93, 49-60	29
1459	The relationship between pluripotency and mitochondrial DNA proliferation during early embryo development and embryonic stem cell differentiation. **2009**, 5, 140-58	183
1458	Ethical and policy issues surrounding the donation of cryopreserved and fresh embryos for human embryonic stem cell research. **2009**, 5, 116-22	24
1457	Emerging ethical, legal and social issues associated with stem cell research & and the current role of the moral status of the embryo. **2009**, 5, 96-101	41

1456	The molecular mechanism of induced pluripotency: a two-stage switch. **2009**, 5, 204-23	42
1455	Blastocyst injection of embryonic stem cells: a simple approach to unveil mechanisms of corrections in mouse models of human disease. **2009**, 5, 369-77	12
1454	A three dimensional anchorage independent in vitro system for the prolonged growth of embryoid bodies to study cancer cell behaviour and anticancer agents. **2009**, 5, 410-9	12
1453	Induced pluripotent stem cells for retinal degenerative diseases: a new perspective on the challenges. **2009**, 88, 417-24	51
1452	Current progress and prospects of induced pluripotent stem cells. **2009**, 52, 622-36	21
1451	Generation of pancreatic islet cells from human embryonic stem cells. **2009**, 52, 615-21	16
1450	Nuclear reprogramming by nuclear transplantation and defined transcription factors. **2009**, 54, 14-18	3
1449	Generation and application of human iPS cells. **2009**, 54, 9-13	3
1448	Induced pluripotent stem cell (iPS) technology: promises and challenges. **2009**, 54, 2-8	3
1447	Advances and prospect of nanotechnology in stem cells. **2009**, 4, 593-605	63
1446	Policy Design for Human Embryo Research in Canada: An Analysis (Part 2 of 2). **2009**, 6, 351-365	5
1445	Cell reprogramming for the creation of patient-specific pluripotent stem cells by defined factors. **2009**, 3, 199-208	
1444	Panoramic view of the Fifth International Symposium on Stem Cell Therapy and Applied Cardiovascular Biotechnology, April 2008, Madrid (Spain). **2009**, 2, 108-13	
1443	Immunogenicity and allogenicity: a challenge of stem cell therapy. **2009**, 2, 130-8	26
1442	Gamètes artificiels: spermatozoïdes sans testicules ou ovocytes sans ovaires, est-ce possible ?. **2009**, 19, 189-190	
1441	Induced pluripotent stem cells: a new tool for toxicology screening?. **2009**, 83, 641-4	22
1440	Stem cell therapy in stroke. **2009**, 66, 757-72	105
1439	Role of SoxB1 transcription factors in development. **2009**, 66, 3675-84	37

1438	Human stem cells as a model for cardiac differentiation and disease. **2009**, 66, 800-13	29
1437	MHC class I A loci polymorphism and diversity in three Southeast Asian populations of cynomolgus macaque. **2009**, 61, 635-48	39
1436	Adult palatum as a novel source of neural crest-related stem cells. **2009**, 27, 1899-910	120
1435	Efficient adipocyte and osteoblast differentiation from mouse induced pluripotent stem cells by adenoviral transduction. **2009**, 27, 1802-11	107
1434	Nanog regulates proliferation during early fish development. **2009**, 27, 2081-91	48
1433	Sall4 is essential for stabilization, but not for pluripotency, of embryonic stem cells by repressing aberrant trophectoderm gene expression. **2009**, 27, 796-805	78
1432	KLF4 and PBX1 directly regulate NANOG expression in human embryonic stem cells. **2009**, 27, 2114-25	94
1431	Genetic basis of inherited macular dystrophies and implications for stem cell therapy. **2009**, 27, 2833-45	9
1430	Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible. **2009**, 27, 2509-15	85
1429	Long-term, stable differentiation of human embryonic stem cell-derived neural precursors grafted into the adult mammalian neostriatum. **2009**, 27, 2414-26	46
1428	Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. **2009**, 27, 2427-34	351
1427	Signaling pathways controlling pluripotency and early cell fate decisions of human induced pluripotent stem cells. **2009**, 27, 2655-66	135
1426	Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. **2009**, 27, 2667-74	405
1425	Clone- and gene-specific aberrations of parental imprinting in human induced pluripotent stem cells. **2009**, 27, 2686-90	159
1424	Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer. **2009**, 27, 3103-11	58
1423	Generation of human-induced pluripotent stem cells in the absence of exogenous Sox2. **2009**, 27, 2992-3000	260
1422	Non cell-autonomous reprogramming of adult ocular progenitors: generation of pluripotent stem cells without exogenous transcription factors. **2009**, 27, 3053-62	30
1421	Reprogramming of human fibroblasts to induced pluripotent stem cells under xeno-free conditions. **2010**, 28, 36-44	77

1420	Challenges of stem cell therapy for spinal cord injury: human embryonic stem cells, endogenous neural stem cells, or induced pluripotent stem cells?. **2010**, 28, 93-9	153
1419	Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. **2010**, 28, 64-74	213
1418	Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. **2010**, 28, 164-73	35
1417	Mesenchymal stromal cells: current understanding and clinical status. **2010**, 28, 585-96	677
1416	Oct4 and klf4 reprogram dermal papilla cells into induced pluripotent stem cells. **2010**, 28, 221-8	105
1415	Generation of histocompatible androgenetic embryonic stem cells using spermatogenic cells. **2010**, 28, 229-39	7
1414	Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. **2009**, 27, 806-11	288
1413	Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. **2009**, 27, 1021-31	89
1412	Polycistronic lentiviral vector for "hit and run" reprogramming of adult skin fibroblasts to induced pluripotent stem cells. **2009**, 27, 1042-9	166
1411	Reprogramming retinal pigment epithelium to differentiate toward retinal neurons with Sox2. **2009**, 27, 1376-87	30
1410	Alternative translation of OCT4 by an internal ribosome entry site and its novel function in stress response. **2009**, 27, 1265-75	97
1409	Epigenetic reprogramming by somatic cell nuclear transfer in primates. **2009**, 27, 1255-64	37
1408	Gene targeting in a HUES line of human embryonic stem cells via electroporation. **2009**, 27, 1496-506	71
1407	Bioluminescence imaging of Olig2-neural stem cells reveals improved engraftment in a demyelination mouse model. **2009**, 27, 1582-91	35
1406	Direct transdifferentiation of stem/progenitor spermatogonia into reproductive and nonreproductive tissues of all germ layers. **2009**, 27, 1666-75	67
1405	Wnt3a-induced mesoderm formation and cardiomyogenesis in human embryonic stem cells. **2009**, 27, 1869-78	107
1404	Proteomic analysis of membrane proteins expressed specifically in pluripotent murine embryonic stem cells. **2009**, 9, 126-37	22
1403	A thin carbon-fiber web as a scaffold for bone-tissue regeneration. **2009**, 5, 1540-6	31

1402	Metaplasia and somatic cell reprogramming. **2009**, 217, 161-8	25
1401	Post-translational modifications of orphan nuclear receptor TR2 - new insights into drug targets for stem cell therapy and the effect of retinoic acid. **2009**, 3, 279-85	1
1400	Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. **2009**, 69, 401-10	74
1399	AICAR activates the pluripotency transcriptional network in embryonic stem cells and induces KLF4 and KLF2 expression in fibroblasts. **2009**, 9, 2	15
1398	Cyclic GMP signalling in human ES and iPS-derived vascular cells. **2009**, 9,	78
1397	Simultaneous detection of mRNA and protein stem cell markers in live cells. **2009**, 9, 30	49
1396	Proteomic analysis of blastema formation in regenerating axolotl limbs. **2009**, 7, 83	97
1395	Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. **2009**, 35, 380-393	36
1394	Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts. **2009**, 14, 683-94	113
1393	Regenerative medicine: a 2009 overview. **2009**, 266, 303-10	14
1392	Roles of TGF-beta family signaling in stem cell renewal and differentiation. **2009**, 19, 103-15	319
1391	Serial imaging of human embryonic stem-cell engraftment and teratoma formation in live mouse models. **2009**, 19, 370-9	43
1390	Generation of induced pluripotent stem cells from human beta-thalassemia fibroblast cells. **2009**, 19, 1120-3	44
1389	More synergetic cooperation of Yamanaka factors in induced pluripotent stem cells than in embryonic stem cells. **2009**, 19, 1127-38	44
1388	Efficient generation of hepatocyte-like cells from human induced pluripotent stem cells. **2009**, 19, 1233-42	398
1387	Generation of iPS cells using defined factors linked via the self-cleaving 2A sequences in a single open reading frame. **2009**, 19, 296-306	64
1386	Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. **2009**, 19, 429-38	458
1385	OCT4: less is more. **2009**, 19, 527-8	8

1384	Raf kinase inhibitory protein suppresses a metastasis signalling cascade involving LIN28 and let-7. **2009**, 28, 347-58	302
1383	A 'higher order' of telomere regulation: telomere heterochromatin and telomeric RNAs. **2009**, 28, 2323-36	163
1382	Myc-regulated microRNAs attenuate embryonic stem cell differentiation. **2009**, 28, 3157-70	159
1381	Induced pluripotent stem cells and the stability of the differentiated state. **2009**, 10, 714-21	28
1380	Destroying unwanted embryos in research. Talking Point on morality and human embryo research. **2009**, 10, 307-12	12
1379	Transplantation prospects for the inner retina. **2009**, 23, 1980-4	32
1378	Neuroprotective effects of mesenchymal stem cells derived from human embryonic stem cells in transient focal cerebral ischemia in rats. **2009**, 29, 780-91	55
1377	Human embryonic stem cells: 10 years on. **2009**, 89, 259-62	9
1376	Induced pluripotent stem cells from a spinal muscular atrophy patient. **2009**, 457, 277-80	1154
1375	Virus-free induction of pluripotency and subsequent excision of reprogramming factors. **2009**, 458, 771-5	1063
1374	Generation of transgenic non-human primates with germline transmission. **2009**, 459, 523-7	551
1373	Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. **2009**, 460, 53-9	580
1372	Distinctive chromatin in human sperm packages genes for embryo development. **2009**, 460, 473-8	1007
1371	Elite and stochastic models for induced pluripotent stem cell generation. **2009**, 460, 49-52	410
1370	miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. **2009**, 460, 705-10	1198
1369	Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. **2009**, 460, 1132-5	1073
1368	iPS cells produce viable mice through tetraploid complementation. **2009**, 461, 86-90	633
1367	Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. **2009**, 460, 1145-8	706

1366	A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. **2009**, 460, 1149-53	842
1365	The Ink4/Arf locus is a barrier for iPS cell reprogramming. **2009**, 460, 1136-9	794
1364	Adult mice generated from induced pluripotent stem cells. **2009**, 461, 91-4	386
1363	Linking the p53 tumour suppressor pathway to somatic cell reprogramming. **2009**, 460, 1140-4	906
1362	Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. **2009**, 461, 402-6	701
1361	Direct reprogramming of human neural stem cells by OCT4. **2009**, 461, 649-3	561
1360	Direct cell reprogramming is a stochastic process amenable to acceleration. **2009**, 462, 595-601	814
1359	Transgenic mice with defined combinations of drug-inducible reprogramming factors. **2009**, 27, 169-71	84
1358	Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. **2009**, 27, 275-80	2430
1357	Variation in the safety of induced pluripotent stem cell lines. **2009**, 27, 743-5	702
1356	Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. **2009**, 27, 1033-7	404
1355	Next-generation synthetic gene networks. **2009**, 27, 1139-50	274
1354	Stem cells: Low-risk reprogramming. **2009**, 458, 715-6	11
1353	50 & 100 years ago. **2009**, 458, 716-716	
1352	Physical chemistry: How to improve your image. **2009**, 458, 716-7	30
1351	Stem cells: Fast and furious. **2009**, 458, 962-5	34
1350	Experimental basis of cord blood transplantation. **2009**, 44, 627-33	36
1349	Developing safe therapies from human pluripotent stem cells. **2009**, 27, 606-13	110

1348	Stem cell patents: a landscape analysis. **2009**, 27, 722-6	13
1347	KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. **2009**, 11, 1297-304	149
1346	The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. **2009**, 11, 1487-95	1357
1345	A small molecule that directs differentiation of human ESCs into the pancreatic lineage. **2009**, 5, 258-65	412
1344	The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. **2009**, 41, 553-62	356
1343	Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. **2009**, 41, 968-76	337
1342	Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. **2009**, 41, 1350-3	936
1341	Transcription factor ELF4 controls the proliferation and homing of CD8+ T cells via the Krüppel-like factors KLF4 and KLF2. **2009**, 10, 618-26	89
1340	A safer stem cell: inducing pluripotency. **2009**, 15, 1001-2	7
1339	A safer stem cell: on guard against cancer. **2009**, 15, 999-1001	35
1338	Ekiden to iPS Cells. **2009**, 15, 1145-8	14
1337	Complexity in biomaterials for tissue engineering. **2009**, 8, 457-70	1340
1336	Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. **2009**, 6, 363-9	488
1335	Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. **2009**, 6, 370-6	234
1334	Digital RNA allelotyping reveals tissue-specific and allele-specific gene expression in human. **2009**, 6, 613-8	136
1333	A chemical platform for improved induction of human iPSCs. **2009**, 6, 805-8	483
1332	Hippocampal development and neural stem cell maintenance require Sox2-dependent regulation of Shh. **2009**, 12, 1248-56	358
1331	Notch keeps ependymal cells in line. **2009**, 12, 243-5	5

1330	I can see what you see. **2009**, 12, 245	38
1329	Generation of induced pluripotent stem cells from neural stem cells. **2009**, 4, 1464-70	71
1328	EOS lentiviral vector selection system for human induced pluripotent stem cells. **2009**, 4, 1828-44	67
1327	Stepwise differentiation of pluripotent stem cells into retinal cells. **2009**, 4, 811-24	220
1326	Viral manipulation of the host epigenome for oncogenic transformation. **2009**, 10, 290-4	44
1325	From genes to function: the next challenge to understanding multiple sclerosis. **2009**, 9, 408-17	86
1324	Epigenetic dynamics of stem cells and cell lineage commitment: digging Waddington's canal. **2009**, 10, 526-37	399
1323	Systems biology of stem cell fate and cellular reprogramming. **2009**, 10, 672-81	274
1322	Stem cells and future periodontal regeneration. **2009**, 51, 239-51	91
1321	Evolution and regeneration of the planarian central nervous system. **2009**, 51, 185-95	78
1320	Chicken embryonic stem cells as a non-mammalian embryonic stem cell model. **2010**, 52, 101-14	28
1319	AN INCLUSIVE ETHICS FOR THE TWENTY-FIRST CENTURY: IMPLICATIONS FOR STEM CELL RESEARCH. **2009**, 37, 683-722	1
1318	The year in human and medical genetics. Highlights of 2007-2008. **2009**, 1151, 1-21	5
1317	Tumors originating from induced pluripotent stem cells and methods for their prevention. **2009**, 1176, 197-204	34
1316	Hematopoietic development from human induced pluripotent stem cells. **2009**, 1176, 219-27	87
1315	In vitro production of transfusable red blood cells. **2009**, 4, 383-389	2
1314	From human somatic stem cells to human iPS cells State of the art and future needs. **2009**, 4, 286-292	
1313	Preimplantation genetic diagnosis as a source of human embryonic stem cells for disease research and drug discovery. **2009**, 116, 158-65	16

1312	Differential cytotoxic effects of mono-(2-ethylhexyl) phthalate on blastomere-derived embryonic stem cells and differentiating neurons. **2009**, 264, 145-54	16
1311	Laser-assisted selection and passaging of human pluripotent stem cell colonies. **2009**, 143, 224-30	10
1310	New paradigms of myocardial regeneration post-infarction: tissue preservation, cell environment, and pluripotent cell sources. **2009**, 2, 1-8	24
1309	Stem cell engineering for treatment of heart diseases: potentials and challenges. **2009**, 33, 255-67	42
1308	Smooth muscle cell differentiation from human bone marrow: variations in cell type specific markers and Id gene expression in a new model of cell culture. **2009**, 33, 621-31	8
1307	Role of MEF feeder cells in direct reprogramming of mousetail-tip fibroblasts. **2009**, 33, 1268-73	10
1306	Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts. **2009**, 33, 1184-93	108
1305	Engineering organs. **2009**, 20, 575-92	191
1304	Mass preparation of size-controlled mouse embryonic stem cell aggregates and induction of cardiac differentiation by cell patterning method. **2009**, 30, 4384-9	57
1303	Humanise basic research in cardiology from here!. **2009**, 17, 271	1
1302	Potentials of regenerative medicine for liver disease. **2009**, 39, 1019-25	24
1301	Regulation of the Nanog gene by both positive and negative cis-regulatory elements in embryonal carcinoma cells and embryonic stem cells. **2009**, 76, 173-82	8
1300	ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells. **2009**, 76, 722-32	127
1299	Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. **2009**, 69, 2887-95	330
1298	Stem cells to pancreatic beta-cells: new sources for diabetes cell therapy. **2009**, 30, 214-27	86
1297	Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. **2009**, 16, 2638-44	58
1296	Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. **2009**, 16, 3488-98	247
1295	Isolation and characterization of pluripotent human spermatogonial stem cell-derived cells. **2009**, 27, 138-49	244

1294	Role of natural-killer group 2 member D ligands and intercellular adhesion molecule 1 in natural killer cell-mediated lysis of murine embryonic stem cells and embryonic stem cell-derived cardiomyocytes. **2009**, 27, 307-16	44
1293	Molecular characterization of the human NANOG protein. **2009**, 27, 812-21	37
1292	Fibroblast-derived induced pluripotent stem cells show no common retroviral vector insertions. **2009**, 27, 300-6	51
1291	SWI/SNF-Brg1 regulates self-renewal and occupies core pluripotency-related genes in embryonic stem cells. **2009**, 27, 317-28	187
1290	Genetic analysis of the role of the reprogramming gene LIN-28 in human embryonic stem cells. **2009**, 27, 352-62	66
1289	Generation of T lineage cells from human embryonic stem cells in a feeder free system. **2009**, 27, 100-7	37
1288	Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. **2009**, 27, 559-67	289
1287	Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. **2009**, 27, 543-9	527
1286	Generation of pluripotent stem cells from patients with type 1 diabetes. **2009**, 106, 15768-73	461
1285	A decade of progress since the birth of Dolly. **2009**, 21, 95-100	12
1284	Bone-marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. **2009**, 9, 1487-97	88
1283	Polycomb group protein gene silencing, non-coding RNA, stem cells, and cancer. **2009**, 87, 711-46	66
1282	MicroRNAs as a therapeutic target for cardiovascular diseases. **2009**, 13, 778-89	117
1281	Can cellular models revolutionize drug discovery in Parkinson's disease?. **2009**, 1792, 1043-51	44
1280	The prospect of pluripotent stem cell-based therapy. **2009**, 3, 248-258	
1279	Induced pluripotent stem cells. **2009**, 45, 139-146	1
1278	Generation of functional ventricular heart muscle from mouse ventricular progenitor cells. **2009**, 326, 426-9	182
1277	Mesenchymal stromal cells derived from human umbilical cord tissues: primitive cells with potential for clinical and tissue engineering applications. **2010**, 123, 29-54	35

1276	A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress. **2009**, 23, 208-22		94
1275	In vivo expansion of the mammary stem/ progenitor cell population by xanthosine infusion. **2009**, 234, 475-82		38
1274	Toxicity testing in the 21st century: bringing the vision to life. **2009**, 107, 324-30		236
1273	Synthesis at the interface of chemistry and biology. **2009**, 131, 12497-515		82
1272	Renin-angiotensin system and hemangioblast development from human embryonic stem cells. **2009**, 2, 137-43		6
1271	Improved electrospray ionization efficiency compensates for diminished chromatographic resolution and enables proteomics analysis of tyrosine signaling in embryonic stem cells. **2009**, 81, 3440-7		90
1270	Transdifferentiation of stem cells: a critical view. **2009**, 114, 73-106		8
1269	Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro. **2009**, 23, 4168-80		105
1268	Transforming Growth Factor type beta and Smad family signaling in stem cell function. **2009**, 20, 449-58		39
1267	Urothelial transdifferentiation to prostate epithelia is mediated by paracrine TGF-beta signaling. **2009**, 77, 95-102		35
1266	Gene expression profiles of human inner cell mass cells and embryonic stem cells. **2009**, 78, 18-23		35
1265	Can nitric oxide enhance Oct-4 expression and induce pluripotency in adult neural stem cells?. **2009** , 2, 272-273		
1264	A review of gene and stem cell therapy in cutaneous wound healing. **2009**, 35, 171-80		211
1263	Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. **2009**, 280, 134-44		94
1262	Role of the murine reprogramming factors in the induction of pluripotency. *Cell*, **2009**, 136, 364-77	56.2	517
1261	Oct4-induced pluripotency in adult neural stem cells. *Cell*, **2009**, 136, 411-9	56.2	773
1260	Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. *Cell*, **2009**, 136, 964-77	56.2	1262
1259	MicroRNA-145 regulates OCT4, SOX2, and KLF4 and represses pluripotency in human embryonic stem cells. *Cell*, **2009**, 137, 647-58	56.2	945

1258	A fresh look at iPS cells. *Cell*, **2009**, 137, 13-7	56.2	580
1257	Nanog is the gateway to the pluripotent ground state. *Cell*, **2009**, 138, 722-37	56.2	785
1256	Reprogramming to pluripotency: from frogs to stem cells. *Cell*, **2009**, 138, 1047-50	56.2	6
1255	iPS cells: mapping the policy issues. *Cell*, **2009**, 139, 1032-7	56.2	58
1254	Cell replacement therapy for Parkinson's disease. **2009**, 1792, 688-702		48
1253	Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. **2009**, 1792, 380-91		52
1252	Generation of megakaryocytes and platelets from human subcutaneous adipose tissues. **2009**, 378, 716-20		28
1251	Independent transcription of miR-281 in the intron of ODA in Drosophila melanogaster. **2009**, 378, 883-9		23
1250	Cyclosporin-A potently induces highly cardiogenic progenitors from embryonic stem cells. **2009**, 379, 115-20		39
1249	Embryonic stem cell markers expression in cancers. **2009**, 383, 157-62		183
1248	Transduction of MyoD protein into myoblasts induces myogenic differentiation without addition of protein transduction domain. **2009**, 382, 473-7		16
1247	In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes. **2009**, 385, 497-502		190
1246	Development of effective isolation method of ES cells for analysis of differentiation. **2009**, 387, 64-9		1
1245	The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. **2009**, 387, 482-8		144
1244	Gene targeting in human pluripotent stem cells with adeno-associated virus vectors. **2009**, 388, 711-7		45
1243	Differentiation of murine embryonic stem and induced pluripotent stem cells to renal lineage in vitro. **2009**, 390, 1334-9		91
1242	Expression and activation of the reprogramming transcription factors. **2009**, 390, 1081-6		11
1241	Progress toward effective treatments for human photoreceptor degenerations. **2009**, 19, 283-9		13

1240	[Human embryonic stem cells: from the human embryo transgressed to the regenerative medicine of tomorrow]. **2009**, 37, 620-6	6
1239	Generation of induced pluripotent stem cell lines from adult rat cells. **2009**, 4, 11-5	281
1238	Generation of rat and human induced pluripotent stem cells by combining genetic reprogramming and chemical inhibitors. **2009**, 4, 16-9	473
1237	One breath closer to making engineered tissues a clinical reality. **2009**, 4, 5-6	1
1236	Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. **2009**, 4, 141-54	384
1235	Distribution of human embryonic stem cell lines: who, when, and where. **2009**, 4, 107-10	26
1234	Histone deacetylase inhibition elicits an evolutionarily conserved self-renewal program in embryonic stem cells. **2009**, 4, 359-69	136
1233	Molecules that promote or enhance reprogramming of somatic cells to induced pluripotent stem cells. **2009**, 4, 301-12	308
1232	Fishing for a WNT-PGE2 link: beta-catenin is caught in the stem cell net-work. **2009**, 4, 280-2	16
1231	Genetic control of wayward pluripotent stem cells and their progeny after transplantation. **2009**, 4, 289-300	55
1230	Recreating stem cells: a novel entrance to the fountain of youth. **2009**, 4, 279-80	3
1229	Generation of induced pluripotent stem cells using recombinant proteins. **2009**, 4, 381-4	1469
1228	Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. **2009**, 4, 472-6	1506
1227	Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. **2009**, 5, 97-110	454
1226	Phosphoproteomic analysis of human embryonic stem cells. **2009**, 5, 204-13	163
1225	Induced pluripotent stem cells and embryonic stem cells are distinguished by gene expression signatures. **2009**, 5, 111-23	816
1224	Ethics report on interspecies somatic cell nuclear transfer research. **2009**, 5, 27-30	9
1223	iPS cells can support full-term development of tetraploid blastocyst-complemented embryos. **2009**, 5, 135-8	368

1222	Hypoxia enhances the generation of induced pluripotent stem cells. **2009**, 5, 237-41	608
1221	Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. **2009**, 5, 504-14	423
1220	Generation of induced pluripotent stem cells from human cord blood. **2009**, 5, 434-41	380
1219	Regeneration next: toward heart stem cell therapeutics. **2009**, 5, 364-77	153
1218	Generation of induced pluripotent stem cells from human cord blood using OCT4 and SOX2. **2009**, 5, 353-7	334
1217	The human egg is back. **2009**, 5, 345-6	3
1216	A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. **2009**, 5, 491-503	650
1215	Technical challenges in using human induced pluripotent stem cells to model disease. **2009**, 5, 584-95	328
1214	Common astrocytic programs during brain development, injury and cancer. **2009**, 32, 303-11	41
1213	Squelching glioblastoma stem cells by targeting REST for proteasomal degradation. **2009**, 32, 559-65	26
1212	Fate plasticity of adult hippocampal progenitors: biological relevance and therapeutic use. **2009**, 30, 61-5	14
1211	Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. **2009**, 30, 536-45	66
1210	Embryonic stem cell-derived cardiomyocytes as a model system to study cardioprotective effects of dexamethasone in doxorubicin cardiotoxicity. **2009**, 23, 1422-8	25
1209	Pluripotent stem cells. **2009**, 16, 65-9	11
1208	Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease. **2009**, 61, 337-9	29
1207	Immune influence on adult neural stem cell regulation and function. **2009**, 64, 79-92	172
1206	Cell based vaccination using transplantation of iPSC-derived memory B cells. **2009**, 27, 5728-9	3
1205	Regulation of mouse embryonic stem cell neural differentiation by retinoic acid. **2009**, 328, 456-71	75

1204	Modeling epilepsy with pluripotent human cells. **2009**, 14 Suppl 1, 81-5	18
1203	Differential methylation status of imprinted genes in nuclear transfer derived ES (NT-ES) cells. **2009** , 93, 112-9	25
1202	Cardiac interstitial cells express GATA4 and control dedifferentiation and cell cycle re-entry of adult cardiomyocytes. **2009**, 46, 653-62	44
1201	Notch1 represses osteogenic pathways in aortic valve cells. **2009**, 47, 828-34	154
1200	Parthenogenesis-derived multipotent stem cells adapted for tissue engineering applications. **2009**, 47, 90-7	21
1199	A new perspective on the treatment of aromatic L-amino acid decarboxylase deficiency. **2009**, 97, 6-14	44
1198	[Induced pluripotent stem cells (iPS cells)]. **2009**, 57, 555-9	
1197	Comparison of human fetal liver, umbilical cord blood, and adult blood hematopoietic stem cell engraftment in NOD-scid/gammac-/-, Balb/c-Rag1-/-gammac-/-, and C.B-17-scid/bg immunodeficient mice. **2009**, 70, 790-802	100
1196	Do immunotherapy and beta cell replacement play a synergistic role in the treatment of type 1 diabetes?. **2009**, 85, 549-56	11
1195	Isolation of neural stem/progenitor cells by using EGF/FGF1 and FGF1B promoter-driven green fluorescence from embryonic and adult mouse brains. **2009**, 41, 348-63	29
1194	Altered nuclear retention of mRNAs containing inverted repeats in human embryonic stem cells: functional role of a nuclear noncoding RNA. **2009**, 35, 467-78	483
1193	Induced pluripotent stem cells: current progress and potential for regenerative medicine. **2009**, 15, 59-68	288
1192	Stem cell-based cell replacement strategies for the central nervous system. **2009**, 456, 107-11	40
1191	Generation of retinal cells from mouse and human induced pluripotent stem cells. **2009**, 458, 126-31	354
1190	Epigenetic reprogramming and induced pluripotency. **2009**, 136, 509-23	435
1189	Patient-specific pluripotent stem cells: promises and challenges. **2009**, 5, 195-203	26
1188	Mesenchymal stem cells derived from dental tissues vs. those from other sources: their biology and role in regenerative medicine. **2009**, 88, 792-806	1258
1187	Obtaining consent for future research with induced pluripotent cells: opportunities and challenges. **2009**, 7, e42	55

1186	Cancer stem cell genomics: the quest for early markers of malignant progression. **2009**, 9, 545-54	17
1185	Stem Cells in Aquatic Invertebrates: Common Premises and Emerging Unique Themes. **2009**, 61-103	10
1184	Adult stem and progenitor cells. **2009**, 114, 1-21	4
1183	Microenvironmental Determinants of Stem Cell Fate. **2009**, 647-663	
1182	The human embryo: ethical and legal aspects. **2009**, 550, 281-305	4
1181	Stem cell therapy for cartilage regeneration in osteoarthritis. **2009**, 9, 1399-405	51
1180	Efficient genetic reprogramming of unmodified somatic neural progenitors uncovers the essential requirement of Oct4 and Klf4. **2009**, 18, 707-16	22
1179	A big promise from the very small identification of circulating embryonic stem-like pluripotent cells in patients with acute myocardial infarction. **2009**, 53, 10-2	14
1178	Long-term outcome of stem cell therapy for acute myocardial infarction: right results, wrong reasons. **2009**, 53, 2270-2	27
1177	Cell therapy for heart disease: great expectations, as yet unmet. **2009**, 18, 245-56	32
1176	Transgenic Farm Animals: Current Status and Perspectives for Agriculture and Biomedicine. **2009**, 1-30	4
1175	Quantities of cells used for regenerative medicine and some implications for clinicians and bioprocessors. **2009**, 4, 153-7	37
1174	Assessing the value of autologous and allogeneic cells for regenerative medicine. **2009**, 4, 835-53	48
1173	In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction. **2009**, 122, 3169-79	343
1172	MicroRNA profiling of human-induced pluripotent stem cells. **2009**, 18, 749-58	208
1171	Tissue engineering for cutaneous wounds: selecting the proper time and space for growth factors, cells and the extracellular matrix. **2009**, 22, 83-93	65
1170	Stem cells derived from amniotic fluid: new potentials in regenerative medicine. **2009**, 18 Suppl 1, 17-27	124
1169	Non-viable human embryos as a source of viable cells for embryonic stem cell derivation. **2009**, 18, 301-8	20

1168	Differentiation and transplantation of human embryonic stem cell-derived hepatocytes. **2009**, 136, 990-9	418
1167	EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. **2009**, 136, 1012-24	897
1166	Cell transplantation to replace whole liver transplantation. **2009**, 136, 767-9	15
1165	Plasticity of stem cells derived from adult periodontal ligament. **2009**, 4, 809-21	104
1164	Stem cells and somatic cells: reprogramming and plasticity. **2009**, 9 Suppl 3, S319-28	11
1163	Strategies for retinal repair: cell replacement and regeneration. **2009**, 175, 23-31	66
1162	Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. **2009**, 18, 1179-90	118
1161	Mitochondrial functionality in reproduction: from gonads and gametes to embryos and embryonic stem cells. **2009**, 15, 553-72	289
1160	Chaotic expression dynamics implies pluripotency: when theory and experiment meet. **2009**, 4, 17	35
1159	Induced pluripotent stem cells in regenerative medicine: an argument for continued research on human embryonic stem cells. **2009**, 4, 759-69	44
1158	The Cancer Stem Cell Hypothesis. **2009**, 3-14	4
1157	Mechanisms of stem cell self-renewal. **2009**, 25, 377-406	418
1156	Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. **2009**, 18, 1093-108	319
1155	Reprogramming of murine and human somatic cells using a single polycistronic vector. **2009**, 106, 157-62	406
1154	Spermatogonial stem cells: unlimited potential. **2009**, 21, 15-21	33
1153	Senescence impairs successful reprogramming to pluripotent stem cells. **2009**, 23, 2134-9	472
1152	Telomeres and Telomerase in Cancer. **2009**,	9
1151	Pharming. **2009**,	6

1150	Mouse embryonic stem cells give rise to gut-like morphogenesis, including intestinal stem cells, in the embryoid body model. **2009**, 18, 113-26	11
1149	Human iPS cell derivation/reprogramming. **2009**, Chapter 4, Unit 4A.1	24
1148	2A to the fore - research, technology and applications. **2010**, 26, 223-60	35
1147	The Neural Crest and Neural Crest Cells in Vertebrate Development and Evolution. **2009**,	61
1146	Teeth and Hearts: The Odontogenic and Cardiac Neural Crests. **2009**, 247-265	
1145	Induced pluripotent stem cells free of exogenous reprogramming factors. **2009**, 10, 220	13
1144	TFCat: the curated catalog of mouse and human transcription factors. **2009**, 10, R29	146
1143	Musings on genome medicine: is there hope for ethical and safe stem cell therapeutics?. **2009**, 1, 70	6
1142	Tissue engineering in the rheumatic diseases. **2009**, 11, 211	50
1141	Stem cells in gastroenterology and hepatology. **2009**, 6, 724-37	91
1140	Effects of ectopic Nanog and Oct4 overexpression on mesenchymal stem cells. **2009**, 18, 1013-22	129
1139	Carbon nanotubes: biomaterial applications. **2009**, 38, 1897-903	201
1138	Genetic Engineering in Livestock. **2009**,	
1137	Role of bioinspired polymers in determination of pluripotent stem cell fate. **2009**, 4, 561-78	30
1136	Pancreatic Stem Cells. **2009**,	4
1135	Development and Engineering of Dopamine Neurons. **2009**,	4
1134	Neural Cell Transplantation. **2009**,	1
1133	Engineering of Stem Cells. **2009**,	

1132	Stem Cells: It's Good To Have Choices. **2009**, 1, 92-4	4
1131	Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases. **2009**, 84, 893-902	142
1130	Application of induced pluripotent stem cells to hematologic disease. **2009**, 11, 980-9	21
1129	Differentiation of germ cells and gametes from stem cells. **2009**, 15, 379-90	71
1128	Stem Cell Therapy and Regenerative Medicine. **2009**, 84, 859-861	21
1127	Functional cardiomyocytes derived from human induced pluripotent stem cells. **2009**, 104, e30-41	1023
1126	Stem cells for cardiac regeneration by cell therapy and myocardial tissue engineering. **2009**, 114, 107-28	5
1125	Ontological and ethical implications of direct nuclear reprogramming. **2009**, 19, 23-32; discussion 33-40	21
1124	Pancreas Engineering. **2009**, 411-427	
1123	Pulp and dentin tissue engineering and regeneration: current progress. **2009**, 4, 697-707	142
1122	Improvement of cardiac efficacy and safety models in drug discovery by the use of stem cell-derived cardiomyocytes. **2009**, 4, 357-72	18
1121	Future alternative therapies for β-thalassemia. **2009**, 2, 685	21
1120	New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. **2009**, 113, 2488-97	121
1119	Progress and future challenges in stem cell-derived liver technologies. **2009**, 297, G241-8	69
1118	The golden age of cardiomyogenic stem cells: avoiding a fool's fate. **2009**, 7, 1-4	3
1117	Totipotency, pluripotency and nuclear reprogramming. **2009**, 114, 185-99	86
1116	Potential of stem cells for skin regeneration following burns. **2009**, 4, 97-99	3
1115	Stem cell biology and cell transplantation therapy in the retina. **2010**, 26, 297-334	24

1114	Hemangioblasts from human embryonic stem cells generate multilayered blood vessels with functional smooth muscle cells. **2009**, 4, 37-47	30
1113	Implantation of c-mycER TAM immortalized human mesencephalic-derived clonal cell lines ameliorates behavior dysfunction in a rat model of Parkinson's disease. **2009**, 18, 307-19	20
1112	Bovine ooplasm partially remodels primate somatic nuclei following somatic cell nuclear transfer. **2009**, 11, 187-202	38
1111	Regenerative Medicine: Past and Present. **2009**, 1, 11-31	3
1110	Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. **2009**, 3, 106-12	63
1109	Stem cell therapy for cardiac repair: benefits and barriers. **2009**, 11, e20	91
1108	Using stem cells to mend the retina in ocular disease. **2009**, 4, 855-64	23
1107	Gallbladder epithelial cells that engraft in mouse liver can differentiate into hepatocyte-like cells. **2009**, 174, 842-53	11
1106	Small molecules for stem cells. **2009**, 19, 275-81	21
1105	Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. **2009**, 84, 263-72	43
1104	Histamine regulates relevant murine dendritic cell functions via H4 receptor. **2009**, E3, 1414	
1103	Amniotic membrane and amniotic fluid-derived cells: potential tools for regenerative medicine?. **2009**, 4, 275-91	121
1102	Potential of cell therapy to treat pediatric motility disorders. **2009**, 18, 263-73	37
1101	Parkin gene therapy. **2009**, 15 Suppl 1, S43-5	8
1100	How useful are stem cells in PD therapy?. **2009**, 15 Suppl 3, S171-5	2
1099	Ethical issues in stem cell research. **2009**, 30, 204-13	264
1098	Generation of functional hepatocytes from mouse induced pluripotent stem cells. **2010**, 222, 492-501	33
1097	Human induced pluripotent stem cells free of vector and transgene sequences. **2009**, 324, 797-801	1871

1096	Human embryonic stem cell phosphoproteome revealed by electron transfer dissociation tandem mass spectrometry. **2009**, 106, 995-1000	175
1095	Regulation of stem cell pluripotency and neural differentiation by lysophospholipids. **2009**, 17, 242-54	50
1094	Generation and characterization of human induced pluripotent stem cells. **2009**, Chapter 4, Unit 4A.2	98
1093	SOX2 has gender-specific genetic effects on diabetic nephropathy in samples from patients with type 1 diabetes mellitus in the GoKinD study. **2009**, 6, 555-64	14
1092	Stem cell therapy: a primer for interventionalists and imagers. **2009**, 20, 999-1012	9
1091	Cardiac Cell Repair Therapy: A Clinical Perspective. **2009**, 84, 876-892	116
1090	Mature, adipocyte derived, dedifferentiated fat cells can differentiate into smooth muscle-like cells and contribute to bladder tissue regeneration. **2009**, 182, 355-65	89
1089	Stem cells--a source of adult red blood cells for transfusion purposes: present and future. **2009**, 25, 383-98, Table of Contents	26
1088	Generation of induced pluripotent stem cell lines from Tibetan miniature pig. **2009**, 284, 17634-40	319
1087	Multiple antigen-targeted immunotherapy with alpha-galactosylceramide-loaded and genetically engineered dendritic cells derived from embryonic stem cells. **2009**, 32, 219-31	21
1086	Regeneration of the mammalian inner ear sensory epithelium. **2009**, 17, 373-80	7
1085	Harnessing dendritic cells for the induction of transplantation tolerance. **2009**, 14, 344-50	18
1084	Transplantation of progenitor cells and regeneration of damaged myocardium: more facts or doubts? Insights from experimental and clinical studies. **2009**, 10, 624-34	6
1083	Current status of stem cell therapy for liver diseases. **2009**, 18, 1261-79	32
1082	Towards personalized cell-replacement therapies for brain repair. **2009**, 6, 293-313	1
1081	Transplantation tolerance in an age of induced pluripotency. **2009**, 14, 321-5	12
1080	Drug development targeting the glycogen synthase kinase-3beta (GSK-3beta)-mediated signal transduction pathway: targeting the Wnt pathway and transplantation therapy as strategies for retinal repair. **2009**, 109, 168-73	27
1079	1. Possibility of IPS Cells (-induced Pluripotent Stem Cell) and Its Challenge. **2009**, 98, 2141-2145	

1078	[Recent progress in therapy for diabetes mellitus--transplantation of Island of Langerhans and regenerative therapy]. **2009**, 98, 817-23	
1077	2. Current Status and Future in Tissue Engineering of Heart Structures. **2009**, 98, 343-350	
1076	Epigenetic signatures in stem cells and cancer stem cells. **2009**, 1, 261-80	15
1075	Stem cell and regenerative medicine. **2009**, 4, 287-97	7
1074	micRo-manageMeNT of MYC during hypoxia. **2009**, 8, 2865	2
1073	KLF4 gene expression is inhibited by the notch signaling pathway that controls goblet cell differentiation in mouse gastrointestinal tract. **2009**, 296, G490-8	80
1072	Human embryonic stem cells differentiate into a homogeneous population of natural killer cells with potent in vivo antitumor activity. **2009**, 113, 6094-101	177
1071	Medium spiny neurons for transplantation in Huntington's disease. **2009**, 37, 323-8	25
1070	The endothelial antigen ESAM marks primitive hematopoietic progenitors throughout life in mice. **2009**, 113, 2914-23	57
1069	Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. **2009**, 114, 3513-23	123
1068	Functional neutrophils from human ES cells. **2009**, 113, 6503-5	1
1067	Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. **2009**, 114, 5473-80	314
1066	Neoplastic blood cells become pluripotent. **2009**, 114, 5409-10	2
1065	Increasing the punch of reduced-intensity transplants. **2009**, 114, 5410-1	1
1064	Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. **2009**, 85, 348-62	1000
1063	Higher susceptibility of NOG mice to xenotransplanted tumors. **2009**, 34, 123-7	33
1062	Dedifferentiation of Human Epidermal Keratinocytes Induced by UV In Vitro. **2009**, 55, 709-719	5
1061	HapMap scanning of novel human minor histocompatibility antigens. **2009**, 113, 5041-8	46

1060	Potential implications of cell therapy for osteogenesis imperfecta. **2009**, 4, 57-66	23
1059	Generation of induced pluripotent stem cells by reprogramming human fibroblasts with the stemgent human TF lentivirus set. **2009**,	10
1058	Techniques for engineering bladder tissue. **2009**, 532-549	
1057	????iPS ????. **2009**, 6, 11-15	
1056	Stem Cell Migration in Health and Disease. **2009**, 7-27	
1055	Krüppel-like factor 4 regulates adaptive expression of the zinc transporter Zip4 in mouse small intestine. **2009**, 296, G517-23	51
1054	Regenerative medicine for diabetes mellitus. **2009**, 18, 491-6	17
1053	TRANSLATIONAL PERSPECTIVES TRANSIENT EPIGENETIC GENE THERAPY: HAZARD-FREE CELL REPROGRAMMING APPROACH AND RISING ARM OF A UNIVERSAL STEM CELL GENE THERAPY PLATFORM. **2009**, 04, 11-39	5
1052	Primate adult brain cell autotransplantation, a pilot study in asymptomatic MPTP-treated monkeys. **2009**, 18, 787-99	18
1051	MicroRNAs regulation modulated self-renewal and lineage differentiation of stem cells. **2009**, 18, 1039-45	57
1050	Krüppel-like factors 4 and 5: unity in diversity. **2009**, 10, 594-603	7
1049	Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis. **2009** , 4, 178-99	34
1048	Ex vivo liver-directed gene therapy for the treatment of metabolic diseases: advances in hepatocyte transplantation and retroviral vectors. **2009**, 9, 136-49	28
1047	Lost in translation: what is limiting cardiomyoplasty and can tissue engineering help?. **2009**, 4, 210-23	4
1046	Hypoxic tumor microenvironment and cancer cell differentiation. **2009**, 9, 425-34	128
1045	Adult and Embryonic Stem Cells in Cartilage Repair. **2009**, 5, 15-23	3
1044	Introduction to stem cell therapy. **2009**, 24, 98-103; quiz 104-5	107
1043	Cardiac applications for human pluripotent stem cells. **2009**, 15, 2791-806	53

1042	Alternative strategies for the derivation of human embryonic stem cell lines and the role of dead embryos. **2009**, 4, 81-6	9
1041	A review of gene expression profiling of human embryonic stem cell lines and their differentiated progeny. **2009**, 4, 98-106	40
1040	Cell Therapy Using Induced Pluripotent Stem (iPS) Cells Meets Next-Next Generation DNA Sequencing Technology. **2009**, 10, 303-5	1
1039	The biological restoration of central nervous system architecture and function: part 1-foundations and historical landmarks in contemporary stem cell biology. **2009**, 64, 15-39; discussion 34	7
1038	Colorectal cancer stem cells. **2009**, 52, 1788-96	10
1037	Cell therapy for cardiac regeneration after myocardial infarct: which cell is the best?. **2010**, 8, 227-43	9
1036	Genetic modification of donor hepatocytes improves therapeutic efficacy for hemophilia B in mice. **2010**, 19, 1169-80	10
1035	Industry Update: Latest developments in stem cell research and regenerative medicine. **2010**, 5, 695-700	1
1034	Combination of functional cardiomyocytes derived from human stem cells and a highly-efficient microelectrode array system: an ideal hybrid model assay for drug development. **2010**, 5, 227-32	46
1033	A tale of two tissues: stem cells in cartilage and corneal tissue engineering. **2010**, 5, 37-48	13
1032	Production of pancreatic beta-cells from stem cells. **2010**, 6, 184-90	29
1031	Do We Need More Human Embryonic Stem Cell Lines?. **2010**, 24, 1921-1927	6
1030	Targeting the perpetrator: breast cancer stem cell therapeutics. **2010**, 11, 1147-56	11
1029	You Don't Muck with MYC. **2010**, 1, 547-554	65
1028	Stem cells for hepatic regeneration: the role of adipose tissue derived mesenchymal stem cells. **2010**, 5, 182-9	65
1027	Role of leukaemia inhibitory factor in the induction of pluripotent stem cells in mice. **2010**, 34, 791-7	5
1026	Recent progress and challenges for the use of stem cell derivatives in neuron replacement therapy for Parkinson's disease. **2010**, 5, 161-165	8
1025	Transplantation of reprogrammed embryonic stem cells improves visual function in a mouse model for retinitis pigmentosa. **2010**, 89, 911-9	62

1024	Cancer epigenetics: from disruption of differentiation programs to the emergence of cancer stem cells. **2010**, 75, 251-8	18
1023	The future of regenerating the myocardium. **2010**, 25, 575-82	16
1022	Sustained factor VIII production in hemophiliac mice 1 year after engraftment with induced pluripotent stem cell-derived factor VIII producing endothelial cells. **2010**, 21, 502-4	8
1021	Recent advances in liver stem cell therapy. **2010**, 26, 395-402	55
1020	Reprogramming adult hematopoietic cells. **2010**, 17, 271-5	21
1019	Inducible pluripotent stem cells: not quite ready for prime time?. **2010**, 15, 61-7	25
1018	Stem cells. **2010**, 126, 1163-1171	28
1017	Recent progress in congenital long QT syndrome. **2010**, 25, 216-21	46
1016	Oct4 expression in immature teratoma of the ovary: relevance to histologic grade and degree of differentiation. **2010**, 34, 1842-8	42
1015	Induced pluripotent stem cell therapies for retinal disease. **2010**, 23, 4-9	29
1014	Current Opinion in Neurology. Current world literature. **2010**, 23, 433-44	
1013	Importance of quantitative analysis in the generation of insulin-expressing cells from human embryonic stem cells. **2010**, 39, 105-7	8
1012	Tissue engineering in plastic surgery: a review. **2010**, 126, 858-868	25
1011	Evolution of induced pluripotent stem cell technology. **2010**, 17, 276-80	41
1010	Human embryonic and induced pluripotent stem cells in basic and clinical research in cardiology. **2010**, 5, 215-26	11
1009	Use of lectins to enrich mouse ES-derived retinal progenitor cells for the purpose of transplantation therapy. **2010**, 19, 9-19	16
1008	Realizing the potential of therapeutic stem cells with effective delivery. **2010**, 1, 11-5	2
1007	New advances on the expansion and storage of human spermatogonial stem cells. **2010**, 20, 510-4	13

1006	In vitro differentiation of human amniotic fluid-derived cells: augmentation towards a neuronal dopaminergic phenotype. **2010**, 34, 959-67	17
1005	Distinct epigenetic regulation of tumor suppressor genes in putative cancer stem cells of solid tumors. **2010**, 37, 1537-46	10
1004	Early diagnosis and treatment may prevent the development of complications in an adult patient with glycogen storage disease type Ia. **2010**, 49, 1787-92	6
1003	Hepatic differentiation of mouse iPS cells in vitro. **2010**, 19, 841-7	34
1002	Cancer stem-like cells of glioblastoma characteristically express MMP-13 and display highly invasive activity. **2010**, 37, 1121-31	45
1001	Modulation of mitochondrial biogenesis and bioenergetic metabolism upon in vitro and in vivo differentiation of human ES and iPS cells. **2010**, 54, 1729-41	107
1000	Cryopreserving and recovering of human iPS cells using complete Knockout Serum Replacement feeder-free medium. **2010**,	3
999	Cell transplantation in Parkinson's disease: problems and perspectives. **2010**, 23, 426-32	48
998	Comparative analysis of endoderm formation efficiency between mouse ES cells and iPS cells. **2010** , 19, 831-9	15
997	Feeder-free adaptation, culture and passaging of human IPS cells using complete Knockout Serum Replacement feeder-free medium. **2010**,	9
996	Emerging use of stem cells in regenerative medicine. **2010**, 428, 11-23	77
995	Stem Cells in Drug Discovery. **2010**, 363-371	
994	Induction of pluripotent stem cells from adult somatic cells by protein-based reprogramming without genetic manipulation. **2010**, 116, 386-95	188
993	Role of stem-cell-derived hepatic endoderm in human drug discovery. **2010**, 38, 1033-6	14
992	Evaluating the utility of cardiomyocytes from human pluripotent stem cells for drug screening. **2010**, 38, 1037-45	97
991	Imaging-based chemical screens using normal and glioma-derived neural stem cells. **2010**, 38, 1067-71	24
990	Biocompatibility of engineered soft tissue created by stem cells. **2010**, 19-50	
989	Characterization of X-chromosome inactivation status in human pluripotent stem cells. **2010**, Chapter 1, Unit 1B.6	16

988	Fundamental Principles of Cell-Based Assays. **2010**, 213-238	
987	[Dopaminergic neuroprotection and reconstruction of neural network tiara]. **2010**, 130, 1263-72	0
986	Bio-resource of human and animal-derived cell materials. **2010**, 59, 1-7	7
985	Neural stem cells and strategies for the regeneration of the central nervous system. **2010**, 86, 438-50	41
984	Combined treatment of tumor-tropic human neural stem cells containing the CD suicide gene effectively targets brain tumors provoking a mild immune response. **2010**, 25,	
983	Generation of mature blood cells from pluripotent stem cells. **2010**, 95, 1621-3	5
982	The Epigenome and Its Relevance to Somatic Cell Nuclear Transfer and Nuclear Reprogramming. **2010**, 291-316	
981	Neurogenic differentiation of mesenchymal stem cells: Transgenic approach. **2010**, 4, 309-312	1
980	The heterogeneity of cell subtypes from a primary culture of human amniotic fluid. **2010**, 15, 424-39	16
979	Hybrid cells differentiate to hepatic lineage cells and repair oxidative damage. **2010**, 15, 451-72	4
978	Stem cell therapies for spinal cord injury. **2010**, 6, 363-72	172
977	Cell plasticity in homeostasis and regeneration. **2010**, 77, 837-55	57
976	Properties and identification of cancer stem cells: a changing insight into intractable cancer. **2010**, 40, 608-13	8
975	Carbohydrate engineered cells for regenerative medicine. **2010**, 62, 671-82	53
974	Bioartificial pancreas microencapsulation and conformal coating of islet of Langerhans. **2010**, 62, 827-40	148
973	Cellular cardiomyoplasty and cardiac tissue engineering for myocardial therapy. **2010**, 62, 784-97	142
972	Cell delivery therapeutics for musculoskeletal regeneration. **2010**, 62, 765-83	92
971	Nuclear receptors in stem cells and their therapeutic potential. **2010**, 62, 1299-306	10

970	The Wnt signaling pathway in cellular proliferation and differentiation: A tale of two coactivators. **2010**, 62, 1149-55	160
969	Microengineering Approach for Directing Embryonic Stem Cell Differentiation. **2010**, 153-171	2
968	Roles of integrins in human induced pluripotent stem cell growth on Matrigel and vitronectin. **2010** , 19, 1231-40	117
967	Polyethylenimine-cationized beta-catenin protein transduction activates the Wnt canonical signaling pathway more effectively than cationic lipid-based transduction. **2010**, 5, 385-92	12
966	New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. **2010**, 9, 192	52
965	Dopaminergic neurons derived from human induced pluripotent stem cells survive and integrate into 6-OHDA-lesioned rats. **2010**, 19, 1017-23	115
964	Chapter 18:Possible Clinical Applications of Stem-Cell Strategies in AD Therapies. **2010**, 78-94	
963	Extracellular matrix formation after transplantation of human embryonic stem cell-derived cardiomyocytes. **2010**, 67, 277-90	51
962	Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. **2010**, 67, 1165-76	108
961	Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells. **2010**, 67, 3837-47	61
960	Translating tissue-engineered tracheal replacement from bench to bedside. **2010**, 67, 4185-96	39
959	[Stem and progenitor cell-based therapy approaches: current developments on treatment of acute myocardial infarction and chronic ischemic cardiomyopathy]. **2010**, 35, 445-56	5
958	Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. **2010**, 88, 249-65	29
957	Capture of endothelial progenitor cells by a bispecific protein/monoclonal antibody molecule induces reendothelialization of vascular lesions. **2010**, 88, 687-99	24
956	Tissue transplantation by stealth‐coherent alginate microcapsules for immunoisolation. **2010**, 48, 337-347	27
955	Toward engineering of vascularized three-dimensional liver tissue equivalents possessing a clinically significant mass. **2010**, 48, 348-361	32
954	Development of Scalable Culture Systems for Human Embryonic Stem Cells. **2010**, 48, 378	48
953	ES, iPS, MSC, and AFS cells. Stem cells exploitation for Pediatric Surgery: current research and perspective. **2010**, 26, 3-10	61

952	Chromosomal and telomeric reprogramming following ES-somatic cell fusion. **2010**, 119, 167-76	17
951	Orthopedic research in the final year of the Bone and Joint Decade. **2010**, 15, 610-1	1
950	Extending the knowledge in histochemistry and cell biology. **2010**, 133, 1-40	1
949	Akt and PKC are involved not only in upregulation of telomerase activity but also in cell differentiation-related function via mTORC2 in leukemia cells. **2010**, 134, 555-63	12
948	Animal transgenesis: an overview. **2010**, 214, 91-109	100
947	Hepatic progenitor cells. **2010**, 342, 131-7	16
946	Rescue of developmental defects by blastocyst stem cell injection: towards elucidation of neomorphic corrective pathways. **2010**, 3, 66	4
945	Cardiogenesis: an embryological perspective. **2010**, 3, 37-48	10
944	Stem cell therapy: pieces of the puzzle. **2010**, 3, 49-60	18
943	Stem cells and ethics: current issues. **2010**, 3, 122-7	14
942	The paradoxical role of inflammation in cardiac repair and regeneration. **2010**, 3, 410-6	60
941	Stem Cell Science and Its Public: The Case of Singapore. **2010**, 4, 7-29	
940	Traitement du cancer par thérapie cellulaire: cellules souches embryonnaires versus cellules souches adultes. Quels sont les aspects éthiques ?. **2010**, 2, 1-3	
939	Suppression of metastatic murine ovarian cancer cells by transduced embryonic progenitor cells. **2010**, 1, 291-6	3
938	Diabetes mellitus: new challenges and innovative therapies. **2010**, 1, 138-63	35
937	Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. **2010**, 1, 22-32	61
936	Cellular models for disease exploring and drug screening. **2010**, 1, 355-362	6
935	Interrogating cell signalling network sensitively monitors cell fate transition during early differentiation of mouse embryonic stem cells. **2010**, 53, 78-86	4

934	Epigenetic reprogramming: roads to pluripotency. **2010**, 5, 8-11	1
933	Regulation beyond genome sequences: DNA and histone methylation in embryonic stem cells. **2010** , 5, 41-47	
932	Differential effects of recombinant fusion proteins TAT-OCT4 and TAT-NANOG on adult human fibroblasts. **2010**, 5, 424-430	1
931	Understanding of stem cells in bone biology and translation into clinical applications. **2010**, 5, 396-406	4
930	The promise of stem cell research in pigs and other ungulate species. **2010**, 6, 31-41	69
929	Promising new sources for pluripotent stem cells. **2010**, 6, 15-26	53
928	Presence of a ROCK inhibitor in extracellular matrix supports more undifferentiated growth of feeder-free human embryonic and induced pluripotent stem cells upon passaging. **2010**, 6, 96-107	76
927	Familiarity and prudence of the Japanese public with research into induced pluripotent stem cells, and their desire for its proper regulation. **2010**, 6, 1-7	17
926	Laser-assisted photoablation of human pluripotent stem cells from differentiating cultures. **2010**, 6, 260-9	16
925	Progress and promise towards safe induced pluripotent stem cells for therapy. **2010**, 6, 297-306	55
924	Advances in reprogramming somatic cells to induced pluripotent stem cells. **2010**, 6, 367-80	150
923	Endoplasmic reticulum stress signals in defined human embryonic stem cell lines and culture conditions. **2010**, 6, 462-72	15
922	A transcriptional roadmap to the induction of pluripotency in somatic cells. **2010**, 6, 282-96	65
921	The iPS technique provides hope for Parkinson's disease treatment. **2010**, 6, 398-404	11
920	Regulation of human stem cell research in South Korea. **2010**, 6, 340-4	2
919	G-protein coupled receptors in stem cell self-renewal and differentiation. **2010**, 6, 351-66	19
918	Pluripotent stem cells: origin, maintenance and induction. **2010**, 6, 633-49	39
917	Reprogramming of human umbilical cord stromal mesenchymal stem cells for myogenic differentiation and muscle repair. **2010**, 6, 512-22	34

916	Human embryonic stem cell-extracts inhibit the differentiation and function of monocyte-derived dendritic cells. **2010**, 6, 611-21	28
915	Generation of liver disease-specific induced pluripotent stem cells along with efficient differentiation to functional hepatocyte-like cells. **2010**, 6, 622-32	137
914	Progenitor cells for regenerative medicine and consequences of ART and cloning-associated epimutations. **2010**, 45, 187-97	
913	Differentiation of mesodermal cells from pluripotent stem cells. **2010**, 91, 373-83	12
912	Pluripotent stem cells as source of dendritic cells for immune therapy. **2010**, 91, 392-400	30
911	The molecular pathogenesis of Barrett's esophagus: common signaling pathways in embryogenesis metaplasia and neoplasia. **2010**, 14 Suppl 1, S81-7	26
910	The establishment of 20 different human embryonic stem cell lines and subclones; a report on derivation, culture, characterisation and banking. **2010**, 46, 217-30	14
909	Derivation of new human embryonic stem cell lines from preimplantation genetic screening and diagnosis-analyzed embryos. **2010**, 46, 395-402	21
908	High-efficiency derivation of human embryonic stem cell lines following pre-implantation genetic diagnosis. **2010**, 46, 376-85	35
907	College Students Conceptions of Stem Cells, Stem Cell Research, and Cloning. **2010**, 19, 177-186	8
906	Growth of primary embryo cells in a microculture system. **2010**, 12, 253-61	7
905	Genome-wide microarray evidence that 8-cell human blastomeres over-express cell cycle drivers and under-express checkpoints. **2010**, 27, 265-76	36
904	Expression of Oct4 in HCC and modulation to wnt/ catenin and TGF- signal pathways. **2010**, 343, 155-62	47
903	RA induces the neural-like cells generated from epigenetic modified NIH/3T3 cells. **2010**, 37, 1197-202	15
902	Ethical aspects of the use of stem cell derived gametes for reproduction. **2010**, 18, 267-78	13
901	Stem cells for heart failure in the aging heart. **2010**, 15, 447-56	19
900	Optimizing the success of cell transplantation therapy for stroke. **2010**, 37, 275-83	159
899	Epigenetics, hippocampal neurogenesis, and neuropsychiatric disorders: unraveling the genome to understand the mind. **2010**, 39, 73-84	121

898	Neurodevelopmental disorders involving genomic imprinting at human chromosome 15q11-q13. **2010**, 39, 13-20	77
897	A mechanism-based complementary screening approach for the amelioration and reversal of neurobehavioral teratogenicity. **2010**, 32, 109-13	6
896	Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery. **2010**, 126, 109-18	16
895	Molecular and cellular aspects of amphibian lens regeneration. **2010**, 29, 543-55	74
894	Pluripotency genes overexpressed in primate embryonic stem cells are localized on homologues of human chromosomes 16, 17, 19, and X. **2010**, 4, 25-37	3
893	Environmental epigenetic modifications and reprogramming-recalcitrant genes. **2010**, 4, 157-64	15
892	Progressive maturation in contracting cardiomyocytes derived from human embryonic stem cells: Qualitative effects on electrophysiological responses to drugs. **2010**, 4, 201-13	95
891	Generation of induced pluripotent stem cells from newborn marmoset skin fibroblasts. **2010**, 4, 180-8	92
890	Collaboration between WNT and BMP signaling promotes hemoangiogenic cell development from human fibroblast-derived iPS cells. **2010**, 4, 223-31	12
889	Long term expansion of undifferentiated human iPS and ES cells in suspension culture using a defined medium. **2010**, 5, 51-64	136
888	Derivation, characterization, and gene expression profile of two new human ES cell lines from India. **2010**, 5, 173-87	8
887	Engineering strategies to emulate the stem cell niche. **2010**, 28, 117-24	65
886	Switching cell fate: the remarkable rise of induced pluripotent stem cells and lineage reprogramming technologies. **2010**, 28, 214-23	66
885	Single cell analysis: the new frontier in 'omics'. **2010**, 28, 281-90	532
884	Site-specific DNA excision via engineered zinc finger nucleases. **2010**, 28, 445-6	7
883	The minipig as a platform for new technologies in toxicology. **2010**, 62, 227-35	57
882	Human functional genetic studies are biased against the medically most relevant primate-specific genes. **2010**, 10, 316	14
881	The ancient mammalian KRAB zinc finger gene cluster on human chromosome 8q24.3 illustrates principles of C2H2 zinc finger evolution associated with unique expression profiles in human tissues. **2010**, 11, 206	24

880	Strategies for the derivation of pluripotent cells from farm animals. **2010**, 45 Suppl 3, 25-31	4
879	Stochastic modeling of B lymphocyte terminal differentiation and its suppression by dioxin. **2010**, 4, 40	19
878	Hypoxia enhances colony formation and proliferation but inhibits differentiation of human dental pulp cells. **2010**, 55, 648-54	69
877	Neuronal intrinsic barriers for axon regeneration in the adult CNS. **2010**, 20, 510-8	160
876	Homologous recombination in human iPS and ES cells for use in gene correction therapy. **2010**, 15, 198-202	13
875	Stem cell therapies for ocular surface disease. **2010**, 15, 306-13	45
874	Impact of new technologies for cellular screening along the drug value chain. **2010**, 15, 384-90	34
873	Helpers of the cellular gatekeeper-miRNAs dance in P53 network. **2010**, 1805, 218-25	3
872	Gene therapy, gene targeting and induced pluripotent stem cells: applications in monogenic disease treatment. **2010**, 28, 715-24	6
871	SOX2 identified as a target gene for the amplification at 3q26 that is frequently detected in esophageal squamous cell carcinoma. **2010**, 202, 82-93	64
870	Examination of the expanding pathways for the regulation of p21 expression and activity. **2010**, 22, 1003-12	300
869	Effective generation of iPS cells from CD34+ cord blood cells by inhibition of p53. **2010**, 38, 154-62	79
868	Induction of pluripotency in human cord blood unrestricted somatic stem cells. **2010**, 38, 809-18, 818.e1-2	51
867	Magnetic manipulation device for the optimization of cell processing conditions. **2010**, 109, 182-8	10
866	Generation of human induced pluripotent stem cells from oral mucosa. **2010**, 110, 345-50	76
865	Epigenetic changes to human umbilical cord blood cells cultured with three proteins indicate partial reprogramming to a pluripotent state. **2010**, 316, 927-39	11
864	The Yin and Yang functions of the Myc oncoprotein in cancer development and as targets for therapy. **2010**, 316, 1429-37	82
863	Neurodegenerative disease-specific induced pluripotent stem cell research. **2010**, 316, 2560-4	22

862	Induction of pluripotency by defined factors. **2010**, 316, 2565-70	66
861	In vitro regeneration of kidney from pluripotent stem cells. **2010**, 316, 2571-7	22
860	Genetic recombination pathways and their application for genome modification of human embryonic stem cells. **2010**, 316, 2578-86	11
859	Injectable cardiac tissue engineering for the treatment of myocardial infarction. **2010**, 14, 1044-55	69
858	Recent highlights on bone stem cells: a report from Bone Stem Cells 2009, and not only **2010**, 14, 2614-21	5
857	Generation of functional human hepatic endoderm from human induced pluripotent stem cells. **2010**, 51, 329-35	347
856	Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. **2010**, 51, 297-305	903
855	Hepatocytes from induced pluripotent stem cells: a giant leap forward for hepatology. **2010**, 51, 20-2	11
854	Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. **2010**, 51, 1754-65	387
853	Generation of endoderm-derived human induced pluripotent stem cells from primary hepatocytes. **2010**, 51, 1810-9	195
852	Is iPS cell the panacea?. **2010**, 62, 170-5	9
851	Porcine induced pluripotent stem cells may bridge the gap between mouse and human iPS. **2010**, 62, 277-82	8
850	Valproic acid enhances Oct4 promoter activity in myogenic cells. **2010**, 110, 995-1004	36
849	Teratomas from pluripotent stem cells: A clinical hurdle. **2010**, 111, 769-81	166
848	Genome modification in human embryonic stem cells. **2010**, 222, 278-81	32
847	miRNAs give worms the time of their lives: small RNAs and temporal control in Caenorhabditis elegans. **2010**, 239, 1477-89	40
846	Multiphoton Imaging and Nanoprocessing of Human Stem Cells. **2010**, 7-34	0
845	A step closer to complete chemical reprogramming for generating iPS cells. **2010**, 11, 755-7	12

844	Stable propagation of human embryonic and induced pluripotent stem cells on decellularized human substrates. **2010**, 26, 1126-34	19
843	Extracellular matrix provides an optimal niche for the maintenance and propagation of mesenchymal stem cells. **2010**, 90, 45-54	74
842	AID in reprogramming: quick and efficient: identification of a key enzyme called AID, and its activity in DNA demethylation, may help to overcome a pivotal epigenetic barrier in reprogramming somatic cells toward pluripotency. **2010**, 32, 385-7	9
841	Returning to the stem state: epigenetics of recapitulating pre-differentiation chromatin structure. **2010**, 32, 791-9	20
840	The Janus face of pluripotent stem cells--connection between pluripotency and tumourigenicity. **2010**, 32, 993-1002	11
839	Effect of cell lysates on retroviral transduction efficiency of cells in suspension culture. **2010**, 105, 1168-77	
838	Transcriptional regulation of Rex1 (zfp42) in normal prostate epithelial cells and prostate cancer cells. **2010**, 224, 17-27	13
837	Competitiveness for the niche and mutual dependence of the germline and somatic stem cells in the Drosophila testis are regulated by the JAK/STAT signaling. **2010**, 223, 500-10	50
836	Origin of cardiac progenitor cells in the developing and postnatal heart. **2010**, 225, 321-5	17
835	Generation of neural crest progenitors from human embryonic stem cells. **2010**, 314, 95-103	9
834	Controlled nonviral gene delivery and expression using stable neural stem cell line transfected with a hypoxia-inducible gene expression system. **2010**, 12, 990-1001	22
833	On fixing broken muscle...fall seven times, stand up eight--Japanese proverb. **2010**, 41, 737-9	
832	Bone marrow-derived stem cells in liver repair: 10 years down the line. **2010**, 16, 118-29	67
831	On the dynamics of random Boolean networks subject to noise: attractors, ergodic sets and cell types. **2010**, 265, 185-93	79
830	Stem cell-derived hepatocytes and their use in toxicology. **2010**, 270, 3-9	76
829	Factors to consider in the use of stem cells for pharmaceutic drug development and for chemical safety assessment. **2010**, 270, 18-34	40
828	Challenges of using pluripotent stem cells for safety assessments of substances. **2010**, 270, 10-7	31
827	Characterization of human fibroblast-derived extracellular matrix components for human pluripotent stem cell propagation. **2010**, 6, 4622-33	39

826	The microwell control of embryoid body size in order to regulate cardiac differentiation of human embryonic stem cells. **2010**, 31, 1885-93	159
825	Control of cell attachment through polyDNA hybridization. **2010**, 31, 2229-35	65
824	Transient in vitro epigenetic reprogramming of skin fibroblasts into multipotent cells. **2010**, 31, 2779-87	25
823	Cartilage repair using hyaluronan hydrogel-encapsulated human embryonic stem cell-derived chondrogenic cells. **2010**, 31, 6968-80	206
822	Immunity to stemness genes in human cancer. **2010**, 22, 245-50	24
821	Autologous blood cell therapies from pluripotent stem cells. **2010**, 24, 27-37	57
820	Differentiation of human multipotent dermal fibroblasts into islet-like cell clusters. **2010**, 11, 46	27
819	Culture of human pluripotent stem cells using completely defined conditions on a recombinant E-cadherin substratum. **2010**, 10, 60	146
818	Generation of human induced pluripotent stem cells by simple transient transfection of plasmid DNA encoding reprogramming factors. **2010**, 10, 81	169
817	Regeneration and reprogramming compared. **2010**, 8, 5	80
816	Combination stem cell therapy for heart failure. **2010**, 3, 5	32
815	Histone H3 lysine 4 methylation is associated with the transcriptional reprogramming efficiency of somatic nuclei by oocytes. **2010**, 3, 4	34
814	Cellules souches embryonnaires et applications thérapeutiques. **2010**, 2010, 41-46	
813	Bioéthique et cellules souches. **2010**, 2010, 61-67	
812	Low-density Taqman miRNA array reveals miRNAs differentially expressed in prostatic stem cells and luminal cells. **2010**, 70, 297-304	13
811	Distinguishing between mouse and human pluripotent stem cell regulation: the best laid plans of mice and men. **2010**, 28, 419-30	65
810	Human induced pluripotent stem cell lines show stress defense mechanisms and mitochondrial regulation similar to those of human embryonic stem cells. **2010**, 28, 661-73	239
809	Hemangioblastic derivatives from human induced pluripotent stem cells exhibit limited expansion and early senescence. **2010**, 28, 704-12	320

808	No evidence for clonal selection due to lentiviral integration sites in human induced pluripotent stem cells. **2010**, 28, 687-94	32
807	Engineering musculoskeletal tissues with human embryonic germ cell derivatives. **2010**, 28, 765-74	37
806	Butyrate greatly enhances derivation of human induced pluripotent stem cells by promoting epigenetic remodeling and the expression of pluripotency-associated genes. **2010**, 28, 713-20	355
805	The senescence-related mitochondrial/oxidative stress pathway is repressed in human induced pluripotent stem cells. **2010**, 28, 721-33	485
804	Induced pluripotent stem cells : it looks simple but can looks deceive?. **2010**, 28, 845-50	14
803	Optimal suppression of protein phosphatase 2A activity is critical for maintenance of human embryonic stem cell self-renewal. **2010**, 28, 874-84	22
802	Concise review: isoforms of OCT4 contribute to the confusing diversity in stem cell biology. **2010**, 28, 885-93	156
801	Adult ciliary epithelial cells, previously identified as retinal stem cells with potential for retinal repair, fail to differentiate into new rod photoreceptors. **2010**, 28, 1048-59	94
800	Comparison of reprogramming efficiency between transduction of reprogramming factors, cell-cell fusion, and cytoplast fusion. **2010**, 28, 1338-48	26
799	Major histocompatibility complex-I expression on embryonic stem cell-derived vascular progenitor cells is critical for syngeneic transplant survival. **2010**, 28, 1465-75	19
798	Krüppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells. **2010**, 28, 1510-7	69
797	Concise review: Kidney stem/progenitor cells: differentiate, sort out, or reprogram?. **2010**, 28, 1649-60	75
796	Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. **2010**, 28, 1728-40	330
795	Efficient generation of functional dopaminergic neurons from human induced pluripotent stem cells under defined conditions. **2010**, 28, 1893-904	246
794	Novel hyperactive transposons for genetic modification of induced pluripotent and adult stem cells: a nonviral paradigm for coaxed differentiation. **2010**, 28, 1760-71	35
793	Canonical Wnt/β-catenin regulation of liver receptor homolog-1 mediates pluripotency gene expression. **2010**, 28, 1794-804	108
792	Memory in induced pluripotent stem cells: reprogrammed human retinal-pigmented epithelial cells show tendency for spontaneous redifferentiation. **2010**, 28, 1981-91	156
791	Induced adult stem (iAS) cells and induced transit amplifying progenitor (iTAP) cells-a possible alternative to induced pluripotent stem (iPS) cells?. **2010**, 4, 159-62	6

790	Skeletal tissue engineering using embryonic stem cells. **2010**, 4, 165-80	39
789	Passaged human chondrocytes accumulate extracellular matrix when induced by bovine chondrocytes. **2010**, 4, 233-41	21
788	Induced pluripotent stem cells (iPSCs): the emergence of a new champion in stem cell technology-driven biomedical applications. **2010**, 4, 413-21	19
787	Transdifferentiation of adipose-derived stem cells into hepatocytes: a new approach. **2010**, 30, 913-22	42
786	In vitro organogenesis using multipotent cells. **2010**, 23, 1-14	5
785	Establishment of induced pluripotent stem cells from human neonatal tissues. **2010**, 23, 113-8	17
784	Regenerative medicine in dermatology: biomaterials, tissue engineering, stem cells, gene transfer and beyond. **2010**, 19, 697-706	72
783	Hematopoietic differentiation from human ESCs as a model for developmental studies and future clinical translations. Invited review following the FEBS Anniversary Prize received on 5 July 2009 at the 34th FEBS Congress in Prague. **2010**, 277, 5014-25	12
782	Generating induced pluripotent stem cells from common marmoset (Callithrix jacchus) fetal liver cells using defined factors, including Lin28. **2010**, 15, 959-69	103
781	Stem cell therapies for recessive dystrophic epidermolysis bullosa. **2010**, 163, 1149-56	19
780	Prospects for the manufacture of red cells for transfusion. **2010**, 149, 22-34	28
779	An introduction to induced pluripotent stem cells. **2010**, 151, 16-24	22
778	Neural stem cell systems: physiological players or in vitro entities?. **2010**, 11, 176-87	251
777	Embryoid body formation of human amniotic fluid stem cells depends on mTOR. **2010**, 29, 966-77	65
776	Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast. **2010**, 29, 1732-40	125
775	EWS-Oct-4B, an alternative EWS-Oct-4 fusion gene, is a potent oncogene linked to human epithelial tumours. **2010**, 102, 436-46	6
774	Efficient and rapid generation of induced pluripotent stem cells using an alternative culture medium. **2010**, 20, 383-6	27
773	Induced pluripotent stem cells: paths to new medicines. A catalyst for disease modelling, drug discovery and regenerative therapy. **2010**, 11, 161-5	28

772	Restoration of cellular function of mesenchymal stem cells from a hypophosphatasia patient. **2010**, 17, 494-502	17
771	Comparative efficacy of dermal fibroblast-mediated and direct adenoviral bone morphogenetic protein-2 gene therapy for bone regeneration in an equine rib model. **2010**, 17, 733-44	26
770	Reprogramming towards pluripotency requires AID-dependent DNA demethylation. **2010**, 463, 1042-7	564
769	Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. **2010**, 464, 292-6	260
768	Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. **2010**, 465, 808-12	573
767	Extrinsic regulation of pluripotent stem cells. **2010**, 465, 713-20	243
766	Nuclear reprogramming to a pluripotent state by three approaches. **2010**, 465, 704-12	579
765	A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. **2010**, 468, 316-20	358
764	L1 retrotransposition in neurons is modulated by MeCP2. **2010**, 468, 443-6	479
763	Direct conversion of human fibroblasts to multilineage blood progenitors. **2010**, 468, 521-6	581
762	An allosteric inhibitor of substrate recognition by the SCF(Cdc4) ubiquitin ligase. **2010**, 28, 733-7	118
761	Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. **2010**, 28, 848-55	949
760	Epigenetic modifications in pluripotent and differentiated cells. **2010**, 28, 1079-88	302
759	Stem cell biologists sure play a mean pinball. **2010**, 28, 333-5	10
758	RNA interference in three humans. **2010**, 28, 335	1
757	DPPA4 modulates chromatin structure via association with DNA and core histone H3 in mouse embryonic stem cells. **2010**, 15, 327-37	13
756	Genetics and epigenetics of the X chromosome. **2010**, 1214, E18-33	33
755	Cell therapy strategies and improvements for muscular dystrophy. **2010**, 17, 1222-9	38

754	Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine. **2010**, 17, 1230-7	35
753	Pluripotent patents make prime time: an analysis of the emerging landscape. **2010**, 28, 557-9	13
752	Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. **2010**, 42, 1113-7	773
751	Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. **2010**, 11, 207-15	91
750	Combinatorial development of biomaterials for clonal growth of human pluripotent stem cells. **2010**, 9, 768-78	464
749	A defined glycosaminoglycan-binding substratum for human pluripotent stem cells. **2010**, 7, 989-94	214
748	Induced pluripotent stem cell technology for the study of human disease. **2010**, 7, 25-7	43
747	Sorting cardiomyocytes: a simple solution after all?. **2010**, 7, 40-2	11
746	Generation of mouse-induced pluripotent stem cells with plasmid vectors. **2010**, 5, 418-28	174
745	Isolation and cultivation of human keratinocytes from skin or plucked hair for the generation of induced pluripotent stem cells. **2010**, 5, 371-82	211
744	An efficient and easy-to-use cryopreservation protocol for human ES and iPS cells. **2010**, 5, 588-94	56
743	Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2. **2010**, 5, 811-20	80
742	A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. **2010**, 5, 647-60	46
741	Human stem cells and drug screening: opportunities and challenges. **2010**, 9, 367-72	125
740	The challenge of immunogenicity in the quest for induced pluripotency. **2010**, 10, 868-75	63
739	Active DNA demethylation: many roads lead to Rome. **2010**, 11, 607-20	840
738	Achieving pluripotency. **2010**, 11, 677	1
737	Islet cell transplantation for Type 1 diabetes. **2010**, 2, 16-22	63

736	The integrative aspects of cardiac physiology and their implications for cell-based therapy. **2010**, 1188, 7-14	18
735	iPS cell technology in regenerative medicine. **2010**, 1192, 38-44	76
734	Purification of human muscle-derived cells using an immunoselective method for potential use in urological regeneration. **2010**, 105, 1598-603	6
733	Germ plasm-like Dot cells maintain their wound regenerative function after in vitro expansion. **2010**, 37, e136-44	9
732	Embryonic and adult stem cell systems in mammals: ontology and regulation. **2010**, 52, 115-29	19
731	Generation of genetically modified animals using spermatogonial stem cells. **2010**, 52, 303-10	20
730	Direct reprogramming 101. **2010**, 52, 319-33	15
729	Fishing Cat Cell Biobanking for Conservation.	
728	NvPrdm14d-expressing neural progenitor cells contribute to non-ectodermal neurogenesis in Nematostella vectensis.	
727	Pancreatic Transdifferentiation Using Cell Transcription Factors for Type 1 Diabetes Treatment. **2022**, 11, 2145	1
726	3D in vitro Models of Pathological Skeletal Muscle: Which Cells and Scaffolds to Elect?. 10,	0
725	Nutritional assessment models for diabetes and aging.	0
724	Human iPSC-derived cerebral organoids model features of Leigh syndrome and reveal abnormal corticogenesis. **2022**, 149,	3
723	Cortical Organoids to Model Microcephaly. **2022**, 11, 2135	0
722	The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders. **2022**, 11,	1
721	Stem cells differentiation into insulin-producing cells (IPCs): recent advances and current challenges. **2022**, 13,	2
720	Establishment of autaptic culture with human induced pluripotent stem cell-derived astrocytes. **2022**, 104762	
719	Developmental genetics with model organisms. **2022**, 119,	7

718	CELLoGeNe - an Energy Landscape Framework for Logical Networks Controlling Cell Decisions. **2022**, 104743	
717	Aberrant NOVA1 function disrupts alternative splicing in early stages of amyotrophic lateral sclerosis.	0
716	Promising Stem Cell therapy in the Management of HIV and AIDS: A Narrative Review. Volume 16, 89-105	0
715	Large-scale genome editing based on high-capacity adenovectors and ´CRISPR-Cas9 nucleases rescues full-length dystrophin synthesis in DMD muscle cells.	0
714	Manipulating Cardiomyocyte Plasticity for Heart Regeneration. 10,	0
713	Generation of human myogenic progenitors from pluripotent stem cells for in vivo regeneration. **2022**, 79,	1
712	Single transcription factor efficiently leads human induced pluripotent stem cells to functional microglia. **2022**, 42,	1
711	P97/VCP ATPase inhibitors can rescue p97 mutation-linked motor neuron degeneration. **2022**, 4,	0
710	iPSCs in NK Cell Manufacturing and NKEV Development. 13,	0
709	PAX8 in the Junction between Development and Tumorigenesis. **2022**, 23, 7410	0
708	T-Cell Progenitors As A New Immunotherapy to Bypass Hurdles of Allogeneic Hematopoietic Stem Cell Transplantation. 13,	
707	Probing the molecular and cellular pathological mechanisms of schizophrenia using human induced pluripotent stem cell models. **2022**,	0
706	Droplet microarray based screening identifies proteins for maintaining pluripotency of hiPSCs. 2200718	
705	Step-by-step protocols for non-viral derivation of transgene-free induced pluripotent stem cells from somatic fibroblasts of multiple mammalian species.	0
704	Apoptotic vesicles inherit SOX2 from pluripotent stem cells to accelerate wound healing by energizing mesenchymal stem cells. **2022**,	2
703	Cerebral malaria □modelling interactions at the bloodBrain barrier in vitro. **2022**, 15,	0
702	Efficient Dlx2-mediated astrocyte-to-neuron conversion and inhibition of neuroinflammation by NeuroD1.	0
701	Induced neural stem cells from Macaca fascicularis show potential of dopaminergic neuron specification and efficacy in a mouse Parkinson's disease model. **2022**, 124, 151927	

700	Opportunities and impediments of human pluripotent stem cell-derived islets in the treatment of diabetes. **2022**, 17, 100064	0
699	Impaired migration of autologous induced neural stem cells from patients with schizophrenia and implications for genetic risk for psychosis. **2022**, 246, 225-234	0
698	Establishment of effective and safe recipient preparation for germ-cell transplantation with intra-testicular busulfan treatment in pre-pubertal Barbari goats. **2022**, 189, 270-279	
697	Opening up the black box of human cell plasticity. **2022**, 3, 100276	
696	Quality criteria for in vitro human pluripotent stem cell-derived models of tissue-based cells. **2022**, 112, 36-50	0
695	Maturation of induced pluripotent stem cell-derived cardiomyocytes and its therapeutic effect on myocardial infarction in mouse. **2023**, 20, 286-305	0
694	Attention-deficit/hyperactivity disorder. **2023**, 29-44	
693	Cellular analysis of SOD1 protein-aggregation propensity and toxicity: a case of ALS with slow progression harboring homozygous SOD1-D92G mutation. **2022**, 12,	0
692	Liver Regeneration by Hematopoietic Stem Cells: Have We Reached the End of the Road?. **2022**, 11, 2312	0
691	Gametogenesis: Exploring an Endogenous Rejuvenation Program to Understand Cellular Aging and Quality Control. **2022**, 56,	
690	The progress of pluripotent stem cell-derived pancreatic β-cells regeneration for diabetic therapy. 13,	0
689	Generation of Human Induced Pluripotent Stem Cell Lines SPPHIi003-A and SPPHIi004-A from Two Patients with Sporadic Alzheimer's Disease in Southwestern China. **2022**, 102876	
688	Enhanced efficiency of generating human-induced pluripotent stem cells using Lin28-30Kc19 fusion protein. 10,	0
687	Approaches to kidney replacement therapies: opportunities and challenges. 10,	0
686	Human Cellular Models for Retinal Disease: From iPSCs to Organoids. **2022**, Publish Ahead of Print,	
685	Automatic differentiation of human induced pluripotent stem cells toward synchronous neural networks on an arrayed monolayer of nanofiber membrane. **2022**,	
684	Genome-wide association study of hyperthyroidism based on electronic medical record from Taiwan. 9,	0
683	Disease Modeling of Pituitary Adenoma Using Human Pluripotent Stem Cells. **2022**, 14, 3660	0

682	Chemical Replacement of Noggin with Dorsomorphin Homolog 1 for Cost-Effective Direct Neuronal Conversion.	
681	Transcriptomic and proteomic retinal pigment epithelium signatures of age-related macular degeneration. **2022**, 13,	1
680	A transcriptional regulatory network of HNF4 and HNF1 involved in human diseases and drug metabolism. 1-25	
679	Stem cell challenge in cancer progression, oncology and therapy. **2022**, 840, 146748	1
678	Generation of neuronal/glial mixed cultures from human induced pluripotent stem cells (hiPSCs). **2022**, 229-245	
677	Biotechnology applications in neurodegenerative diseases. **2022**, 89-103	
676	Patient-derived cells an irreplaceable tool for research of reduced penetrance in movement disorders. **2022**, 34, 125-130	
675	Identifying type Os: Spelling out the future of red blood cell products in military medicine.	
674	Durable alveolar engraftment of PSC-derived lung epithelial cells into immunocompetent mice.	0
673	Regenerative Therapy for Chronic Heart Failure: Prospects for the Use of Cellular and Acellular Technologies. **2022**, 12, 293-301	
672	The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits.	1
671	Podocytes derived from human induced pluripotent stem cells: characterization, comparison, and modeling of diabetic kidney disease. **2022**, 13,	1
670	Artificial Scaffolds in Cardiac Tissue Engineering. **2022**, 12, 1117	1
669	Medical Adhesives and Their Role in Laparoscopic Surgery A Review of Literature. **2022**, 15, 5215	0
668	Paracrine IGF-1 Activates SOD2 Expression and Regulates ROS/p53 Axis in the Treatment of Cardiac Damage in D-Galactose-Induced Aging Rats after Receiving Mesenchymal Stem Cells. **2022**, 11, 4419	0
667	Influence of Cell Type in In Vitro Induced Reprogramming in Cattle. **2022**, 12, 1139	0
666	Adipose-derived stem cells attenuate acne-related inflammation via suppression of NLRP3 inflammasome. **2022**, 13,	0
665	Using 2D and 3D pluripotent stem cell models to study neurotropic viruses. 2,	

664	A multimodal iPSC platform for cystic fibrosis drug testing. **2022**, 13,	0
663	THE MAIN SIGNALING SYSTEMS INVOLVED IN THE FUNCTIONING OF STEM CELLS (review of literature data). **2022**, 327-354	
662	Methionine metabolism regulates pluripotent stem cell pluripotency and differentiation through zinc mobilization. **2022**, 40, 111120	0
661	Assessing the consistency of iPSC and animal models in cystic fibrosis modelling: A meta-analysis. **2022**, 17, e0272091	
660	Suspension culture of human induced pluripotent stem cell-derived intestinal organoids using natural polysaccharides. **2022**, 121696	
659	What can we learn from kidney organoids?. **2022**,	1
658	Bilirubin-Induced Neurological Damage: Current and Emerging iPSC-Derived Brain Organoid Models. **2022**, 11, 2647	0
657	Recent Advances in Animal Models, Diagnosis, and Treatment of Temporomandibular Joint Osteoarthritis.	
656	Advances in construction and modeling of functional neural circuits in vitro.	0
655	The negative regulation of gene expression by microRNAs as key driver of inducers and repressors of cardiomyocyte differentiation. **2022**, 136, 1179-1203	
654	Stem cell-based therapy for human diseases. **2022**, 7,	10
653	Metabolic Maturation Increases Susceptibility to Hypoxia-induced Damage in Human iPSC-derived Cardiomyocytes.	0
652	1H NMR Metabolite Monitoring during the Differentiation of Human Induced Pluripotent Stem Cells Provides New Insights into the Molecular Events That Regulate Embryonic Chondrogenesis. **2022**, 23, 9266	1
651	Secretory co-factors in next-generation cellular therapies for cancer. 13,	
650	Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies. **2022**, 5, 517-535	0
649	Genome Maintenance in Mammalian Stem Cells. **2022**, 56,	1
648	Application of CRISPR-Cas9 Gene Editing for HIV Host Factor Discovery and Validation. **2022**, 11, 891	0
647	Epigenetic profiling and incidence of disrupted development point to gastrulation as aging ground zero in Xenopus laevis.	0

646	Iris-derived induced pluripotent stem cells that express GFP in all somatic cells of mice and differentiate into functional retinal neurons.	
645	Strategies to Improve the Safety of iPSC-Derived Cells for Cell Replacement in Diabetes. 35,	0
644	Metabolic Profile Variations along the Differentiation of Human-Induced Pluripotent Stem Cells to Dopaminergic Neurons. **2022**, 10, 2069	
643	Motor neuron-derived induced pluripotent stem cells as a drug screening platform for amyotrophic lateral sclerosis. 10,	
642	Accelerated neuronal aging in vitro ~melting watch ~. 14,	0
641	Type 1 Diabetes and Engineering Enhanced Islet Transplantation. **2022**, 114481	2
640	Case report: Transplantation of human induced pluripotent stem cell-derived cardiomyocyte patches for ischemic cardiomyopathy. 9,	2
639	Development of a platform to investigate long-term potentiation in human iPSC-derived neuronal networks. **2022**,	0
638	Chromatin structure meets cryo-EM: Dynamic building blocks of the functional architecture. **2022**, 194851	0
637	Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models.	1
636	Cortical interneuron development is affected in leukodystrophy 4H.	
635	Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today?. **2022**, 14, 3758	0
634	Improving the differentiation potential of pluripotent stem cells by optimizing culture conditions. **2022**, 12,	0
633	A scalable and tunable thermoreversible polymer for 3D human pluripotent stem cell biomanufacturing. **2022**, 104971	0
632	Challenges and innovation: Disease modeling using human-induced pluripotent stem cell-derived cardiomyocytes. 9,	0
631	In Vivo Cellular Magnetic Imaging: Labeled versus Unlabeled Cells. 2207626	0
630	MSH2 and MSH6 as size dependent cellular determinants for prime editing in human embryonic stem cells.	
629	Molecular evolution and inheritance pattern of Sox gene family among Bovidae.	

628	Manufacturing with pluripotent stem cells (PSConf 2021): Key issues for future research and development. **2022**, 55,	0
627	Advanced Cell Therapies for Glioblastoma. 13,	0
626	Human iPSC-derived astrocytes generated from donors with globoid cell leukodystrophy display phenotypes associated with disease. **2022**, 17, e0271360	
625	Stepwise differentiation of functional pancreatic β-cells from human pluripotent stem cells. **2022**, 11,	0
624	Quantifying Chromosome Structural Reorganizations during Differentiation, Reprogramming, and Transdifferentiation. **2022**, 129,	1
623	Development of lacrimal gland organoids from iPSC derived multizonal ocular cells.	
622	Differentiation of human induced pluripotent stem cells into cortical neural stem cells.	
621	Maiden voyage: induced pluripotent stem cell-based drug screening for amyotrophic lateral sclerosis.	0
620	Identification of DOT1L Inhibitor in a Screen for Factors that Promote Dopaminergic Neuron Survival.	
619	Mass spectrometry imaging reveals early metabolic priming of cell lineage in differentiating human induced pluripotent stem cells.	
618	The Advantages, Challenges, and Future of Human-Induced Pluripotent Stem Cell Lines in Type 2 Long QT Syndrome.	
617	Generation and Characterization of Novel iPSC Lines from a Portuguese Family Bearing Heterozygous and Homozygous GRN Mutations. **2022**, 10, 1905	0
616	Identification of putative enhancer-like elements predicts regulatory networks active in planarian adult stem cells. 11,	1
615	Recent Advances in 3D-Cultured Brain Tissue Models Derived from Human iPSCs.	0
614	Reliable multiplex generation of pooled induced pluripotent stem cells for genetic testing.	
613	Comparative Functional RNA Editomes of Neural Differentiation from Human PSCs.	1
612	Mutated KLF4(K409Q) in meningioma binds STRs and activates FGF3 gene expression. **2022**, 25, 104839	0
611	Concise review: Cancer cell reprogramming and therapeutic implications. **2022**, 24, 101503	0

610	SHOX2 refines the identification of human sinoatrial nodal cell population in the in´vitro cardiac differentiation. **2022**, 21, 239-249	
609	Growth and differentiation of human induced pluripotent stem cell (hiPSC)-derived kidney organoids using fully synthetic peptide hydrogels. **2023**, 21, 142-156	0
608	Cell-Based and Selected Cell-Free Therapies for Myocardial Infarction: How Do They Compare to the Current Treatment Options?. **2022**, 23, 10314	1
607	The heterogeneity of microglial activation and its epigenetic and non-coding RNA regulations in the immunopathogenesis of neurodegenerative diseases. **2022**, 79,	1
606	The Impairment of Blood-Brain Barrier in Alzheimer‐s Disease: Challenges and Opportunities with Stem Cells. **2022**, 23, 10136	1
605	Acquisition and maintenance of pluripotency are influenced by fibroblast growth factor, leukemia inhibitory factor, and 2i in bovine-induced pluripotent stem cells. 10,	0
604	Microfluidic Formulation of Topological Hydrogels for Microtissue Engineering.	2
603	Current status of umbilical cord blood storage and provision to private biobanks by institutions handling childbirth in Japan. **2022**, 23,	0
602	Generation of an induced pluripotent stem cell lines HMSCASTi001-A from peripheral blood mononuclear cells of a 35-year-old healthy male. **2022**, 64, 102908	0
601	Human PSCs determine the competency of cerebral organoid differentiation via FGF signaling and epigenetic mechanisms. **2022**, 25, 105140	1
600	Chemically-induced osteogenic cells for bone tissue engineering and disease modeling. **2022**, 289, 121792	0
599	Generation of an induced pluripotent stem cell lines HMSCASTi002-A from peripheral blood mononuclear cells of a 38-year-old healthy female individual. **2022**, 64, 102907	0
598	The past, present, and future for constitutional ring chromosomes: A report of the international consortium for human ring chromosomes. **2022**, 3, 100139	0
597	Progress in human stem cell-derived models for developmental and reproductive toxicology studies. **2022**, 113, 170-171	0
596	Induced hepatic stem cells are suitable for human hepatocyte production. **2022**, 25, 105052	0
595	Locally transplanted human urine-induced nephron progenitor cells contribute to renal repair in mice kidney with diabetic nephropathy. **2022**, 629, 128-134	1
594	Primary failure of tooth eruption: Etiology and management. **2022**, 58, 258-267	0
593	A new path to mental disorders: Through gap junction channels and hemichannels. **2022**, 142, 104877	0

592	Models to study basic and applied aspects of lysosomal storage disorders. **2022**, 190, 114532	0
591	Recent advances for using human induced-pluripotent stem cells as pain-in-a-dish models of neuropathic pain. **2022**, 358, 114223	0
590	Efficient reprogramming of human fibroblasts using RNA reprogramming with DAPT and iDOT1L under normoxia conditions. **2022**, 21, 389-397	0
589	Geroscience: a unifying view on aging as a risk factor. **2023**, 587-600	0
588	Adult Stem Cell Therapy as Regenerative Medicine for End-Stage Liver Disease. **2022**,	0
587	Modulating Specific Pathways In Vitro to Understand the Synaptic Dysfunction of Schizophrenia. **2022**, 121-127	0
586	The Establishment of In-Vitro Human Induced Pluripotent Stem Cell-Derived Neurons.	0
585	Advances in clinical molecular pathology research using organoid-based patient-derived models. **2022**, 157, 387-387	0
584	Intracerebroventricular transplantation of human iPSC-derived neural stem cells (hiPSC-NSCs) into neonatal mice. **2022**, 127-147	0
583	Responses to antibiotics in human iPSC-derived neurons based on the clinical antibiotic-associated encephalopathy classification. **2022**, 47, 429-437	0
582	Leveraging Microelectrode Array Technology for Phenotyping Stem Cell-Derived Neurodevelopmental Disease Models. **2022**, 117-133	0
581	Stem Cells and Kidney Regeneration. **2022**, 115-141	0
580	Hyperoxaluria. **2022**, 831-846	0
579	Preparation of Functional Human Hepatocytes Ex Vivo. **2022**, 269-278	0
578	Modeling Schizophrenia In Vitro: Challenges and Insights on Studying Brain Cells. **2022**, 35-51	0
577	An agent-based model for cost-effectiveness analysis in the manufacture of allogeneic human induced pluripotent cells in Japan. **2022**, 2203-2208	2
576	Fabrication of Textile-Based Scaffolds Using Electrospun Nanofibers for Biomedical Applications. **2022**,	0
575	Messenger RNA Therapeutics: Start of a New Era in Medicine. **2022**, 41-71	0

574	Generation and Application of Directly Reprogrammed Endothelial Cells. **2022**, 52, 643	0
573	CRISPR/Cas9 Gene Editing of RYR2 in Human iPSC-Derived Cardiomyocytes to Probe Ca2+ Signaling Aberrancies of CPVT Arrhythmogenesis. **2022**, 41-52	0
572	The Role of TRAF7 in Tumorigenesis. **2022**, 12, 188-198	0
571	Molecular Signature of Stem Cells Undergoing Cardiomyogenic Differentiation. **2022**, 1-43	0
570	DNA damage signaling, cell reprogramming, and differentiation. **2022**, 157-166	0
569	Imbalance in glutamatergic and GABAergic transmission in Down syndrome and therapeutic targets. **2022**, 275-320	0
568	A CRISPR/Cas9-Based Toolkit to Test Gain- and Loss-of-Gene Function in Brain Organoids. **2022**, 75-92	0
567	Semi-3D cultures using Laminin 221 as a coating material for human induced pluripotent stem cells. **2022**, 9,	0
566	New Prospects for Retinal Pigment Epithelium Transplantation. **2022**, 11, 302-313	1
565	????, ??????, iPS ??????????????????. **2022**, 125, 1281-1287	0
564	Chimpanzee and pig-tailed macaque iPSCs: Improved culture and generation of primate cross-species embryos. **2022**, 40, 111264	1
563	From a Single Cell to a Whole Human Liver: Disease Modeling and Transplantation.	0
562	DJ-1 is an essential downstream mediator in PINK1/parkin-dependent mitophagy.	1
561	A small-molecule approach towards the Fountain of Youth: chemically induced pluripotent stem cells (CiPSCs).	0
560	CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics. **2022**, 40, 1597-1623	1
559	Analysis of Dormancy-Associated Transcriptional Networks Reveals a Shared Quiescence Signature in Lung and Colorectal Cancer. **2022**, 23, 9869	1
558	Abnormal morphology and function in retinal ganglion cells derived from patients-specific iPSCs generated from individuals with Leber hereditary optic neuropathy.	1
557	Cryostorage of Mesenchymal Stem Cells and Biomedical Cell-Based Products. **2022**, 11, 2691	1

556	Human stem cell models to study placode development, function and pathology. **2022**, 149,	1
555	Biomaterialien Nachbildung der Stammzellnische in Bioreaktoren. **2022**, 28, 501-503	0
554	Stammzelltherapien f Muskeldystrophien. **2022**, 28, 493-496	0
553	Investigation of PTC124-mediated translational readthrough in a retinal organoid model of AIPL1-associated Leber congenital amaurosis. **2022**,	2
552	Retinoic acid delays initial photoreceptor differentiation and results in a highly structured mature retinal organoid. **2022**, 13,	0
551	Comparative characteristics of human stem cells.	0
550	Human-induced pluripotent stem cell-atrial-specific cardiomyocytes and atrial fibrillation. **2022**, 10, 9588-9601	0
549	Deciphering the transcriptional landscape of human pluripotent stem cell-derived GnRH neurons: the role of Wnt signaling in patterning the neural fate.	1
548	iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine. **2022**, 12, 1485	0
547	Retinal organoids provide unique insights into molecular signatures of inherited retinal disease throughout retinogenesis.	0
546	Ribosomal RNA 2 O-methylation dynamics impact cell fate decisions.	0
545	hPSC gene editing for cardiac disease therapy.	0
544	Microfluidics for Neuronal Cell and Circuit Engineering. **2022**, 122, 14842-14880	1
543	Revisiting the bad luck hypothesis: Cancer risk and aging are linked to replication-driven changes to the epigenome.	0
542	Excitation-contraction coupling in mammalian skeletal muscle: Blending old and last-decade research. 13,	1
541	Successful Derivation of Hepatoblasts, Cholangiocytes and Hepatocytes from Simian Induced Pluripotent Stem Cells. **2022**, 23, 10861	0
540	Diseased, differentiated and difficult: Strategies for improved engineering of in vitro neurological systems. 16,	0
539	Aberrant autophagy in lysosomal storage disorders marked by a lysosomal SNARE protein shortage due to suppression of endocytosis.	0

538	Multiplatform Modeling of Atrial Fibrillation Identifies Phospholamban as Central Regulator of Cardiac Rhythm.	0
537	HOX genes in stem cells: Maintaining cellular identity and regulation of differentiation. 10,	0
536	Donors for nerve transplantation in craniofacial soft tissue injuries. 10,	0
535	New Prospects in Skin Tissue Engineering and Fabrication. **2022**, 423-459	0
534	Direct Cell Conversion of Somatic Cells into Dopamine Neurons: Achievements and Perspectives.	0
533	Novel strategies in nephrology: what to expect from the future?.	1
532	Assessment of Myocardial Diastolic Dysfunction as a Result of Myocardial Infarction and Extracellular Matrix Regulation Disorders in the Context of Mesenchymal Stem Cell Therapy. **2022**, 11, 5430	0
531	Stimuli-responsive Hydrogels: Smart State of-the-art Platforms for Cardiac Tissue Engineering.	1
530	Molecular Pathophysiology of Chronic Wounds: Current State and Future Directions. a041243	0
529	Effective use of genetically-encoded optical biosensors for profiling signalling signatures in iPSC-CMs derived from idiopathic dilated cardiomyopathy patients.	0
528	Production and nonclinical evaluation of an autologous iPSC-derived platelet product for the iPLAT1 clinical trial.	1
527	Enhancing Sox/Oct cooperativity induces higher-grade developmental reset.	0
526	Organoids and microphysiological systems: Promising models for accelerating AAV gene therapy studies. 13,	1
525	An optimized workflow to generate and characterize iPSC-derived motor neuron (MN) spheroids.	1
524	Building in vitro models of the brain to understand the role of APOE in Alzheimer's disease. **2022**, 5, e202201542	2
523	Development of the T-ALLiPSC-based therapeutic cancer vaccines for T-cell acute lymphoblastic leukemia. **2022**, 39,	0
522	Quantitative Assessment of Fluorescent Reporter Expression in 3D Retinal Organoids. **2023**, 121-138	0
521	Modelling metabolic diseases and drug response using stem cells and organoids.	2

520	Transplantation of Human Induced Pluripotent Stem Cell-Derived Neural Progenitor Cells Promotes Forelimb Functional Recovery after Cervical Spinal Cord Injury. **2022**, 11, 2765	0
519	SOX2 inhibits LLGL2 polarity protein in esophageal squamous cell carcinoma via miRNA-142-3p. **2022**, 23, 1-15	0
518	An Alternate Approach to Generate Induced Pluripotent Stem Cells with Precise CRISPR/Cas9 Tool. **2022**, 2022, 1-17	0
517	Passage number affects differentiation of sensory neurons from human induced pluripotent stem cells. **2022**, 12,	1
516	In vitro skeletal muscle models for type 2 diabetes. **2022**, 3, 031306	1
515	Rare and undiagnosed diseases: From disease-causing gene identification to mechanism elucidation. **2022**,	0
514	Gene therapy using genome-edited iPS cells for targeting malignant glioma.	0
513	Cord Blood-Derived Natural Killer Cell Exploitation in Immunotherapy Protocols: More Than a Promise?. **2022**, 14, 4439	0
512	Modelling urea cycle disorders using iPSCs. **2022**, 7,	1
511	Comparative roadmaps of reprogramming and oncogenic transformation identify Bcl11b and Atoh8 as broad regulators of cellular plasticity. **2022**, 24, 1350-1363	0
510	Human embryonic stem cells overexpressing dopaminergic transcription factors survive and differentiate in the substantia nigra in vivo.	0
509	A next-generation iPSC-derived forebrain organoid model of tauopathy with tau fibrils by AAV-mediated gene transfer. **2022**, 2, 100289	0
508	Cell-based experimental strategies for myelin repair in multiple sclerosis.	0
507	HiPSC encapsulation geometry impacts 3D developing human engineered cardiac tissue functionality.	0
506	Platform-Agnostic CellNet (PACNet) enables cross-study meta-analysis of cell fate engineering protocols.	0
505	ADSCs increase the autophagy of chondrocytes through decreasing miR-7-5p in Osteoarthritis rats by targeting ATG4A.	0
504	Assessing kidney development and disease using kidney organoids and CRISPR engineering. 10,	0
503	Latest models for the discovery and development of rheumatoid arthritis drugs.	0

502	Dipeptidyl peptidase-4 cell surface expression marks an abundant adipose stem/progenitor cell population with high stemness in human white adipose tissue. **2022**, 11, 601-615	0
501	The genome-wide mutational consequences of DNA hypomethylation.	0
500	Inhibition of Glycogen Synthase Kinase 3β Enhances Functions of Induced Pluripotent Stem Cell-Derived Brain Microvascular Endothelial Cells in the Blood–Brain Barrier. **2022**, 45, 1525-1530	0
499	Micro and milli-chamber bioreactors for human induced pluripotent stem cell culture: model and experimental validation. **2022**, 108660	0
498	A transcriptional network of cell cycle dysregulation in noninvasive papillary urothelial carcinoma. **2022**, 12,	0
497	Biomimetic Strategies for Peripheral Nerve Injury Repair: An Exploration of Microarchitecture and Cellularization.	0
496	Liver Organoids, Novel and Promising Modalities for Exploring and Repairing Liver Injury.	0
495	Development of appropriate fatty acid formulations to raise the contractility of constructed myocardial tissues. **2022**, 21, 413-423	0
494	Challenges of cell therapies for retinal diseases. **2022**,	0
493	Generation of Whole Kidney and Other Possible Strategies to Renal Replacement Therapy in the Future. **2022**, 201-216	0
492	Cerebral Organoids in Developmental Neuroscience. **2022**, 551-567	0
491	Human-Induced Pluripotent Stem Cells are a Unique Approach for Modeling Schizophrenia: Calcium Homeostasis. **2022**, 10, 98-112	0
490	Machine-guided cell-fate engineering.	0
489	A single short reprogramming early in life initiates and propagates an epigenetically related mechanism improving fitness and promoting an increased healthy lifespan.	4
488	iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors.	0
487	Capability of Human Dendritic Cells Pulsed with Autologous Induced Pluripotent Stem Cell Lysate to Induce Cytotoxic T Lymphocytes against HLA-A33-Matched Cancer Cells. **2022**, 23, 12992	0
486	The Role of Genetically Modified Human Feeder Cells in Maintaining the Integrity of Primary Cultured Human Deciduous Dental Pulp Cells. **2022**, 11, 6087	0
485	Functional Integration of 3D-Printed Cerebral Cortical Tissue into a Brain Lesion.	0

484	Restoration of functional PAX6 in aniridia patient iPSC-derived ocular tissue models using repurposed nonsense suppression drugs.	0
483	Stem cell-based models of early mammalian development. **2022**, 149,	2
482	Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection. **2022**, 105427	0
481	Tuning pro-survival effects of human induced pluripotent stem cell-derived exosomes using elastin-like polypeptides. **2022**, 121864	0
480	Mixed Models Quantify Annual Volume Change; Linear Regression Determines Thalamic Volume as the Best Subcortical Structure Volume Predictor in Alzheimer's Disease and Aging.	0
479	Current advances of CRISPR-Cas technology in cell therapy. **2022**, 100067	0
478	The centrosomal protein 83 (CEP83) regulates human pluripotent stem cell differentiation toward the kidney lineage. 11,	0
477	Interplay of phytohormones and epigenetic regulation: A recipe for plant development and plasticity.	0
476	Establishment of human induced trophoblast stem cells via reprogramming of fibroblasts.	0
475	TheSYNGAP13'UTR variant in ALS patients causes aberrantSYNGAP1splicing and dendritic spine loss by recruiting HNRNPK. JN-RM-0455-22	0
474	Transcriptional Control of Peripheral Nerve Regeneration.	0
473	Induced Pluripotent Stem Cells, a Stepping Stone to In Vitro Human Models of Hearing Loss. **2022**, 11, 3331	0
472	Analyses of the autism-associated neuroligin-3 R451C mutation in human neurons reveal a gain-of-function synaptic mechanism.	0
471	Combining stem cell rejuvenation and senescence targeting to synergistically extend lifespan.	0
470	Effective NGN2-based neuronal programming of hiPSCs in an automated microfluidic platform.	0
469	Generation and maturation of human iPSC-derived 3D organotypic cardiac microtissues in long-term culture. **2022**, 12,	1
468	Adaptation of cardiomyogenesis to the generation and maturation of cardiomyocytes from human pluripotent stem cells.	0
467	Human endometrium derived induced pluripotent stem cells are amenable to directed erythroid differentiation.	0

466	Curative Measures for Cystic Fibrosis: A Perspective on Current Stem CellBased, Gene, and Small Molecule Therapies.	0
465	Induced pluripotent stem cells of endangered avian species. **2022**, 5,	1
464	New insights into the epitranscriptomic control of pluripotent stem cell fate.	0
463	Molecular Evolution and Inheritance Pattern of Sox Gene Family among Bovidae. **2022**, 13, 1783	0
462	A stem cell zoo uncovers intracellular scaling of developmental tempo across mammals.	0
461	Characterization of cellular phenotypes in neurons derived from induced pluripotent stem cells of male patients with Fabry disease.	1
460	Past, Present, and Future of Direct Cell Reprogramming. **2022**, 24, 205-211	0
459	Biphasic cell cycle defect causes impaired neurogenesis in down syndrome. 13,	1
458	Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery. **2022**, 13,	1
457	Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.	0
456	In´vitro germ cell induction from fertile and infertile monozygotic twin research participants. **2022**, 3, 100782	0
455	A Review of Stem Cell Technology Targeting Hepatocyte Growth as an Alternative to Organ Transplantation. **2023**, 181-193	0
454	Identification of RNA-based cell-type markers for the stem cell manufacture system with a statistical scoring function.	0
453	Merits of hiPSC-Derived Cardiomyocytes for In Vitro Research and Testing Drug Toxicity. **2022**, 10, 2764	0
452	Modeling placental development and disease using human pluripotent stem cells. **2022**,	0
451	Bioengineering Human Pluripotent Stem Cell-Derived Retinal Organoids and Optic Vesicle-Containing Brain Organoids for Ocular Diseases. **2022**, 11, 3429	0
450	Efficient and safe single-cell cloning of human pluripotent stem cells using the CEPT cocktail.	0
449	iPS cells from Chediak-Higashi syndrome patients recapitulate the giant granules in myeloid cells.	0

448	Advancements in MAFLD Modeling with Human Cell and Organoid Models. **2022**, 23, 11850	1
447	Trends in using mesenchymal stromal/stem cells (MSCs) in treating corneal diseases. **2022**, 26, 255-267	0
446	Therapeutic function of a novel rat induced pluripotent stem cell line in a 6-OHDA-induced rat model of Parkinson's disease. **2022**, 50,	0
445	Elucidating effects of environmental exposure using human-induced pluripotent stem cell disease modeling.	0
444	Improving three-dimensional human pluripotent cell culture efficiency via surface molecule coating. 4,	0
443	A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify .	0
442	Induced Pluripotent Stem Cell (iPSC) Lines from a Family with Resistant Epileptic Encephalopathy Caused by Compound Heterozygous Mutations in SZT2 Gene. **2022**, 23, 13095	0
441	Regeneration of the human segmentation clock in somitoids in´vitro.	0
440	Identification of marker genes to monitor residual iPSCs in iPSC-derived products. **2022**,	0
439	Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I -specific cytotoxic T cells isolated from the melanoma patient with minor HLAs : The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology.	0
438	Novel strategies for designing regenerative skin products for accelerated wound healing. **2022**, 12,	1
437	Large-Scale Production of Wholly-Cellular Bioinks via the Optimization of Human Induced Pluripotent Stem Cell Aggregate Culture in Automated Bioreactors. 2201138	0
436	Patients' views on using human embryonic stem cells to treat Parkinson's disease: an interview study. **2022**, 23,	0
435	Druggable transcriptomic pathways revealed in Parkinson's patient-derived midbrain neurons. **2022**, 8,	0
434	Generation of glucose sensitive insulin-secreting cells from human induced pluripotent stem cells on optimized polyethersulfone hybrid nanofibrous scaffold.	0
433	Naïve-like conversion of bovine induced pluripotent stem cells from sertoli cells. **2022**,	0
432	Hydrogels for brain repair: application to Parkinson's disease. **2022**, 19, 1521-1537	0
431	16p13.11 deletion variants associated with neuropsychiatric disorders cause morphological and synaptic changes in induced pluripotent stem cell-derived neurons. 13,	0

430	Induced pluripotent stem cells and cerebral organoids from the critically endangered Sumatran rhinoceros. **2022**, 25, 105414	0
429	Early neurogenic properties of iPSC-derived neurosphere formation in Japanese macaque monkeys. **2022**, 128, 33-42	0
428	Importance of beating rate control for the analysis of drug effects on contractility in human induced pluripotent stem cell-derived cardiomyocytes. **2022**, 118, 107228	1
427	BRD9-containing non-canonical BAF complex maintains somatic cell transcriptome and acts as a barrier to human reprogramming. **2022**,	0
426	Reciprocal interplays between MicroRNAs and pluripotency transcription factors in dictating stemness features in human cancers. **2022**, 87, 1-16	0
425	Plasticity of muscle stem cells in homeostasis and aging. **2022**, 77, 101999	0
424	Single-cell mass cytometry analysis reveals stem cell heterogeneity. **2022**, 208, 9-18	0
423	Cytidine-containing tails robustly enhance and prolong protein production of synthetic mRNA in cell and in´vivo. **2022**, 30, 300-310	1
422	Epigenetic aging and its reversal. **2023**, 9-38	0
421	Developing clinically translatable screens using iPSC-derived neural cells. **2023**, 265-287	0
420	Development of transcription factor-based strategies for neuronal differentiation from pluripotent stem cells. **2023**, 73-96	0
419	Probing the electrophysiological properties of patient-derived neurons across neurodevelopmental disorders. **2023**, 229-242	0
418	Derivation of cortical interneurons from human pluripotent stem cells to model neurodevelopmental disorders. **2023**, 45-72	0
417	Brain organoids. **2023**, 121-151	0
416	Human models as new tools for drug development and precision medicine. **2023**, 155-171	0
415	iPSC culture. **2023**, 3-24	0
414	iPSC-derived models of autism. **2023**, 201-227	0
413	Fabricating 3-dimensional human brown adipose microtissues for transplantation studies. **2023**, 22, 518-534	0

412	Cell Sources for Cardiac Tissue Engineering. **2012**, 27-40	0
411	The Function of Stem Cells in Ocular Homeostasis. **2022**, 587-606	0
410	Common Ethical Considerations of Human-Induced Pluripotent Stem Cell Research. **2022**, 1161-1177	0
409	Stem Cells in Wound Healing and Scarring. **2022**, 103-126	0
408	Molecular Signature of Stem Cells Undergoing Cardiomyogenic Differentiation. **2022**, 725-767	0
407	Induced Pluripotent Stem Cells. **2022**, 895-919	0
406	Therapeutic Uses of Stem Cells for Heart Failure: Hype or Hope. **2022**, 511-544	0
405	Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs) as a Platform for Modeling Arrhythmias. **2022**, 875-893	0
404	Human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte modelling of cardiovascular diseases for natural compound discovery. **2023**, 157, 113970	1
403	The combination of SMRT sequencing and Illumina sequencing highlights organ-specific and age-specific expression patterns of miRNAs in Sika Deer. 9,	0
402	The Role of Autophagy in the Regulation of Hematopoietic Stem Cells. **2023**, 107-135	0
401	Single-nucleus transcriptomics of IDH1- and TP53-mutant glioma stem cells displays diversified commitment on invasive cancer progenitors. **2022**, 12,	1
400	Regulation of osteogenesis in bone marrow-derived mesenchymal stem cells via histone deacetylase 1 and 2 co-cultured with human gingival fibroblasts and periodontal ligament cells.	0
399	Epigenetic regulation of aging: implications for interventions of aging and diseases. **2022**, 7,	8
398	Characterization of Novel Antibodies that Recognize Sialylated Keratan Sulfate and Lacto-N-fucopentaose I on Human Induced Pluripotent Cells: Comparison with Existing Antibodies.	0
397	Imaging Analysis of Neurotrophic Effects by CCN2 Protein in Neuronal Precursor Cells Derived from Human-Induced Pluripotent Stem Cells. **2023**, 269-280	0
396	Allele-specific gene editing approach for vision loss restoration in RHO-associated Retinitis Pigmentosa.	0
395	A clinical-grade HLA haplobank of human induced pluripotent stem cells matching approximately 40% of the Japanese population. **2022**,	0

394	Chondrogenic Differentiation of Human-Induced Pluripotent Stem Cells. **2023**, 87-114	0
393	Generation of Lens Progenitor Cells and Lentoid Bodies from Pluripotent Stem Cells: Novel Tools for Human Lens Development and Ocular Disease Etiology. **2022**, 11, 3516	0
392	Identification of transcription factors dictating blood cell development using a bidirectional transcription network-based computational framework. **2022**, 12,	0
391	Immunosuppressants Tacrolimus and Sirolimus revert the cardiac antifibrotic properties of p38-MAPK inhibition in 3D-multicellular human iPSC-heart organoids. 10,	0
390	In vitro methods to ensure absence of residual undifferentiated human induced pluripotent stem cells intermingled in induced nephron progenitor cells. **2022**, 17, e0275600	0
389	A complete endocannabinoid signaling system modulates synaptic transmission between human induced pluripotent stem cell-derived neurons. MOLPHARM-AR-2022-000555	0
388	Defining transcription factor nucleosome binding with Pioneer-seq.	0
387	Pluripotent Stem Cells in Clinical Cell Transplantation: Focusing on Induced Pluripotent Stem Cell-Derived RPE Cell Therapy in Age-Related Macular Degeneration. **2022**, 23, 13794	0
386	Generation of red blood cells from stem cells: Achievements, opportunities and perspectives for malaria research. 12,	0
385	Generation of induced pluripotent stem cells (cmESF-iPS-C5) derived from cynomolgus monkey ear skin fibroblasts (cmESF). **2022**, 102977	0
384	Deletion ofTRPC6, an autism risk gene, induces hyperexcitability in cortical neurons derived from human pluripotent stem cells.	0
383	Duplication Versus Deletion Through the Lens of 15q13.3: Clinical and Research Implications of Studying Copy Number Variants Associated with Neuropsychiatric Disorders in Induced Pluripotent Stem Cell-Derived Neurons.	0
382	The expression of Oct3/4A mRNA and not its isoforms is upregulated by the HPV16 E7 oncoprotein.	0
381	Neural progenitor cell-derived extracellular matrix as a new platform for neural differentiation of human induced pluripotent stem cells. **2022**, 100070	0
380	Elevated alpha-synuclein attenuates phagocytosis in SNCA triplication human iPSC-derived neuron:microglia co-cultures.	0
379	Enhancing iPSC-CM Maturation Using a Matrigel-Coated Micropatterned PDMS Substrate. **2022**, 2,	0
378	Human iPSC-Derived Cortical Neurons Display Homeostatic Plasticity. **2022**, 12, 1884	0
377	Generation of the First Human In Vitro Model for McArdle Disease Based on iPSC Technology. **2022**, 23, 13964	0

376	Cell Behavioral Dynamics as a Cue in Optimizing Culture Stabilization in the Bioprocessing of Pluripotent Stem Cells. **2022**, 9, 669	0
375	Acute severe hypoxia induces apoptosis of human pluripotent stem cells by a HIF-1 and P53 independent mechanism. **2022**, 12,	0
374	Establishment of fishing cat cell biobanking for sustainable conservation. 9,	0
373	Indirect Mechanisms of Transcription Factor-Mediated Gene Regulation during CELL Fate Changes. 2200015	0
372	Inside the stemness engine: Mechanistic links between deregulated transcription factors and stemness in cancer. **2022**, 87, 48-83	1
371	Biofabrication of synthetic human liver tissue with advanced programmable functions. **2022**, 25, 105503	0
370	Structure and Function of the Skin. 1-52	1
369	Modeling Alzheimer Disease Using Human Brain Organoids. **2023**, 135-158	0
368	A single cell-based computational platform to identify chemical compounds targeting desired sets of transcription factors for cellular conversion. **2022**,	0
367	A review of regenerative therapy for spinal cord injury using human iPS cells. **2022**, 100184	0
366	iPSC-derived neurons from patients with POLG mutations exhibit decreased mitochondrial content and dendrite simplification. **2022**,	0
365	Evaluation of hiPSC-Derived Muscle Progenitor Cell Transplantation in a Mouse Duchenne Muscular Dystrophy Model. **2023**, 527-536	0
364	Human-Induced Pluripotent Stem Cell (hiPSC)-Derived Neurons and Glia for the Elucidation of Pathogenic Mechanisms in Alzheimer Disease. **2023**, 105-133	1
363	BNIP3-dependent mitophagy safeguards ESC genomic integrity via preventing oxidative stress-induced DNA damage and protecting homologous recombination. **2022**, 13,	0
362	Designed peptide-grafted hydrogels for human pluripotent stem cell culture and differentiation.	0
361	Cell-based therapeutic strategies for treatment of spinocerebellar ataxias: an update. **2023**, 18, 1203	0
360	Pluripotent Cells: New Tools for Disease Research and Therapies. **2016**, 134-138	0
359	Cis-regulatory Element Frequency Modules and their Phase Transition across Hominidae. **2022**, 371-395	0

358	Stem cell therapy in retinal diseases. **2023**, 18, 1478	0
357	Human proto-oncogene promoters. **2023**, 123-139	0
356	Label-free and non-destructive identification of naïve and primed embryonic stem cells based on differences in cellular metabolism. **2023**, 293, 121939	0
355	Practical pursuit in stem cell biology: Innovation, translation, and incomplete theorization. **2023**, 97, 1-12	0
354	Comparative study of differentiating human pluripotent stem cells into vascular smooth muscle cells in hydrogel-based culture methods. **2023**, 22, 39-49	0
353	Neurovascular Development. **2022**,	0
352	Immunobiological characteristics of microglial cells and in vitro models for their obtaining. **2022**, 4-13	0
351	Comprehensive comparison of gene expression diversity among a variety of human stem cells. **2022**, 4,	0
350	Brain organoids: Establishment and application. 10,	2
349	Activation of embryonic/germ cell-like axis links poor outcomes of gliomas. **2022**, 22,	0
348	Clinical Trials of Stem Cell Therapy in Japan: The Decade of Progress under the National Program. **2022**, 11, 7030	0
347	Molecular Challenges and Advances in Clinical Islet Transplantation.	0
346	Scalable Generation of Nanovesicles from Human-Induced Pluripotent Stem Cells for Cardiac Repair. **2022**, 23, 14334	3
345	KLF4 inhibits early neural differentiation of ESCs by coordinating specific 3D chromatin structure. **2022**, 50, 12235-12250	0
344	Modelling premature cardiac aging with induced pluripotent stem cells from a hutchinson-gilford Progeria Syndrome patient. 13,	0
343	Alignment of Skeletal Muscle Cells Facilitates Acetylcholine Receptor Clustering and Neuromuscular Junction Formation with Co-Cultured Human iPSC-Derived Motor Neurons. **2022**, 11, 3760	0
342	Profile of biological characterizations and clinical application of corneal stem/progenitor cells. 14, 777-797	0
341	Determining epigenetic memory in kidney proximal tubule cell derived induced pluripotent stem cells using a quadruple transgenic reprogrammable mouse. **2022**, 12,	0

340	Histomorphological study of the alveolar bone in periodontitis in the experiment. **2022**, 32-38	0
339	The Role of Bone Morphogenetic Protein Receptor Type 2 (BMPR2) and the Prospects of Utilizing Induced Pluripotent Stem Cells (iPSCs) in Pulmonary Arterial Hypertension Disease Modeling. **2022**, 11, 3823	0
338	The miR-34a-5p-c-MYC-CHK1/CHK2 Axis Counteracts Cancer Stem Cell-Like Properties and Enhances Radiosensitivity in Hepatocellular Cancer Through Repression of the DNA Damage Response. **2022**,	0
337	Differentiation of pluripotent stem cells for modeling human skin development and potential applications. 10,	0
336	The Influence of Interdisciplinary Work towards Advancing Knowledge on Human Liver Physiology. **2022**, 11, 3696	0
335	Cancer Metastasis and Treatment Resistance: Mechanistic Insights and Therapeutic Targeting of Cancer Stem Cells and the Tumor Microenvironment. **2022**, 10, 2988	0
334	Therapeutic Strategies Targeting Pancreatic Islet Cell Proliferation, Regeneration, and Replacement. **2022**, 164,	0
333	Modeling Movement Disorders via Generation of hiPSC-Derived Motor Neurons. **2022**, 11, 3796	0
332	Generation of neural organoids for spinal-cord regeneration via the direct reprogramming of human astrocytes.	0
331	Development of allogeneic iPS cell-based therapy: from bench to bedside.	0
330	NSC Physiological Features in Spinal Muscular Atrophy: SMN Deficiency Effects on Neurogenesis. **2022**, 23, 15209	0
329	Tau depletion in human neurons mitigates A beta-driven toxicity.	0
328	An Optogenetic-Controlled Cell Reprogramming System for Driving Cell Fate and Light-Responsive Chimeric Mice. 2202858	0
327	Attitudes and values among the Swedish general public to using human embryonic stem cells for medical treatment. **2022**, 23,	0
326	Opportunities and Challenges of Human IPSC Technology in Kidney Disease Research. **2022**, 10, 3232	0
325	De-erosion of X chromosome dosage compensation by the editing of XIST regulatory regions restores the differentiation potential in hPSCs. **2022**, 2, 100352	0
324	Golgi damage caused by dysfunction of PiT-2 in primary familial brain calcification. **2022**,	0
323	Induced pluripotent stem cell-derived and directly reprogrammed neurons to study neurodegenerative diseases: The impact of aging signatures. 14,	1

322	Genome Editing and Cardiac Regeneration. **2023**, 37-52	0
321	Biodegradable and Non-Biodegradable Biomaterials and Their Effect on Cell Differentiation. **2022**, 23, 16185	0
320	The Efficiency of Direct Maturation: the Comparison of Two hiPSC Differentiation Approaches into Motor Neurons. **2022**, 2022, 1-17	0
319	Non-thermal atmospheric-pressure plasma potentiates mesodermal differentiation of human induced pluripotent stem cells. **2022**, 8, e12009	0
318	Membrane-to-Nucleus Signaling in Human Blood Progenitor Cells Reveals an Efficient GM-Free Reprogramming to Pluripotency.	0
317	Feeder cells treated with ethanol can be used to maintain self-renewal and pluripotency of human pluripotent stem cells.	0
316	Current treatments after spinal cord injury: Cell engineering, tissue engineering, and combined therapies.	0
315	Non-Coding RNAs in the Regulation of Hippocampal Neurogenesis and Potential Treatment Targets for Related Disorders. **2023**, 13, 18	0
314	Action potential variability in human pluripotent stem cell-derived cardiomyocytes obtained from healthy donors. 13,	1
313	Patient-derived three-dimensional cortical neurospheres to model Parkinson disease. **2022**, 17, e0277532	0
312	Gene Editing and Human iPSCs in Cardiovascular and Metabolic Diseases. **2023**, 275-298	0
311	A new stage of experimental surgery for organoid based intestinal regeneration A review of organoid research and recent advance. **2022**, 75, 261-264	0
310	Induced Pluripotent Stem Cells and Genome-Editing Tools in Determining Gene Function and Therapy for Inherited Retinal Disorders. **2022**, 23, 15276	0
309	Current Application of iPS Cells in the Dental Tissue Regeneration. **2022**, 10, 3269	0
308	Alzheimer disease like neuropathology in Down syndrome cortical organoids. 16,	0
307	Advances in Cellular Reprogramming-Based Approaches for Heart Regenerative Repair. **2022**, 11, 3914	1
306	A reference human induced pluripotent stem cell line for large-scale collaborative studies. **2022**, 29, 1685-1702.e22	0
305	Isogenic Human-Induced Pluripotent Stem-Cell-Derived Cardiomyocytes Reveal Activation of Wnt Signaling Pathways Underlying Intrinsic Cardiac Abnormalities in Rett Syndrome. **2022**, 23, 15609	0

304	Attempts for deriving extended pluripotent stem cells from common marmoset embryonic stem cells.	0
303	Future prospects for cancer immunotherapy using induced pluripotent stem cell-derived dendritic cells or macrophages.	0
302	Single short reprogramming early in life promotes increased healthspan.	1
301	A Comprehensive Update of Cerebral Organoids between Applications and Challenges. **2022**, 2022, 1-10	0
300	Current advances in stem cell therapy in the treatment of multiple sclerosis. **2022**,	0
299	From Representation to Care: Emerging Shifts in Laboratory Studies. 1-8	0
298	Blastocyst complementation and interspecies chimeras in gene edited pigs. 10,	0
297	Expression analysis and regulation of GLI and its correlation with stemness and metabolic alteration in human brain tumor. **2023**, 13,	0
296	Biomaterial application strategies to enhance stem cell-based therapy for ischemic stroke. 14, 851-867	0
295	Transcription Factor-Mediated Differentiation of Motor Neurons from Human Pluripotent Stem Cells. **2023**, 245-258	0
294	LncRNA Osilr9 coordinates promoter DNA demethylation and the intrachromosomal loop structure required for maintaining stem cell pluripotency. **2022**,	0
293	Emerging toolset of three-dimensional pulmonary cell culture models for simulating lung pathophysiology towards mechanistic elucidation and therapeutic treatment of SARS-COV-2 infection. 13,	0
292	Variation of DNA methylation on the IRX1/2 genes is responsible for the neural differentiation propensity in human induced pluripotent stem cells. **2022**, 21, 620-630	0
291	Lung Organoids for Hazard Assessment of Nanomaterials. **2022**, 23, 15666	0
290	Blood–Brain Barrier Disruption and Its Involvement in Neurodevelopmental and Neurodegenerative Disorders. **2022**, 23, 15271	1
289	Gangliosides and Their Role in Multilineage Differentiation of Mesenchymal Stem Cells. **2022**, 10, 3112	0
288	Integrative metabolomics-genomics analysis identifies key networks in a stem cell-based model of schizophrenia..	0
287	Zinc transporter ZIP13 is involved in myogenic differentiation: establishment of Ehlers–Danlos syndrome spondylodysplastic type 3 induced pluripotent stem cells.	0

286	Reconstituting human somitogenesis in vitro.	0
285	Long-term calcium imaging reveals functional development in hiPSC-derived cultures comparable to human but not rat primary cultures. **2022**,	0
284	A functional neuron maturation device provides convenient application on microelectrode array for neural network measurement. **2022**, 26,	1
283	Protocol for the generation of human induced hepatic stem cells using Sendai virus vectors. **2022**, 3, 101884	0
282	Latest developments in engineered skeletal muscle tissues for drug discovery and development. 1-17	0
281	Bioprocess Economic Modeling: Decision Support Tools for the Development of Stem Cell Therapy Products. **2022**, 9, 791	0
280	Photoreceptor Cell Replacement Using Pluripotent Stem Cells: Current Knowledge and Remaining Questions. a041309	0
279	Stabilized generation of human iPSC-derived liver organoids using a modified coating approach.	0
278	Identification of DOT1L inhibitor in a screen for factors that promote dopaminergic neuron survival. 14,	0
277	Ageing Skeletal Muscle: The Ubiquitous Muscle Stem Cell. **2023**, 365-377	0
276	The dynamics of chromatin states mediated by epigenetic modifications during somatic cell reprogramming. 11,	0
275	Miniature-swine iPSC-derived GABA progenitor cells function in a rat Parkinson disease model.	0
274	Whole-Heart Tissue Engineering and Cardiac Patches: Challenges and Promises. **2023**, 10, 106	0
273	Dysregulated cholesterol metabolism, aberrant excitability and altered cell cycle of astrocytes in fragile X syndrome.	0
272	RCSN Cell System for Identifying Dopaminergic Neurotoxicity. **2022**, 239-254	0
271	Type 1 Diabetes Mellitus: A Review on Advances and Challenges in Creating Insulin Producing Devices. **2023**, 14, 151	0
270	The cellular model for Alzheimer's disease research: PC12 cells. 15,	0
269	Alzheimer's Disease and Synapse Loss: What Can We Learn from Induced Pluripotent Stem Cells?. **2023**,	0

268	Establishment of quantitative and consistent in vitro skeletal muscle pathological models of myotonic dystrophy type 1 using patient-derived iPSCs. **2023**, 13,	1
267	Cardiac muscle patches containing four types of cardiac cells derived from human pluripotent stem cells improve recovery from cardiac injury in mice.	0
266	Involvement of mTOR pathway in neurodegeneration in NSF-related developmental and epileptic encephalopathy.	0
265	Disruption of DDX53 coding sequence has limited impact on iPSC-derived human NGN2 neurons. **2023**, 16,	0
264	Development of lacrimal gland organoids from iPSC derived multizonal ocular cells. 10,	0
263	Development of a Method for the In Vivo Generation of Allogeneic Hearts in Chimeric Mouse Embryos. **2023**, 24, 1163	0
262	High-throughput telomere length measurement at nucleotide resolution using the PacBio high fidelity sequencing platform. **2023**, 14,	1
261	A human iPSC-basedin vitroneural network formation assay to investigate neurodevelopmental toxicity of pesticides.	0
260	In vitro in vivo extrapolation (IVIVE) in safety pharmacology to improve human predictability New evaluation systems for new drug modalities **2023**, 158, 77-81	0
259	MPS for Blood Brain Barrier. **2023**, 143, 45-53	0
258	Pathophysiology of Sandhoff Disease and Novel Thrapeutic Targets. **2023**, 143, 65-75	0
257	Automated high-content imaging in iPSC-derived neuronal progenitors. **2023**,	0
256	Stem Cells for Cancer Therapy: Translating the Uncertainties and Possibilities of Stem Cell Properties into Opportunities for Effective Cancer Therapy. **2023**, 24, 1012	0
255	Mesoangioblasts at 20: From the embryonic aorta to the patient bed. 13,	0
254	Differentiation of human induced pluripotent stem cells into cortical neural stem cells. 10,	0
253	Lung Cancer Gene Regulatory Network of Transcription Factors Related to the Hallmarks of Cancer. **2023**, 45, 434-464	1
252	Transcriptional and functional effects of lithium in bipolar disorder iPSC-derived cortical spheroids.	0
251	Amyloid beta accumulations and enhanced neuronal differentiation in cerebral organoids of Dutch-type cerebral amyloid angiopathy patients. 14,	0

250	Stem Cell Models in Prion Research. **2023**, 295-312	0
249	Multifunctional Intrinsically Disordered Regions in Transcription Factors.	0
248	De Novo Generation of Human Hematopoietic Stem Cells from Pluripotent Stem Cells for Cellular Therapy. **2023**, 12, 321	0
247	Alternative lung cell model systems for toxicology testing strategies: Current knowledge and future outlook. **2023**,	0
246	Current status of producing autologous hematopoietic stem cells. **2023**, 71, 103377	0
245	Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids. 13,	0
244	Reversine ameliorates hallmarks of cellular senescence in human skeletal myoblasts via reactivation of autophagy.	0
243	Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson Disease.	1
242	Progress and challenges in directing the differentiation of human iPSCs into spinal motor neurons. 10,	0
241	Intellectual disability and abnormal cortical neuron phenotypes in patients with Bloom syndrome.	0
240	In VivoDelivery of Therapeutic Molecules by Transplantation of Genome-Edited Induced Pluripotent Stem Cells.	0
239	A transcription factor atlas of directed differentiation. **2023**, 186, 209-229.e26	1
238	Development of Cell Therapy for Duchenne Muscular Dystrophy by iPS Cell-derived Muscle Stem Cell, and Potential of Regenerative Rehabilitation with Cell Therapy. **2022**, 59, 1020-1025	0
237	Pituitary stem cells: what do we know?. **2022**, 2, 60-65	0
236	A mutation in DOK7 in congenital myasthenic syndrome forms aggresome in cultured cells, and reduces DOK7 expression and MuSK phosphorylation in patient-derived iPS cells.	1
235	Age effect on mesenchymal stem cell properties: a concise review. **2022**, 4, 109-118	0
234	Stem cells for organoids. **2022**, 1,	0
233	Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.	1

232	Inhibition of Class I Histone Deacetylase Enhances Self-Reprogramming of Spermatogonial Stem Cells into Pluripotent Stem Cells. **2022**,	0
231	Immaturin-Nuclease as a Model System for a Gene-Programmed Sexual Development and Rejuvenescence in Paramecium Life History. **2023**, 11, 82	1
230	Antisense-oligonucleotide-mediated perturbation of long non-coding RNA reveals functional features in stem cells and across cell types. **2022**, 41, 111893	0
229	Induced Pluripotent Stem Cells: Advances and Applications in Regenerative Medicine.	0
228	Progress of 3D Organoid Technology for Preclinical Investigations: Towards Human In Vitro Models. 9	0
227	Ethical and regulatory issues of stem cell-derived 3-dimensional organoid and tissue therapy for personalised regenerative medicine. **2022**, 20,	0
226	Molecular Mechanisms and Clinical Application of Multipotent Stem Cells for Spinal Cord Injury. **2023**, 12, 120	1
225	Modeling Central Nervous System Injury In Vitro: Current Status and Promising Future Strategies. **2023**, 11, 94	0
224	Behavior of adipocytes in the mammary niche during pregnancy and lactation. **2019**, 5, 1-6	0
223	Epigenetic regulation of cis-regulatory elements and transcription factors during development. **2023**, 71-113	0
222	Synthetic genetic circuits to uncover and enforce the OCT4 trajectories of successful reprogramming of human fibroblasts.	0
221	Regeneration and Tissue Microenvironment. **2023**, 1-12	0
220	The Role of Tumoroids in Cancer Research. **2023**,	0
219	The potential of cellular transplantation to harness autoimmunity and reverse clinical diabetes. **2023**, 361-385	0
218	Genes Involved in DNA Repair and Mitophagy Protect Embryoid Bodies from the Toxic Effect of Methylmercury Chloride under Physioxia Conditions. **2023**, 12, 390	0
217	Investigating nanoplastics toxicity using advanced stem cell-based intestinal and lung in vitro models. 5,	0
216	Introduction aux cellules souches. **2023**,	0
215	CRaTER enrichment for on-target gene-editing enables generation of variant libraries in hiPSCs.	0

214	Tau tubulin kinase 1 and 2 regulate ciliogenesis and human pluripotent stem cellsderived neural rosettes.	0
213	Organs-on-a-chip: a union of tissue engineering and microfabrication. **2023**,	0
212	Vascularised Cardiac Spheroids-on-a-Chip for Testing the Toxicity of Therapeutics.	0
211	miR-203 drives breast cancer cell differentiation.	0
210	Experimental Models of In Vitro BloodBrain Barrier for CNS Drug Delivery: An Evolutionary Perspective. **2023**, 24, 2710	0
209	Role of neurogenesis in regenerative medicine. **2023**, 455-475	0
208	Intestinal metaplasia in progression of Barrett esophagus to esophageal adenocarcinoma. **2023**, 31, 41-47	0
207	Establishment of Bactrian Camel Induced Pluripotent Stem Cells and Prediction of Their Unique Pluripotency Genes. **2023**, 24, 1917	0
206	Stem Cells and Therapies in Cardiac Regeneration. **2023**, 127-141	0
205	A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle. **2023**, 28, 1141	0
204	Stem cells, organoids, and cellular therapy. **2023**, 233-263	0
203	Implication of E3 ligase RAD18 in UV-induced mutagenesis in human induced pluripotent stem cells and neuronal progenitor cells.	0
202	Direct Cardiac Reprogramming: Current Status and Future Prospects. **2023**,	0
201	Generation of mesenchymal stromal cells from urine-derived iPSCs of pediatric brain tumor patients. 14,	0
200	Spontaneous Epileptic Recordings from hiPSC-Derived Cortical Neurons Cultured with a Human Epileptic Brain Biopsy on a Multi Electrode Array. **2023**, 13, 1432	0
199	Induced pluripotent stem cell-based models: Are we ready for that heart in a dish?. 11,	0
198	Application of Single-Cell and Spatial Omics in Musculoskeletal Disorder Research. **2023**, 24, 2271	0
197	Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity. **2023**, 14,	0

196	Stem cell- derived extracellular vesicles as new tools in regenerative medicine - Immunomodulatory role and future perspectives. 14,	0
195	Characterization of Stress Granule Protein Turnover in Neuronal Progenitor Cells Using Correlative STED and NanoSIMS Imaging. **2023**, 24, 2546	0
194	Reprogramming of adult human dermal fibroblasts to induced dorsal forebrain precursor cells maintains aging signatures. 17,	0
193	Directed Differentiation of Human Pluripotent Stem Cells to Cytotrophoblast and Syncytiotrophoblast. **2023**,	0
192	Neural cortical organoids from self-assembling human iPSC as a model to investigate neurotoxicity in brain ischemia. 0271678X2311520	0
191	Oct-4 induces cisplatin resistance and tumor stem cell-like properties in endometrial carcinoma cells. **2023**, 62, 16-21	0
190	Derivation of Sendai-Virus-Reprogrammed Human iPSCs-Neuronal Precursors: In Vitro and In Vivo Post-grafting Safety Characterization. **2023**, 32, 096368972311632	0
189	Human in vitro spermatogenesis as a regenerative therapy where do we stand?.	0
188	Organoid intelligence (OI): the new frontier in biocomputing and intelligence-in-a-dish. 1,	0
187	The local topology of dynamical network models for biology.	0
186	CryoET reveals organelle phenotypes in huntington disease patient iPSC-derived and mouse primary neurons. **2023**, 14,	0
185	Pluripotent stem cells: Basic biology or else differentiations aimed at translational research and the role of flow cytometry.	0
184	Current Advancements in Spinal Cord Injury Research Glial Scar Formation and Neural Regeneration. **2023**, 12, 853	0
183	Mass Spectrometry Imaging Reveals Early Metabolic Priming of Cell Lineage in Differentiating Human-Induced Pluripotent Stem Cells. **2023**, 95, 4880-4888	0
182	A human induced pluripotent stem cell model from a patient with hereditary cerebral small vessel disease carrying a heterozygous R302Q mutation in HTRA1. **2023**, 43,	0
181	To be or not to be: The double-edged sword roles of liver progenitor cells. **2023**, 1878, 188870	0
180	Overexpression of KCNJ2 enhances maturation of human-induced pluripotent stem cell-derived cardiomyocytes. **2023**, 14,	0
179	iPSC-derived cells lack immune tolerance to autologous NK-cells due to imbalance in ligands for activating and inhibitory NK-cell receptors. **2023**, 14,	0

178	HIF1α and HIF2α regulate non-small-cell lung cancer dedifferentiation via expression of Sox2 and Oct4 under hypoxic conditions. **2023**, 863, 147288	0
177	Extreme myopia is more susceptible to SOX2 gene than high myopia. **2023**, 230, 109435	0
176	Recent advances in biofabrication strategies based on bioprinting for vascularized tissue repair and regeneration. **2023**, 229, 111885	0
175	Direct cardiac reprogramming: A new technology for cardiac repair. **2023**, 178, 51-58	0
174	Exploring the reprogramming potential of B cells and comprehending its clinical and therapeutic perspective. **2023**, 78, 101804	0
173	Therapeutic restoration of female reproductive and endocrine dysfunction using stem cells. **2023**, 322, 121658	0
172	Artificial intelligence-driven pan-cancer analysis reveals miRNA signatures for cancer stage prediction. **2023**, 4, 100190	0
171	Precise homology-directed installation of large genomic edits in human cells with cleaving and nicking high-specificity Cas9 variants.	0
170	Chenodeoxycholic acid rescues axonal degeneration in induced pluripotent stem cell-derived neurons from spastic paraplegia type 5 and cerebrotendinous xanthomatosis patients. **2023**, 18,	0
169	Bioactive peptides for boosting stem cell culture platform: Methods and applications. **2023**, 160, 114376	0
168	A Review on the Applications of Natural Biodegradable Nano Polymers in Cardiac Tissue Engineering. **2023**, 13, 1374	0
167	Generation of Human Induced Pluripotent Stem Cell line from PBMCs of Healthy Donors using Integration-free Sendai virus Technology. **2023**, 69, 103062	0
166	New insights into KLFs and SOXs in cancer pathogenesis, stemness, and therapy. **2023**, 90, 29-44	0
165	Regenerative Medicine, Disease Modelling, and Drug Discovery in Human Pluripotent Stem Cell-Derived Kidney Tissue. 57-67	0
164	Administration of stem cells against cardiovascular diseases with a focus on molecular mechanisms: Current knowledge and prospects. **2023**, 81, 102030	0
163	Biliary epithelial cell differentiation of bipotent human liver-derived organoids by 2D and 3D culture. **2023**, 33, 101432	0
162	Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions. **2023**, 37, e00784	0
161	Attention-effective multiple instance learning on weakly stem cell colony segmentation. **2023**, 17, 200187	0

160	Sirtuins and redox signaling interplay in neurogenesis, neurodegenerative diseases, and neural cell reprogramming. 17,	0
159	An HLA-homozygous haplobank resource to promote safer cell therapies. **2023**, 30, 118-119	0
158	Engineering 3D micro-compartments for highly efficient and scale-independent expansion of human pluripotent stem cells in bioreactors. **2023**, 295, 122033	0
157	Modeling Nonalcoholic Fatty Liver Disease in the Dish Using Human-Specific Platforms: Strategies and Limitations. **2023**, 15, 1135-1145	0
156	Human-specific genetics: new tools to explore the molecular and cellular basis of human evolution.	0
155	The participation of non-canonical autophagic proteins in the autophagy process and their potential as therapeutic targets. **2023**, 27, 71-86	0
154	Advances in Ophthalmic Epigenetics and Implications for Epigenetic Therapies: A Review. **2023**, 14, 417	0
153	Immune Mechanisms of Pulmonary Fibrosis with Bleomycin. **2023**, 24, 3149	0
152	Rare diseases of epigenetic origin: Challenges and opportunities. 14,	0
151	Oxidative Stress and Aging as Risk Factors for Alzheimer's Disease and Parkinson's Disease: The Role of the Antioxidant Melatonin. **2023**, 24, 3022	3
150	Cell reprogramming for oligodendrocytes: A review of protocols and their applications to disease modeling and cell-based remyelination therapies. **2023**, 101, 1000-1028	0
149	miR-514a promotes neuronal development in human iPSC-derived neurons. 11,	0
148	Editorial: Generation of Functional tissues from human pluripotent stem cells. 11,	0
147	Specific Activation of Yamanaka Factors via HSF1 Signaling in the Early Stage of Zebrafish Optic Nerve Regeneration. **2023**, 24, 3253	1
146	An Optimized Workflow to Generate and Characterize iPSC-Derived Motor Neuron (MN) Spheroids. **2023**, 12, 545	0
145	Transition from Animal-Based to Human Induced Pluripotent Stem Cells (iPSCs)-Based Models of Neurodevelopmental Disorders: Opportunities and Challenges. **2023**, 12, 538	0
144	The Exciting Realities and Possibilities of iPS-Derived Cardiomyocytes. **2023**, 10, 237	0
143	Current developments and therapeutic potentials of exosomes from induced pluripotent stem cells-derived mesenchymal stem cells. **2023**, 86, 356-365	0

142	Pluripotent Stem Cells in Disease Modeling and Drug Discovery for Myotonic Dystrophy Type 1. **2023**, 12, 571	0
141	Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution. **2023**, 42, 197-215	0
140	Opportunities and limitations for studying neuropsychiatric disorders using patient-derived induced pluripotent stem cells.	0
139	Hopes and opportunities of stem cells from human exfoliated deciduous teeth (SHED) in cartilage tissue regeneration. 11,	0
138	Highly efficient induction of functionally mature excitatory neurons from feeder-free human ES/iPS cells.	0
137	Modeling human liver organ development and diseases with pluripotent stem cell-derived organoids. 11,	0
136	Emerging trends in organ-on-a-chip systems for drug screening. **2023**,	0
135	Therapy resistance in neuroblastoma: Mechanisms and reversal strategies. 14,	0
134	Modeling Human Brain Tumors and the Microenvironment Using Induced Pluripotent Stem Cells. **2023**, 15, 1253	0
133	Restorative cell and gene therapies for Parkinson's disease. **2023**, 211-226	0
132	A human stem cell-derived neuronal model of morphine exposure reflects brain dysregulation in opioid use disorder: Transcriptomic and epigenetic characterization of postmortem-derived iPSC neurons. 14,	0
131	Hydrogel-Bondable Asymmetric Planar Membranes with Hierarchical Pore Structures for Cell Scaffolding and Encapsulation. **2023**, 9, 1706-1719	0
130	Induced pluripotent stem cells from domesticated ruminants and their potential for enhancing livestock production. 10,	0
129	Identification of cell-biologic mechanisms of coronary artery spasm and its ex vivo diagnosis using peripheral blood-derived iPSCs. **2023**, 27,	0
128	Epigenetic Regulation of Driver Genes in Testicular Tumorigenesis. **2023**, 24, 4148	0
127	Stem cell programming Prospects for perinatal medicine. **2023**,	0
126	Nonmammalian models in toxicology screening. **2023**,	0
125	Oct4 redox sensitivity potentiates iPSC reprogramming.	0

124	Modulation of WNT, Activin/Nodal and MAPK Signaling Pathways Increases Arterial Hemogenic Endothelium and Hematopoietic Stem/Progenitor Cell Formation During Human iPSC Differentiation.	0
123	Skeletal dysplasia-causing TRPV4 mutations suppress the hypertrophic differentiation of human iPSC-derived chondrocytes. 12,	0
122	Increasingly amplified stimulation mediated by TaNAC69-B is crucial for the leaf senescence in wheat.	0
121	Sertoli cell-only syndrome: advances, challenges, and perspectives in genetics and mechanisms. **2023**, 80,	0
120	The multiomic landscape of meningiomas: a review and update. **2023**, 161, 405-414	0
119	Stem Cell and Other Cell Therapies. **2023**, 397-425	0
118	The adaptation of bovine embryonic stem cells to the changes of feeder layers. **2023**, 59, 85-99	0
117	Induced pluripotent stem cell-derived hematopoietic stem and progenitor cells: potential, challenges, and future perspectives. 3, e2	0
116	Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. **2023**,	0
115	STEM CELLS (references review). **2009**, 46-51	0
114	Automating iPSC generation to enable autologous photoreceptor cell replacement therapy. **2023**, 21,	0
113	Proliferative Activity of Ehrlich Carcinoma Cells After Use of Nanocomplexes. **2023**, 223-242	0
112	Induced human pluripotent stem cells (HEBHMUi013-A) derived from a patient of sporadic Alzheimer's disease. **2023**, 68, 103052	0
111	Patient-derived podocyte spheroids reveal new insights into the etiopathogenesis of Alport syndrome. 11,	0
110	Post-translational proteomics platform identifies neurite outgrowth impairments in Parkinson disease GBA-N370S dopamine neurons. **2023**, 42, 112180	0
109	Novel Calmodulin Variant p.E46K Associated With Severe Catecholaminergic Polymorphic Ventricular Tachycardia Produces Robust Arrhythmogenicity in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. **2023**, 16,	0
108	The epigenetic Oct4 gene regulatory network: stochastic analysis of different cellular reprogramming approaches.	0
107	Recent developments in organ-on-a-chip technology for cardiovascular disease research.	0

106	Fibroblast heterogeneity: Keystone of tissue homeostasis and pathology in inflammation and ageing. 14,	0
105	Modeling mitochondrial DNA diseases: from base editing to pluripotent stem-cell-derived organoids. **2023**, 24,	0
104	A Simplified and Effective Approach for the Isolation of Small Pluripotent Stem Cells Derived from Human Peripheral Blood. **2023**, 11, 787	0
103	Evaluation of Human-Induced Pluripotent Stem Cells Derived from a Patient with Schwartz□ampel Syndrome Revealed Distinct Hyperexcitability in the Skeletal Muscles. **2023**, 11, 814	0
102	Small-Caliber Tissue-Engineered Vascular Grafts Based on Human-Induced Pluripotent Stem Cells: Progress and Challenges.	0
101	Use of in vitro derived human neuronal models to study host-parasite interactions of Toxoplasma gondii in neurons and neuropathogenesis of chronic toxoplasmosis. 13,	0
100	Differentiation of Peritubular Myoid-Like Cells from Human Induced Pluripotent Stem Cells. 2200322	0
99	Neuronal Cultures: Exploring Biophysics, Complex Systems, and Medicine in a Dish. **2023**, 3, 181-202	0
98	Tumor cell plasticity in targeted therapy-induced resistance: mechanisms and new strategies. **2023**, 8,	0
97	Cell-based therapy to boost right ventricular function and cardiovascular performance in hypoplastic left heart syndrome: Current approaches and future directions. **2023**, 151725	0
96	Retinal Ganglion Cells in a Dish: Current Strategies and Recommended Best Practices for Effective In Vitro Modeling of Development and Disease. **2023**,	0
95	Unlocking the potential of induced pluripotent stem cells for neonatal disease modeling and drug development. **2023**, 151729	0
94	Genome-engineering technologies for modeling and treatment of cystic fibrosis. **2023**, 68, 111-120	0
93	Human neural stem cells in developmental neurotoxicology: Current scenario and future prospects. **2023**,	0
92	Simple, Fast, and Efficient Method for Derivation of Dermal Fibroblasts From Skin Biopsies. **2023**, 3,	0
91	Culture Conditions for Human Induced Pluripotent Stem Cell-Derived Schwann Cells: A Two-Centre Study. **2023**, 24, 5366	0
90	N6-methyladenosine reader YTHDF family in biological processes: Structures, roles, and mechanisms. 14,	0
89	The Renin-Angiotensin System and Cancer. **2023**, 277-339	0

88	Molecular and functional characterization of different BrainSphere models for use in neurotoxicity testing on microelectrode arrays.	0
87	Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review. **2023**,	0
86	Development of substrates for the culture of human pluripotent stem cells.	0
85	Correlations between phenotype and gene region-specific episignatures in Rubinstein-Taybi syndrome and Menke-Hennekam syndrome.	0
84	Introduction to stem cells. **2023**,	0
83	Large animal models for cardiac remuscularization studies: A methodological review. 10,	0
82	Epigenetic misactivation of a distal developmental enhancer cluster drivesSOX2overexpression in breast and lung cancer.	0
81	Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments. **2023**, 11, 915	0
80	Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy. **2023**, 24, 5665	0
79	Light-stimulated insulin secretion from pancreatic islet-like organoids derived from human pluripotent stem cells. **2023**,	0
78	Mapping of clonal lineages across developmental stages in human neural differentiation. **2023**, 30, 473-487.e9	0
77	Vascularized organ bioprinting: From strategy to paradigm.	1
76	Glis1 and oxaloacetate in nucleus pulposus stromal cell somatic reprogramming and survival. 9,	0
75	Label-Free Long-Term Methods for Live Cell Imaging of Neurons: New Opportunities. **2023**, 13, 404	0
74	Animal Disease Models and Patient-iPS-Cell-Derived In Vitro Disease Models for Cardiovascular BiologyHow Close to Disease?. **2023**, 12, 468	0
73	Revolutionizing Disease Modeling: The Emergence of Organoids in Cellular Systems. **2023**, 12, 930	0
72	Effect of ZEB1 Associated with microRNAs on Tumor Stem Cells in Head and Neck Cancer. **2023**, 24, 5916	0
71	Recommendations, guidelines, and best practice for the use of human induced pluripotent stem cells for neuropharmacological studies of neuropsychiatric disorders. **2023**, 2, 101125	0

70	Decellularization of Mouse Kidneys to Generate an Extracellular Matrix Gel for Human Induced Pluripotent Stem Cell Derived Renal Organoids. **2023**, 2, 66-78	0
69	Turning Back the Clock: A Retrospective Single-Blind Study on Brain Age Change in Response to Nutraceuticals Supplementation vs. Lifestyle Modifications. **2023**, 13, 520	0
68	Engineering the maturation of stem cell-derived cardiomyocytes. 11,	0
67	Somatic Cell Reprogramming for Nervous System Diseases: Techniques, Mechanisms, Potential Applications, and Challenges. **2023**, 13, 524	0
66	The Comprehensive Effects of Carassius auratus Complex Formula against Lipid Accumulation, Hepatocarcinogenesis, and COVID-19 Pathogenesis via Stabilized G-Quadruplex and Reduced Cell Senescence. 2200310	0
65	Temperature Dependence of the Beating Frequency of hiPSC-CMs Using a MEMS Force Sensor. **2023**, 23, 3370	0
64	Integrated-gut-liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease. **2023**, 6,	0
63	Ubiquitin–Proteasome System in the Induction and Maintenance of Cellular Pluripotency. **2022**, 53, 373-388	0
62	Cellular reprogramming of fibroblasts in heart regeneration. **2023**,	0
61	Induced Pluripotent Stem Cells and Their Applications in Amyotrophic Lateral Sclerosis. **2023**, 12, 971	1
60	Generation of functional posterior spinal motor neurons from hPSCs-derived human spinal cord neural progenitor cells. **2023**, 12,	0
59	Molecular Methods to Prevent Adhesion Formation. **2012**, e34-e41	0
58	Direct reprogramming of human fibroblasts into insulin-producing cells using transcription factors. **2023**, 6,	0
57	Application of Human Stem Cells to Model Genetic Sensorineural Hearing Loss and Meniere Disease. **2023**, 12, 988	0
56	Human iPS Cells for Clinical Applications and Cellular Products. **2023**,	0
55	Effective derivation of ventricular cardiomyocytes from hPSCs using ascorbic acid-containing maturation medium. **2023**, 27, 83-93	0
54	Deficits in mitochondrial function and glucose metabolism seen in sporadic and familial Alzheimer's disease derived Astrocytes are ameliorated by increasing hexokinase 1 expression.	0
53	Cell-type dependent regulation of pluripotency and chromatin remodeling genes by hydralazine. **2023**, 14,	0

52	Diabetes Mellitus and iPSC-Based Therapy. **2023**, 225-246	0
51	Modeling ciliopathies in patient-derived primary cells. **2023**,	0
50	ETV2/ER71, the key factor leading the paths to vascular regeneration and angiogenic reprogramming. **2023**, 14,	0
49	Recent Advances in Generation of In Vitro Cardiac Organoids. **2023**, 24, 6244	0
48	Conserved transcription factors promote cell fate stability and restrict reprogramming potential in differentiated cells. **2023**, 14,	0
47	3D Bioprinting for Next-Generation Personalized Medicine. **2023**, 24, 6357	0
46	Differentiation of Human Fetal Muscle Stem Cells from Induced Pluripotent Stem Cells. **2023**, 143-157	0
45	Human In Vitro Skin Models for Wound Healing and Wound Healing Disorders. **2023**, 11, 1056	0
44	In Vitro Maturation of Human Pluripotent Stem Cell-Derived Myotubes. **2023**, 129-142	0
43	Stem cell-derived retinal pigment epithelium cell therapy: Past and future directions. 11,	0
42	Chapitre 6. R□visions des lois de bio□hique et recherche sur l□embryon humain´: une analyse psychosociale des □ats G□□aux de la Bio□hique. **2023**, Vol. 33, 75-93	0
41	Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies.	0
40	CRaTER enrichment for on-target gene editing enables generation of variant libraries in hiPSCs. **2023**, 179, 60-71	0
39	Multi-omics analysis reveals a crucial role for Retinoic Acid in promoting epigenetic and transcriptional competence of anin vitromodel of human Pharyngeal Endoderm.	0
38	Stem cells in the treatment of Alzheimer's disease □Promises and pitfalls. **2023**, 1869, 166712	0
37	Induced pluripotent stem cell technology in bone biology. **2023**, 116760	0
36	Preclinical Large Animal Porcine Models for Cardiac Regeneration and Its Clinical Translation: Role of hiPSC-Derived Cardiomyocytes. **2023**, 12, 1090	0
35	Monitoring oocyte-based human pluripotency acquisition using synchrotron-based FTIR microspectroscopy reveals specific biomolecular trajectories. **2023**, 297, 122713	0

34	Neuroprotective effects of genome-edited human iPS cell-derived neural stem/progenitor cells on traumatic brain injury.	0
33	Effects of docosahexaenoic acid or arachidonic acid supplementation on the behavior of cardiomyocytes derived from human pluripotent stem cells. **2023**, 47, 1095-1106	0
32	Understanding neural development and diseases using CRISPR screens in human pluripotent stem cell-derived cultures. 11,	0
31	Induction and application of human naive pluripotency. **2023**, 42, 112379	0
30	Stem Cells as Nuclear Donors for Mammalian Cloning. **2023**, 105-119	0
29	Cloning by SCNT: Integrating Technical and Biology-Driven Advances. **2023**, 1-35	0
28	Mitochondrial, cell cycle control and neuritogenesis alterations in an iPSC-based neurodevelopmental model for schizophrenia.	0
27	Cardiac Regenerative Therapy Using Human Pluripotent Stem Cells for Heart Failure: A State-of-the-Art Review. **2023**, 29, 503-513	0
26	Induction of allograft tolerance by adoptive transfer of donor B cells: an immune regulatory strategy for transplantation using MHC-matched iPS cells.	0
25	Three-way Cell-based Screening of Antistress Compounds: Identification, Validation, and Relevance to Old-age Related Pathologies.	0
24	Application of human iPSC-derived macrophages in a miniaturized high-content-imaging-based efferocytosis assay. **2023**,	0
23	Does Enhanced Structural Maturity of hiPSC-Cardiomyocytes Better for the Detection of Drug-Induced Cardiotoxicity?. **2023**, 13, 676	0
22	CRISPR-based functional genomics screening in human-pluripotent-stem-cell-derived cell types. **2023**, 100300	0
21	Endothelial cell direct reprogramming: Past, present, and future. **2023**,	0
20	The Role of Large Animal Models in Cardiac Regeneration Research Using Human Pluripotent Stem Cell-Derived Cardiomyocytes.	0
19	An efficient induction method for human spinal lower motor neurons and high-throughput image analysis at the single cell level.	0
18	Biophysical Stretch Induced Differentiation and Maturation of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. **2023**, 141-179	0
17	Pluripotent Stem Cells as a Model for Human Embryogenesis. **2023**, 12, 1192	0

16	In vitro spermatogenesis from pluripotent stem cells. **2023**, 119-143	0
15	Neurological Disease Modeling Using Pluripotent and Multipotent Stem Cells: A Key Step towards Understanding and Treating Mucopolysaccharidoses. **2023**, 11, 1234	0
14	Role of stem cell engineering and or gene-editing technologies in eye diseases degeneration, and therapy. **2023**, 119-138	0
13	The cell: cell microenvironment and cell handling. **2023**, 5-26	0
12	Retinal cone photoreceptors from pluripotent stem cells for macular regeneration. **2023**, 221-241	0
11	Stem cell-based organoid cultures as innovative approaches for ocular repair and regeneration. **2023**, 1-41	0
10	Update on stem/progenitor cell-based clinical trials for eye disease. **2023**, 243-272	0
9	Human stem cell-derived retinal pigment epithelial cells for retinal regeneration: differentiation and clinical translation. **2023**, 171-192	0
8	In vitro models of human blastocysts and early embryogenesis. **2023**, 311-328	0
7	Application of new technologies in embryos: From gene editing to synthetic embryos. **2023**, 853-886	0
6	Cellular-Based Therapies for Paediatric GI Motility Disorders. **2022**, 617-629	0
5	Determination of stem cell pluripotency in spent cultivation media by Raman spectroscopy.	0
4	Epstein-Barr virus‐associated cellular immunotherapy. **2023**,	0
3	Development of Synthetic Modulator Enabling Long-Term Propagation and Neurogenesis of Human-Derived Neural Progenitor Cells.	0
2	BCL7B, an SWI/SNF complex subunit, orchestrates cancer immunity and stemness.	0
1	A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides. **2023**, 14,	0